## メタクリル酸=2,3 エポキシプロピルのラットを用いた 吸入によるがん原性試験報告書

試験番号:0794

# TABLES

### TABLES

- TABLE ACONCENTRATIONS OF 2,3-EPOXYPROPYL METHACRYLATEIN THE INHALATION CHAMBER OF THE 2-YEAR INHALATIONSTUDY
- TABLEB 1SURVIVAL ANIMAL NUMBERS: MALE
- TABLEB 2SURVIVAL ANIMAL NUMBERS: FEMALE
- TABLE C1 CLINICAL OBSERVATION: MALE
- TABLEC 2CLINICAL OBSERVATION: FEMALE
- TABLED 2BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS: FEMALE
- TABLE D 3 BODY WEIGHT CHANGES: MALE
- TABLED 4BODY WEIGHT CHANGES: FEMALE
- TABLEE 1FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL<br/>NUMBERS: MALE
- TABLEE 2FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL<br/>NUMBERS: FEMALE
- TABLEE 3FOOD CONSUMPTION CHANGES: MALE
- TABLE E 4 FOOD CONSUMPTION CHANGES: FEMALE
- TABLE F 1 HEMATOLOGY: MALE
- TABLE F 2 HEMATOLOGY: FEMALE
- TABLE G 1 BIOCHEMISTRY: MALE
- TABLEG 2BIOCHEMISTRY: FEMALE

## TABLES (CONTINUED)

- TABLE H 1 URINALYSIS: MALE
- TABLEH 2URINALYSIS: FEMALE
- TABLE I 1 GROSS FINDINGS: MALE
- TABLE I 2 GROSS FINDINGS: FEMALE
- TABLE J 1 ORGAN WEIGHT, ABSOLUTE: MALE
- TABLE J 2 ORGAN WEIGHT, ABSOLUTE: FEMALE
- TABLE K 1 ORGAN WEIGHT, RELATIVE: MALE
- TABLE K 2 ORGAN WEIGHT, RELATIVE: FEMALE

- TABLEM 1NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF<br/>TUMORS-TIME RELATED: MALE
- TABLEM 2NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF<br/>TUMORS-TIME RELATED: FEMALE
- TABLE N 1 HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS: MALE
- TABLE N 2 HISTOPATHOLOGICAL FINDINGS: NEOPLASTIC LESIONS: FEMALE
- TABLE
   O 1
   NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS: MALE
- TABLE
   O 2
   NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS: FEMALE

## TABLES (CONTINUED)

- TABLEP 1HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR:<br/>MALE
- TABLEP 2HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR:<br/>FEMALE
- TABLEQ 1HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC<br/>LESIONS IN JAPAN BIOASSAY RESEARCH CENTER :<br/>F344/DuCrlCrlj MALE RATS
- TABLEQ 2HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC<br/>LESIONS IN JAPAN BIOASSAY RESEARCH CENTER :<br/>F344/DuCrlCrlj FEMALE RATS
- TABLE R 1 CAUSE OF DEATH: MALE
- TABLE R 2 CAUSE OF DEATH: FEMALE

## TABLE A

# CONCENTRATIONS OF 2,3-EPOXYPROPYL METHACRYLATE IN THE INHALATION CHAMBER OF THE 2-YEAR INHALATION STUDY

## CONCENTRATIONS OF 2,3-EPOXYPROPYL METHACRYLATE IN THE INHALATION CHAMBER OF THE 2-YEAR INHALATION STUDY

Group Name	$\begin{array}{c} \text{Concentration(ppm)} \\ \text{Mean} \pm \text{S.D.} \end{array}$
Control	$0.0 \pm 0.0$
$3.2~{ m ppm}$	$3.2 \pm 0.1$
8 ppm	$8.1\pm0.1$
$20~{ m ppm}$	$20.1 \pm 0.2$

TABLE B1

SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104 SEX : MALE

Administration (Weeks) Group Name Animals At start 0 1 2 3 4 5 6 7 8 9 10 11 12 13 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 Control 50 50/50 50/50 50/50 100.0 100.0 100.0 100.0 100. 0 100.0 100. 0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 3. 2ppm 50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 100.0 100.0 100. 0 100.0 100.0 100. 0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 50/50 8ppm 50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 100.0 100. 0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 20ppm 50 100.0 100. 0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100. 0 100.0 100.0 100.0 100.0

Number of survival/ Number of effective animals Survival rate(%)

(HAN360)

BA1S5

PAGE: 1

### SURVIVAL ANIMAL NUMBERS

 $\bigcirc$ 

STUDY NO. :	0794
ANIMAL :	RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE	: A1 104
SEX : MALE	

PAGE: 2 Group Name Administration (Weeks) Animals 26 At start 14 15 16 17 18 19 20 21 22 23 24 25 27 50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 Control 50/50 100.0 100. 0 100.0 100.0 100.0 100.0 100. 0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 50/50 50/50 50/50 50/50 50/50 3.2ppm 50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 100.0 100.0 100.0 100. 0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 8ppm 50/50 50/50 50/50 50/50 100. 0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 20ppm 50/50 100. 0 100.0 100.0 100.0 100.0 100. 0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0

Number of survival/ Number of effective animals Survival rate(%)

(HAN360)

BA1S5

SURVIVAL ANIMAL NUMBERS

STUDY NO.	:	0794
ANIMAL	:	RAT F344/DuCrICrIj[F344/DuCrj]
REPORT TY	PE	: A1 104
SEX : MALE	Ε	

PAGE : 3

oup Name	Animals	Administ	ration (Wee	ks)											
	At start	28	29	30	31	32	33	34	35	36	37	38	39	40	41
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100.0	100.0	100.0	100. 0	100.0	100.0	100.0	100.0	100. 0	100.0	100. 0
3. 2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100. 0	100. 0	100.0	100. 0	100. 0	100. 0	100. 0	100. 0	100. 0	100. 0	100. 0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100. 0	100. 0	100.0	100. 0	100.0	100. 0	100. 0	100. 0	100. 0	100. 0	100. 0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100. 0	100. 0	100.0	100. 0	100.0	100. 0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals Survival rate(%)

STUDY NO. :	0794
ANIMAL :	RAT F344/DuCrICrIj[F344/DuCrj]
REPORT TYPE	: A1 104
SEX : MALE	

PAGE : 4

oup Name	Animals	Administ	ration (Wee	ks)											
	At start	42	43	44	45	46	47	48	49	50	51	52	53	54	55
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100.0	100. 0	100.0	100. 0	100.0	100.0	100.0	100.0	100. 0	100.0	100. 0
3. 2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100. 0	100. 0	100.0	100. 0	100. 0	100. 0	100. 0	100. 0	100. 0	100. 0	100. 0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100. 0	100. 0	100.0	100. 0	100. 0	100. 0	100. 0	100. 0	100. 0	100.0	100. 0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100. 0	100.0	100. 0

Number of survival/ Number of effective animals Survival rate(%)

STUDY NO. :	0794
ANIMAL :	RAT F344/DuCrICrIj[F344/DuCrj]
REPORT TYPE	: A1 104
SEX : MALE	

/DuGrj]

PAGE : 5

roup Name	Animals	Administ	ration (Wee	ks)											
	At start	56	57	58	59	60	61	62	63	64	65	66	67	68	69
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100. 0	100.0	100.0
3.2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100. 0	100. 0	100. 0	100. 0	100.0	100. 0	100. 0	100.0	100. 0	100.0	100. 0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	48/50	48/50	48/50
		100.0	100. 0	100.0	100. 0	100. 0	100. 0	100. 0	100.0	98.0	98.0	98.0	96.0	96.0	96.0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	48/50	46/50	46/50	46/50
		100.0	100. 0	100.0	100.0	100.0	100.0	100. 0	100.0	100. 0	98.0	96.0	92.0	92.0	92.0

SURVIVAL ANIMAL NUMBERS

Number of survival/ Number of effective animals Survival rate(%)

STUDY NO. : O ANIMAL : R REPORT TYPE : SEX : MALE	AT F344/DuCrICrIj	[F344/DuCrj]	
Group Name	Animals	Administration	(Weeks)

Group Name	Animals	Administ	ration (Wee	eks)											
	At start	70	71	72	73	74	75	76	77	78	79	80	81	82	83
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	48/50
		100.0	100. 0	100.0	100.0	100.0	100.0	100. 0	100.0	100.0	100.0	100.0	100.0	98.0	96.0
3. 2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100. 0	100.0	100.0	100.0	100.0	100.0	100. 0	100.0	100. 0	100.0	100. 0
8ppm	50	48/50	48/50	48/50	48/50	47/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50
		96.0	96.0	96.0	96.0	94.0	92.0	92.0	92.0	92.0	92.0	92.0	92. 0	92.0	92.0
20ppm	50	46/50	46/50	46/50	45/50	45/50	45/50	44/50	41/50	41/50	37/50	35/50	34/50	31/50	31/50
		92.0	92.0	92.0	90.0	90. 0	90.0	88.0	82.0	82.0	74.0	70.0	68.0	62.0	62.0

Number of survival/ Number of effective animals Survival rate(%)

(HAN360)

oup Name	Animals	Administ	ration (Wee	ks)											
	At start	84	85	86	87	88	89	90	91	92	93	94	95	96	97
Control	50	48/50	48/50	48/50	48/50	48/50	47/50	47/50	47/50	46/50	46/50	46/50	45/50	45/50	45/50
		96.0	96. 0	96.0	96.0	96.0	94.0	94.0	94.0	92. 0	92. 0	92.0	90.0	90.0	90.0
3.2ppm	50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	47/50	47/50	47/50
		100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	96. 0	96.0	94.0	94.0	94. 0
8ppm	50	46/50	46/50	46/50	46/50	46/50	46/50	45/50	45/50	45/50	45/50	44/50	44/50	44/50	44/50
		92.0	92. 0	92.0	92.0	92.0	92.0	90. 0	90.0	90.0	90.0	88.0	88.0	88.0	88.0
20ppm	50	30/50	27/50	27/50	26/50	25/50	23/50	20/50	19/50	18/50	17/50	17/50	17/50	15/50	15/50
		60.0	54.0	54.0	52.0	50.0	46.0	40.0	38.0	36.0	34.0	34.0	34.0	30.0	30.0

Number of survival/ Number of effective animals Survival rate(%)

(HAN360)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]

### SURVIVAL ANIMAL NUMBERS

STUDY NO. :	0794
ANIMAL :	RAT F344/DuCrICrIj[F344/DuCrj]
REPORT TYPE	: A1 104
SEX : MALE	

PAGE : 8

Group Name	Animals	Administ	ration (Wee	ks)				
	At start	98	99	100	101	102	103	104
	50	45 (50	45/50	AE /ED	44/50	49/50	42/50	41 /ED
Control	50	45/50	45/50	45/50	44/50	43/50	43/50	41/50
		90.0	90. 0	90.0	88.0	86.0	86.0	82. 0
3. 2ppm	50	47/50	47/50	47/50	46/50	45/50	45/50	44/50
		94.0	94.0	94.0	92. 0	90.0	90.0	88.0
8ppm	50	43/50	43/50	43/50	42/50	42/50	40/50	39/50
		86.0	86.0	86.0	84.0	84.0	80.0	78.0
20ppm	50	14/50	14/50	14/50	12/50	10/50	9/50	9/50
		28.0	28.0	28.0	24.0	20.0	18.0	18.0

Number of survival/ Number of effective animals Survival rate(%)

(HAN360)

BA1S5

TABLE B2

SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. :	0794
ANIMAL :	RAT F344/DuCrICrIj[F344/DuCrj]
REPORT TYPE	: A1 104
SEX : FEMAL	E

PAGE: 9

oup Name	Animals	Administ	ration (Wee	ks)											
	At start	0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100.0	100.0	100.0	100. 0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
3. 2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100.0	100. 0	100.0	100. 0	100.0	100. 0	100. 0	100.0	100. 0	100.0	100. 0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100. 0	100. 0	100.0	100. 0	100.0	100.0	100. 0	100.0	100. 0	100.0	100. 0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100. 0	100.0	100.0

Number of survival/ Number of effective animals Survival rate(%)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104 SEX : FEMALE

Group Name Administration (Weeks) Animals 26 27 16 17 18 19 20 21 22 23 24 25 At start 14 15 50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 Control 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100. 0 100.0 100.0 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 3.2ppm 50 50/50 50/50 50/50 50/50 50/50 50/50 100.0 100.0 100.0 100.0 100.0 100. 0 100.0 100.0 100.0 100.0 100.0 100. 0 100.0 100.0 50/50 50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 8ppm 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 20ppm 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0

Number of survival/ Number of effective animals Survival rate(%)

(HAN360)

SURVIVAL ANIMAL NUMBERS

## $\bigcirc$

STUDY NO.	:	0794
ANIMAL	:	RAT F344/DuCriCrij[F344/DuCrj]
REPORT TYP	PE	: A1 104
SEX : FEM/	٩LI	Ξ

PAGE : 11

oup Name	Animals	Administ	ration (Wee	eks)											
	At start	28	29	30	31	32	33	34	35	36	37	38	39	40	41
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100.0	100.0	100.0	100.0	100.0	100. 0	100.0	100.0	100.0	100.0	100.0
3.2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100. 0	100. 0	100. 0	100. 0	100.0	100. 0	100. 0	100.0	100. 0	100.0	100.0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100. 0	100.0	100.0	100. 0	100.0	100. 0	100.0	100.0	100. 0	100.0	100. 0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100.0	100. 0	100.0	100. 0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals Survival rate(%)

STUDY NO. :	0794
ANIMAL :	RAT F344/DuCrICrIj[F344/DuCrj]
REPORT TYPE	: A1 104
SEX : FEMALI	E

oup Name	Animals	Administ	ration (Wee	ks)											
	At start	42	43	44	45	46	47	48	49	50	51	52	53	54	55
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100. 0	100.0	100.0
3. 2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100. 0	100. 0	100.0	100. 0	100.0	100.0	100. 0	100. 0	100. 0	100.0	100. 0
8ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50
		100. 0	100.0	100. 0	100. 0	100. 0	100. 0	100. 0	100.0	100. 0	98. 0	98.0	98.0	98.0	98.0
20ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100. 0	100.0	100.0	100.0	100.0	100. 0	100.0	100.0

Number of survival/ Number of effective animals Survival rate(%)

(HAN360)

BA1S5

STUDY NO.	: (	)794
AN I MAL	: F	RAT F344/DuCrICrIj[F344/DuCrj]
REPORT TYP	'E	A1 104
SEX : FEMA	LE	

PAGE : 13

oup Name	Animals	Administ	ration (Wee	ks)											
	At start	56	57	58	59	60	61	62	63	64	65	66	67	68	69
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100. 0	100.0	100.0
3. 2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100. 0	100.0	100. 0	100. 0	100.0	100. 0	100.0	100. 0	100. 0	100. 0	100. 0	100. 0	100. 0
8ppm	50	49/50	49/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50
		98.0	98. 0	96.0	96.0	96. 0	96.0	96. 0	96.0	96.0	96.0	96.0	96.0	96.0	96.0
20ppm	50	50/50	49/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50
		100.0	98.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0

Number of survival/ Number of effective animals Survival rate(%)

Broup Name	Animals	Administ	tration (Wee	aks)											
	At start	70	71	72	73	74	75	76	77	78	79	80	81	82	83
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	48/50	48/50	48/50	48/50	48/50	47/50	47/50	46/50
		100.0	100.0	100.0	100.0	100. 0	100.0	96.0	96.0	96.0	96.0	96.0	94.0	94.0	92.0
3. 2ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50
		100.0	100. 0	100.0	100. 0	100.0	100.0	100. 0	100.0	100. 0	100. 0	98.0	98.0	98.0	98.0
8ppm	50	48/50	48/50	48/50	47/50	47/50	47/50	47/50	47/50	47/50	46/50	46/50	46/50	46/50	45/50
		96.0	96. 0	96.0	94.0	94.0	94.0	94.0	94.0	94.0	92. 0	92.0	92. 0	92.0	90.0
20ppm	50	48/50	48/50	47/50	47/50	47/50	47/50	47/50	47/50	46/50	46/50	46/50	45/50	44/50	43/50
		96.0	96.0	94.0	94.0	94.0	94.0	94. 0	94.0	92. 0	92.0	92.0	90.0	88.0	86.0

Number of survival/ Number of effective animals Survival rate(%)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj]

REPORT TYPE : A1 104

(HAN360)

### SURVIVAL ANIMAL NUMBERS

STUDY NO.	:	0794
ANIMAL	:	RAT F344/DuCrICrIj[F344/DuCrj]
REPORT TYP	ΡĒ	: A1 104
SEX : FEM/	۱L	E

PAGE: 15

oup Name	Animals	Administ	ration (Wee	ks)											
	At start	84	85	86	87	88	89	90	91	92	93	94	95	96	97
Control	50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	45/50	44/50	44/50	44/50
		92.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	90.0	88.0	88.0	88.0
3.2ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	48/50	47/50	46/50	45/50	43/50	43/50
		98.0	98.0	98.0	98.0	98.0	98.0	96.0	96.0	96.0	94.0	92.0	90. 0	86.0	86.0
8ppm	50	45/50	44/50	44/50	43/50	43/50	43/50	42/50	41/50	41/50	40/50	40/50	40/50	39/50	39/50
		90.0	88.0	88.0	86.0	86.0	86.0	84.0	82.0	82.0	80.0	80.0	80. 0	78.0	78.0
20ppm	50	43/50	43/50	42/50	41/50	41/50	39/50	38/50	38/50	37/50	37/50	37/50	37/50	37/50	37/50
		86.0	86.0	84.0	82.0	82.0	78.0	76.0	76.0	74.0	74.0	74.0	74.0	74.0	74.0

Number of survival/ Number of effective animals Survival rate(%)

STUDY NO. :	0794
ANIMAL :	RAT F344/DuCrlCrlj[F344/DuCrj]
REPORT TYPE	: A1 104
SEX : FEMAL	E

Group Name	Animals	Administ	tration (Wee	eks)				
	At start	98	99	100	101	102	103	104
Control	50	42/50	42/50	42/50	41/50	41/50	41/50	39/50
		84.0	84.0	84.0	82.0	82.0	82.0	78.0
3. 2ppm	50	43/50	43/50	42/50	42/50	42/50	42/50	39/50
		86.0	86.0	84.0	84.0	84. 0	84.0	78.0
8ppm	50	38/50	36/50	36/50	36/50	36/50	36/50	35/50
		76.0	72.0	72.0	72.0	72. 0	72.0	70. 0
20ppm	50	37/50	35/50	34/50	31/50	30/50	30/50	29/50
		74.0	70. 0	68.0	62.0	60.0	60.0	58.0

Number of survival/ Number of effective animals Survival rate(%)

(HAN360)

BA1S5

TABLE C1

CLINICAL OBSERVATION : MALE

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

linical sign	Group Name	Admini	stration We	aek-day											
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
5.4.7.V	<b>0</b>		•		<u>,</u>						0	•			<u> </u>
EATH	Control	0	0 0	0	0	0	0	0	0	0	0 0	0 0	0	0	0 0
	3. 2ppm	0 0	0	0	0	0 0	0	0	0	0 0	0	0	0	0	0
	8ppm 20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
										_	_	_	-	_	_
ORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	õ	0	Ő	õ	Ő	Ō	Ő	Ō	0	Ő	õ	Ō
LYTIC GAIT	8ppm	Ő	õ	ŏ	õ	õ	õ	õ	õ	Ő	õ	õ	õ	ŏ	õ
	20ppm	0	0	0	õ	õ	õ	Õ	Ő	õ	Õ	0	0	0	0
ASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
lo i mu	3. 2ppm	õ	0	0	0	0 0	0	0	0	0	0	0	0	0	0
	8ppm	õ	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			_												
DILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	mqq8	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	Ō	õ	õ	õ	Ő	õ	Ő	õ	Ő	Ő	õ	õ
	8ppm	0	0	0	õ	ů 0	Ő	Ő	ŏ	Ő	Ő	Ő	ő	Ő	Õ
	20ppm	Ō	0	õ	0	0	0	0 0	õ	0	0	0	Ö	Ő	0 0
(OPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	^	0
CONTRACTION CONTRACTOR	3. 2ppm	0	0	0		0	0				0	0	-	0	0
		0	0		0		-	0	0	0	-	0	0	0	1
	8ppm	v	U	0	0	0	0	0	0	0	0	0	0	0	0

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

#### CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

SEX : MALE

-----

.

linical sign	Group Name	Admini	stration W	eek-day											
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
АТН	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	õ	0	Ő	0	Ő	0	0 0	Ő	0 0	ŏ	0	õ	õ	ő
	S. 200m 800m	0	0	0	0	0	0	0	0	0	0 0	0	õ	0 0	0 0
	20ppm	õ	0	0	0	o	õ	0	0	0	0	õ	õ	ő	0
ORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
STING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0	0 0										
)ILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	
TECH LAT GENTIALIA	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
								0	0	0	0	0	0	0	0
	8ppm 20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	0	0	0	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	- 0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

•

•

linical sign	Group Name	Admini	stration W	leek-day				•							
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
EATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	Ō	õ	0	Ō	0	Ō	0	0	Ó	0	0	0
	8ppm	0	0	Ō	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0	0 0								
ASTING		•	•			<u>^</u>	•		•	0	0	•	0	0	•
1011110	Control 3.2ppm	0 0	0	0 0	0	0	0 0	0	0 0	0 0	0 0	0 0	0 0	0 0	0
	3.2ppm 8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	Ő	0 0	0	ŏ	õ	0 0	0	ŏ	ŏ	0	õ	ŏ
	8ppm	Ő	Ő	Ő	Ő	Ő	Ő	ő	Ő	õ	Ő	Ő	Ő	Ő	Ő
	20ppm	0	0	0	o	0	o	0	o	0	o	0	0	0	0
ROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	Ō	0	Ō	Ō	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

Clinical sign	Group Name	Admini	stration W	eek-day							· · · · · · · · · · · · · · · · · · ·				
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
ATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ō	Ō	0	ō	0	Ō	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DRIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
ASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOT INC	3. 2ppm	0	0	0	0	õ	0	0 0	0	0	0	0	Ő	0 0	0
	8ppm	0	0 0	0	Ő	0 0	õ	Ő	0 0	Ő	0 0	0	ů 0	0	ő
	20ppm	õ	Õ	õ	õ	õ	õ	õ	o	Ő	Ő	ő	õ	õ	Ő
OILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

.

.

linical sign	Group Name	Admini	stration W	eek-day											
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
EATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LATH	3. 2ppm	0	0	Ő	0 0	0	Ő	ŏ	0	0 0	ů 0	0	õ	Ő	õ
	8ppm	0	0	0	Ő	0	ŏ	Ő	1	1	1	1	1	1	1
	20ppm	0	ŏ	õ	õ	õ	õ	õ	o	0	1	1	1	1	1
ORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	1	1	3	3	3	3
MOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NLYTIC GAIT	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
ASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
All the	3. 2ppm	0 0	ŏ	Ő	Ő	0	õ	ŏ	õ	õ	Ő	0	0 0	Ő	ŏ
	8 Sppm	0 0	õ	0	0	0	õ	0	0	0	õ	0	õ	Ő	ŏ
	20ppm	õ	0	0	õ	õ	õ	0	ŏ	o	0	õ	0	õ	0
OILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	1	0	0	0	0
OPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

Clinical sign	Group Name	Admini	stration W	leek-day											
	·	71-7	727	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
EATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	3. 2ppm	Ő	õ	Ö	Ő	0 0	Ő	õ	0	0	0	0	ō	0	0
	8 Sppm	1	1	1	2	3	3	3	3	3	3	3	3	3	3
	20ppm	1	1	1	1	1	1	3	3	4	5	6	6	6	6
ORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	3	3	4	4	4	5	6	6	9	10	10	13	13	14
COMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
STING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	1	0	0	0
ROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	1	0	0	0	0
NILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

Clinical sign	Group Name	Admini	stration W	eek-dav			<u> </u>								
Similar argit	u oup wane	85-7	86-7	87-7	88-7	89-7	907	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
EATH	Control	1	1	1	1	1	1	1	2	2	2	3	3	3	3
	3. 2ppm	0	0	0	1	1	1	1	1	1	1	1	1	1	1
	8ppm	3	3	3	3	3	4	4	4	4	5	5	5	5	6
	20ppm	6	6	7	7	7	9	9	9	9	9	9	9	9	9
DRIBUND SACRIFICE	Control	1	1	1	1	2	2	2	2	2	2	2	2	2	2
	3.2ppm	0	0	0	0	0	0	0	0	1	1	2	2	2	2
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	17	17	17	18	20	21	22	23	24	24	24	26	26	27
COMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
STING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	1	1	0	0	0	0	0	0	0	0	0
	20ppm	0	1	0	0	1	0	0	0	0	0	0	1	1	0
ILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

#### CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

SEX : MALE

PAGE : 8

Clinical sign	Group Name	Admin	istration	Week-day			
		99-7	100-7	101-7	102-7	103-7	104-7
DEATH	Control	3	3	3	4	4	6
	3.2ppm	1	1	2	3	3	3
	8ppm	6	6	6	6	8	8
	20ppm	9	9	10	12	13	13
MORIBUND SACRIFICE	Control	2	2	3	3	3	3
	3. 2ppm	2	2	2	2	2	3
	8ppm	1	1	2	2	2	3
	20ppm	27	27	28	28	28	28
	Zuppm	21	21	20	20	20	20
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	1	1	0	0	0	0
	20ppm	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	1	1	1	0
	3. 2ppm	ŏ	0	Ó	0	ò	0
	8ppm	0	0	0	0	0 0	0
	20ppm	0	0	0	0	0	0
WASTING	Control	0	0	0	0	1	1
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0
	3. 2ppm	o	0	0 0	0 0	0	0
	8ppm	Ő	0	0	0 0	0	0
	20ppm	0	ŏ	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0
	8ppm	0	0	1	2	1	1
	20ppm	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0
	3. 2ppm	1	1	1	1	1	1
	8ppm	o o	0	0	0	ò	0
	20ppm	ŏ	Ő	õ	õ	ŏ	1
EXOPHTHALMOS	Control	0	0	0	0	0	0
	3.2ppm	1	1	1	1	0	0
	8ppm	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

SEX : MALE

-

.

Clinical sign	Group Name	Admini	stration W	eek-dav											
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
ATARACT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
JATANAO I	3. 2ppm	0	0	0	0	Ő	0 0	õ	0 0	õ	0	õ	ů 0	õ	ŏ
	8ppm	Ő	0 0	Ő	õ	Ő	0 0	õ	ő	0	ŏ	õ	õ	õ	õ
	20ppm	0	õ	õ	õ	0	õ	õ	ŏ	ō	õ	õ	õ	õ	0
ORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
XTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
NTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	õ	õ	õ	õ	õ	Ő	Ő	õ	0	õ	õ	õ	õ	ő
	8ppm	õ	ŏ	Õ	õ	ů 0	Ő	0	ŏ	Ő	Ő	ŏ	Ő	Ő	õ
	20ppm	ō	0	0	Ō	Ő	õ	Ő	Ō	õ	Ő	Ő	ō	0	0
. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
. EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

SEX : MALE

CATARACT

Clinical sign

CORNEAL OPACITY

EXTERNAL MASS

Group Name Administration Week-day 26-7 27-7 15-7 16-7 17-7 18-7 19-7 20-7 21-7 22-7 23-7 24-7 25-7 28-7 Control 3.2ppm 8ppm 20ppm Control 3.2ppm 8ppm 20ppm ANTERIOR CHAMBER OPACITY Control 3, 2ppm 8ppm 20ppm Control 3.2ppm 8ppm 20ppm 

	ZUppm	U	0	0	0	0	0	0	U	U	0	0	U	U	U	
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	20ppm	0	Ō	0	0	0	0	Ő	0 0	0	0	0	0	Ō	0	
M. EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	٥	
111, L. I L.	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	3. 2ppm 8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2000	U	U	U	U	v	U	v	U	U	U	v	U	U	U	
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
M.ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	3. 2ppm	0	0	0	0	0	0	Ő	Ő	0 0	0	Ō	Ő	0	0	
	8ppm	0	Ō	0	0	Ő	õ	Õ	ō	õ	õ	0 0	õ	õ	0	
	20ppm	Ő	Ő	Ő	õ	õ	Ő	Ő	Ő	0	ů	ů	ů 0	õ	õ	
			-	-	·	Ŭ	Ŭ	Ū	0	0	0	U	•	Ū	•	

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

SEX · MALE															TAUL -
Clinical sign	Group Name	Administration Week-day													
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
ATADAOT	Control	4	,	1	1	4		0	0	0	0	0	2	2	2
CATARACT	Control 3.2ppm	1 0	1 0	1 0	1 0	1 0	1 0	2 0	2 1	2 1	2 1	2	2	2	2
	3. 200m 800m	1	1	2	2	3	3	3	3	3	3	3	3	2 3	3
	20ppm	0	0	0	0	0	0	0	õ	0	ő	ő	ő	õ	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0	0	0 0	1 0	1 0	1 0	1 0	1	1 1	1 1
INTERNAL MASS		•	•	0			0				0	•	0	0	0
	Control	0	0 0	0	0 0	0	0	0	0	0	0	0	0 0	0	0 0
	3.2ppm 8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	o	0	0	0	0	0	o	0	0	0	0
M. NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

Clinical sign	Group Name	Admini	stration W	eek-dav											
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
ATARACT	Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	3. 2ppm	2	2	2	2	3	3	3	4	4	4	4	4	4	4
	8ppm	3	3	3	3	3	3	4	4	4	4	4	4	5	5
	20ppm	0	õ	ō	0	0	0	0	0	0	0	0	0	0	0
DRNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
XTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	2	2	2	2	2
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	8ppm 20ppm	1 1	1 1	1 1	1	1 1	1 2	1 3							
NTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ō	ō	0	Ō	0	0	0	0	õ	0	Ō	õ	Ō	Ō
	8ppm	0	0	0	Ō	0	0	0	Ō	0	Ō	0	0	Ō	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EYE	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	1 0	1 0	1 0	1 0	1 0	1 1	1 1	1 1	1	1	1	1 1	1 1	1
ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0 0	0	0	0	0	0	ŏ	0	0	0	0	0	0
	8ppm	0 0	õ	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	õ	0	Ő	0	0	0	0	0 0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

## SEX : MALE

-----

.

Clinical sign	Group Name	Admini	stration W	leek-dav											
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
ATARACT	Control	2	2	3	3	3	3	3	3	3	3	3	3	3	3
	3. 2ppm	4	4	4	4	4	4	4	4	4	4	4	4	4	4
	8ppm	5	5	5	5	5	5	5	4	4	4	4	4	4	4
	20ppm	0	Ö	õ	õ	0	õ	Ö	0	0	0	0	0	0	0
ORNEAL OPACITY	Contro I	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NTERIOR CHAMBER OPACITY	Control	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
KTERNAL MASS	Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	3. 2ppm	1	1	2	2	2	2	2	2	2	2	2	2	3	3
	8ppm 20ppm	2 3	2 3	2 3	2 3	3 3	3 4	3 5	4 5	4 5	4 5	3 4	3 5	3 7	3 7
NTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ő	õ	Õ	ŏ	õ	Ő	õ	ŏ	ő	ŏ	ő	ŏ	õ	Ő
	8ppm	0	ő	õ	õ	0	0 0	ŏ	0 0	0	0	0	õ	õ	0
	20ppm	0	0	Ő	õ	ŏ	õ	ō	õ	õ	õ	õ	õ	õ	0
NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	Ō	0	Ō	0	0	Ō	0	0	0	0	0
	20ppm	0	0	0	0	0	0	1	1	1	1	õ	0	õ	0
EYE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

-----

•

															1 Auc
linical sign	Group Name		stration W												
		71-7	72-7	73–7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
TADAOT	0					-	-	-	-	F	r	c	-	-	-
TARACT	Control	3	3	3	3	5	5	5	5	5	5	5	5	5	5
	3. 2ppm	4	4	4	4	4	4	4	4	4	4	4	4	4	4
	8ppm	4	4	4	4	4	4	4	4	4	4	4	5 1	5 1	5
	20ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
RNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	0	0	0	0	0	0	0
	20ppm	0	0	0	0	1	1	0	0	0	0	0	0	0	0
TERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3, 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TERNAL MASS	Control	2	2	2	2	2	2	2	2	3	4	4	4	3	3
	3. 2ppm	3	3	3	4	5	6	6	6	6	6	6	7	7	7
	8ppm	5	5	5	5	5	5	5	5	5	5	5	5	4	7
	20ppm	7	8	7	7	7	6	6	3	5	5	6	6	7	, 7
TERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ő	Ő	ŏ	õ	ő	õ	Õ	Ő	0 0	õ	Ő	õ	õ	ő
	8ppm	ŏ	0	ő	0	Ő	õ	õ	Õ	õ	0 0	0	Ő	0 0	Ő
	20ppm	õ	0	õ	0	Ő	õ	0	0 0	0 0	0	0	o	0	Ő
NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ő	Ő	Ő	0	õ	ŏ	õ	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0		
	20ppm	ŏ	1	0	0	0	0	0	0	0	0	1	0	0 0	0 0
EYE	Control	1		1											
		•	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	1 0	1 0	1 0	1 0	1 0	1 0	1 0	1 0	1 0	1 0	1 0	1 0	1 0	1 0
		-	-	-	•	Ť		č	ŭ	č	v	v	v	v	Ū
PERI-MOUTH	Control 3.2ppm	1 0	1 0	1 0	1 0	1 0	1	1	1	1	1 0	1	1	1	1
		1	1				0	0	0	0	-	0	0	0	0
	8ppm 20ppm	1	1	1 1	1 1	1 1	1	1	1	1	1	1	1	0 1	0 1
ORAL CAVITY	Orature 1	0	<u>^</u>	<u>^</u>	~	^	-	•	•	~	~	-	•	•	•
	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

Clinical sign	Group Name	Admini	stration W	eek-dav											
		85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
ATARACT	Control	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	3. 2ppm	4	4	4	4	4	5	5	5	5	5	5	5	5	5
	8ppm	5	5	5	6	6	6	6	6	6	6	6	6	6	6
	20ppm	1	1	1	1	1	õ	Ő	õ	0	0	0	0	0	0
DRNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ITERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(TERNAL MASS	Control	4	4	4	4	4	5	5	4	4	4	4	6	6	6
	3. 2ppm	7	7	8	7	8	10	10	10	9	9	8	8	8	9
	8ppm 20ppm	8 6	8 6	10 6	10 7	10 6	10 3	10 5	10 7	10 7	11 7	10 7	10 8	10 8	10 8
ITERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	ō	õ	0	0	0	0 0	Ō	ō	0	0	Ō	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	1	1	1	1	1	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	1	1	0	0	0	1	0	0	0	0	0	0
EYE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PERI-MOUTH	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	2
ORAL CAVITY	Control	0	0	0	0	0	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] REPORT TYPE : A1 104

## CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Admin	istration N	Neek-day					
		99-7	100-7	101-7	102-7	103-7	104-7		
				1				•	
CATARACT	Control	5	5	5	5	5	6		
	3. 2ppm	5	5	5	5	5	5		
	8ppm	6	6	5	5	5	6		
	20ppm	0	0	0	0	0	0		
CORNEAL OPACITY	Control	0	0	0	0	0	0		
	3. 2ppm	0	0	0	0	0	0		
	8ppm	0	0	0	0	0	0		
	20ppm	0	0	0	0	0	0		
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0		
	3. 2ppm	0	0	0	0	0	0		
	8ppm	0	0	0	0	0	0		
	20ppm	0	0	0	0	0	0		
		_	-						
EXTERNAL MASS	Control	6	6	5	4	4	4		
	3. 2ppm	10	10	10	10	11	10		
	8ppm	10	10	11	14	14	14		
	20ppm	8	8	7	6	5	5		
	Osmt	•	0	0	0		0		
INTERNAL MASS	Control	0	0	0 0	0	1 0	0		
	3. 2ppm	0	0		0		0		
	8ppm 20ppm	0 0	0	0 0	0 0	0 0	0 0		
	zoppii	U	U	U	U	U	U		
M. NOSE	Control	0	0	0	0	0	1		
	3. 2ppm	ŏ	ő	0 0	0 0	õ	, O		
	8ppm	õ	Ő	õ	Ő	Ő	ů 0		
	20ppm	ō	0	õ	0	Ő	Ő		
	2000	Ŭ	Ū	v	Ū	Ū	Ū		
M. EYE	Control	1	1	1	1	1	1		
	3.2ppm	0	0	Ó	0	0	0		
	8ppm	1	1	1	1	1	1		
	20ppm	0	0	0	0	0	0		
M. PERI-MOUTH	Control	1	1	0	0	0	0		
	3. 2ppm	0	0	0	0	0	0		
	8ppm	0	0	0	0	0	0		
	20ppm	2	2	1	1	1	1		
N. ORAL CAVITY	Control	1	1	1	1	1	1		
	3.2ppm	0	0	0	0	0	0		
	8ppm	0	0	0	0	0	0		
		0	0	0					

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

## SEX : MALE

our · mail															,,,,,,
Clinical sign	Group Name		stration W												
		1–7	2–7	3–7	4-7	5-7	6-7	7–7	8-7	97	10-7	11-7	127	13-7	147
. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ö	ů 0	0 0	0	Ő	Ö	0	0	Ö	õ	0	õ	õ	ő
	8ppm	0	õ	õ	õ	0	0	õ	Ő	Ō	õ	ů 0	õ	õ	Ő
	20ppm	0	Õ	õ	õ	Ő	0	õ	õ	Ő	0	õ	õ	õ	0
PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VEMTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

\*\*\*\*\*

Clinical sign	Group Name	Admini	stration W	eek-day											
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
I. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
I. LAN		0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm						-	0			0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	U	U	0	U	U	U	U	0
. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ő	Õ	õ	õ	õ	õ	õ	õ	õ	ů 0	ŏ	Õ	õ	Ő
	8ppm	ŏ	Ő	ő	0 0	Ő	õ	õ	ő	Ő	õ	õ	õ	Ő	ő
	20ppm	õ	Ő	0	Ö	0	o	0	Ő	0	0	0	0	0	0
ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
, ABBUNLN		0	0			0	0			0		0	0	0	0
	3. 2ppm			0	0			0	0		0				
	8ppm 20nnm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	Ó	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	õ	ō	õ	õ	0 0	Ő	Õ
	20ppm	Ő	0	õ	0	õ	õ	0	õ	ŏ	õ	0	0	0	0
. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0		0				0		-		
		0				0		0	0	0		0	0	0	0
	8ppm 20ppm	0	0 0	0	0 0	0 0	0 0	0 0	0 0	0 0	0	0 0	0 0	0	0 0
	zoppiii	v	U	U	v	v	v	v	v	v	v	U	v	U	U
. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	Ō	Ō	0
	20ppm	0	0	0	0	0	0	Ō	Ō	õ	0	0	Õ	0 0	Õ

STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

Clinical sign	Group Name	Admin	istration W	eek-day											
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
I. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	õ	0	0 0	0	0	0	ő	0 0	0	0	0	ŏ	0 0	0
		0	0	0	0	0	0	0 0	0 0	0 0	0	0	0	0	ő
	20ppm	0	õ	0	õ	0	ő	õ	õ	õ	õ	õ	õ	õ	0
. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0	0 0								
. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	•	0	0
. ANTERTON. DORGOM	3. 2ppm	0	0	0	0	0	0	0	0	0 0	0	0	0	0 0	0 0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	õ	o	o	ō	ő	ŏ	ō	õ	õ	õ	õ	1	1	1
POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0	0 0	0 0	0 0	0 0
												-			
NEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

-

•

Clinical sign	Group Name	Admini	stration W	eek-dav											
		437	44-7	45-7	46-7	47-7	48-7	497	50-7	51-7	52-7	53-7	54-7	55-7	56-7
EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	õ	Ő	0	0 0	0 0	Ő	Ō	Ō	Ő	Ő	õ	õ	0
	8ppm	õ	ŏ	Ő	õ	0	Ő	õ	Ő	0	Ő	õ	õ	õ	Ő
	20ppm	0	0	0	õ	0	0	Ō	0	0	0	0	0	0	0
PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
ANTERIOR, DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	õ	Õ	ō	ŏ	õ	õ	0 0	ő	õ	õ	õ	ŏ	õ	ŏ
	8ppm	Ō	0	Ō	Ō	Ő	õ	ō	õ	õ	õ	õ	0	õ	õ
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

.

•

Clinical sign	Group Name	Admini	istration W	eek-day											
-	-	57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
	Quarters I		0	<u>,</u>		<u>,</u>	<u> </u>	•		<u> </u>			0	•	^
I. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 80ppm	0 0	0	0	0	1	1	1	1	1	1	1	1	1	1
	20ppm	U	0	0	0	0	0	0	0	0	0	0	0	0	0
. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3. 2ppm 8ppm	ò	ò	0	0	0	0	0	ò	0	0	0 0	0	0	0
	20ppm	0	0	0	ŏ	0	0	0	0	0	0	0	0	0	0
ABDOMEN	0	~	~	~	~	~	~	•	~	~	•	-	-	•	~
. ABDUMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0	0	0 1	0 1
	Ζυρμα	U	U	U	U	U	U	U	U	U	U	U	1	1	1
. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	8ppm	0	0	0	0	0	0	0	1	1	1	0	0	0	0
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	2	2
POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	Ō	0	Ō	0	0	Ō	0
	8ppm	0	0	0	0	0	Ō	0	Ō	0	Ő	õ	Ő	0 0	õ
	20ppm	1	1	1	1	1	2	2	2	2	2	2	2	3	3
HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0		0
	3. 2ppm 8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0	0	•			_		_		-					
. GENITALIA	Control 2 2nnm	0 0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm		0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0	0 0	0 0	0 0	0 0	0	0	0	0	0	0	0	0
	zoppm	U	v	U	U	U	U	0	U	0	U	0	0	0	0
NEM I A	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	1	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

SEX : MALE

.

\*

Clinical sign	Group Name	Admini	stration W	eek-day											
		71-7	72-7	73-7	747	757	76-7	77–7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
I. EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
. LAN	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm 8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	o	0	0	Ó
PERI EAR	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	1	1	1	2	2	2	2	3	3	3	3	3	3	3
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
I. ABDOMEN	Control	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	3. 2ppm	1	1	1	1	2	2	2	2	2	2	2	2	2	2
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
ANTERIOR, DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	1	1	1	1	1	2	2	2	2	2	2	3	3	3
	8ppm 20ppm	1 2	1 2	1 2	1 2	1 2	1 2	1 2	1 0	1 2	1 2	1 2	2 2	2 3	3 3
	ΖΟΡΡιά	2	2	2	2	2	2	Z	U	Z	Z	Z	2	3	ა
.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	3	3	3	3	3	2	2	1	1	1	1	2	2	2
.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	1	0	0	0	0	0	1

•

STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] REPORT TYPE : A1 104

## SEX : MALE

-----

-

linical sign	Group Name	Admin	istration W	leek-day											
		85-7	86-7	877	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
. EAR	Control	0	· 0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ő	Ő	õ	Ő	Õ	0	õ	õ	0 0	ů 0	õ	õ	0	Ő
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
PERI EAR	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BREAST	Control	1	1	1	1	1	1	1	0	0	0	0	1	1	1
	3. 2ppm	3	3	3	2	2	2	2	2	2	2	2	2	2	3
	8ppm	1	1	2	2	2	2	2	2	2	2	2	2	2	2
	20ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
ABDOMEN	Control	1	1	1	1	1	1	1	1	1	1	1	2	2	2
	3. 2ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	8ppm 20ppm	1 1	1 1	2 1	2 1	2 1	2 0	2 0	2 2	2 2	2 2	2 2	2 2	2 2	2 1
ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANTERTOR. DORSON	Control 3.2ppm	3	3	4	0 3	4	4	4	4	3	3	3	3	3	3
	3. 2ppm 8ppm	3	3	3	3	3	3	3	3	3	4	4	4	4	4
	20ppm	2	2	1	1	1	0	1	2	2	2	2	2	2	3
POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	1	1	1	1	1	1	1	1	1
	8ppm	1	1	1	1	1	1	1	1	1	1	0	0	0	0
	20ppm	2	2	2	3	3	2	2	1	1	1	1	1	1	1
HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	1
GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0	0 0	0 0	0 1	0 1	0 1
EMIA	Control	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	3. 2ppm	0	0	0	ŏ	0	0	0	1	0	0	0	0	0	0
	8ppm	0 0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	1	0	0	0	0	0	0	0	0	0	1	0	0	0

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

### CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

SEX : MALE

PAGE : 24

\_\_\_\_\_

SEX - MALE								
Clinical sign	Group Name	Admini	stration	Week-day _			t	
· · · · · · · · · · · · · · · · · · ·		99-7	100-7	101-7	102-7	103-7	104-7	
M. EAR	Control	0	0	0	0	0	0	
	3. 2ppm	0	0	0	0	0	0	
	8ppm	1	1	1	1	1	1	
	20ppm	1	1	1	1	1	1	
M. PERI EAR	Control	1	1	1	0	0	0	
	3.2ppm	0	0	0	0	0	0	
	8ppm	0	0	0	0	0	0	
	20ppm	0	0	0	0	0	0	
M. BREAST	Control	1	2	1	1	2	2	
	3.2ppm	4	5	5	5	6	6	
	8ppm	2	2	2	2	2	2	
	20ppm	1	1	1	1	0	0	
M. ABDOMEN	Control	2	2	2	2	1	1	
	3. 2ppm	2	2	2	2	2	2	
	8ppm	2	2	2	3	3	3	
	20ppm	1	1	2	1	1	1	
M. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	
	3. 2ppm	3	2	2	2	2	1	
	8ppm	4	4	4	6	6	6	
	20ppm	3	3	3	2	2	3	
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	
	3.2ppm	1	1	2	2	2	2	
	8ppm	0	0	2	2	2	2	
	20ppm	2	2	1	1	1	1	
M. HINDLIMB	Control	0	0	0	0	0	0	
	3. 2ppm	Ő	ŏ	ů	õ	Õ	0	
	8ppm	ů	õ	Ö	Ő	0	0	
	20ppm	1	1	1	1	ů 0	0	
M. GENITALIA	<b>Contro I</b>	0	0	0	0	0	0	
	3. 2ppm	0	Ő	Ő	0	0	0	
	8ppm	0	0	0	0	Ő	0	
	20ppm	1	1	1	1	1	1	
NEMIA	Control	1	2	2	0	0	1	
msiii (7)	3. 2ppm	0	2	2	0 0	0 0	1 0	
	3.2ppm 8ppm							
		0	0	3	2	1	2	
	20ppm	0	0	2	1	0	0	

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

SEX : MALE

Clinical sign	Group Name	Admini	stration W	eek-day											
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
LCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3, 2ppm	õ	ő	õ	0 0	0 0	0 0	0 0	0	õ	ő	ů	ő	Õ	õ
	8ppm	0 0	Ő	õ	õ	0 0	Ő	ŏ	0 0	õ	õ	ő	ő	Ő	õ
	20ppm	0	õ	õ	õ	õ	õ	õ	õ	õ	õ	õ	õ	õ	0
OSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

PAGE : 26

Clinical sign	Group Name	Admini	stration W	eek-day											
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
LCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
COLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	Ō	Ö	Ō	Ō	0	Ō	Ő	Ō	0	0	Ō
	8ppm	0	0	0	0	ō	Ō	0 0	0	0	0	õ	0	Ō	ō
	20ppm	0	ō	0	õ	õ	õ	õ	0	0	õ	õ	õ	0 0	Ő
SPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ō	Ő	Ő	õ	õ	õ	õ	ů 0	0	õ	ŏ	õ	0	ŏ
	8ppm	0	Õ	õ	ŏ	õ	ő	ŏ	õ	Ő	ů	õ	ŏ	õ	Ő
	20ppm	0	0	0	Ő	o	Õ	0	õ	o	0	0	õ	0	0
DISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	õ	Ő	0	Ő	ŏ	0	0	0	0	0	0	0	0 0	0
	8ppm	ŏ	0	0	0	0 0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

(HAN190)

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] REPORT TYPE : A1 104

## CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Admini	stration N	leek-day											
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	407	41-7	42-7
JLCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	- 0
	3, 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm 8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ő	õ	0	õ	õ	õ	õ	õ	õ	0 0	0	õ	Ő	0
	8ppm	Ő	õ	õ	Ő	õ	Ő	Ő	õ	õ	Ő	õ	ő	Ő	õ
	20ppm	0 0	õ	õ	õ	0	õ	õ	0	õ	õ	0	õ	0	0
EMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	mqq8	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

(HAN190)

BAIS 5

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

## CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

## SEX : MALE

Clinical sign	Group Name	Admini	stration W	eek-day											
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
JLCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	Ó	0	0	0	0	0	0	0	0	Ō	Ō
	8ppm	0	0	0	0	Ő	Ō	0	0	Ő	õ	õ	õ	õ	õ
	20ppm	0	0	0	0	0	0	0	0	0	õ	0	0	õ	0
ESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ō	Ō	0	Õ	õ	0	Õ	õ	õ	Ő	õ	õ	õ	ŏ
	8ppm	õ	Ő	õ	õ	õ	ŏ	Ő	Ő	Ő	õ	Ő	0	0	0
	20ppm	õ	0	õ	ő	ŏ	õ	0	õ	õ	o	õ	0 0	õ	0
OISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	õ	Õ	õ	0	õ	õ	Ő	õ	ő	õ	õ	0	0	ő
	8ppm	ů	Ő	õ	0	õ	ŏ	0	0	0 0	0 0	0	õ	0	Ő
	20ppm	ŏ	õ	õ	ŏ	õ	ŏ	Ő	0	0	0	0	0	0	0 0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

PAGE : 29

Clinical sign	Group Name	Admini	istration W	leek-day											
-	-	57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
ULCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	Ó	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	Ō	0	0	Ō	0
	8ppm	0	ō	0	ō	Ő	Ō	Ō	õ	õ	õ	õ	õ	õ	õ
	20ppm	ō	0	0	0	õ	0	0	Ő	0	Ő	0	0	0	Ő
ROLAPSE OF PENIS	Control	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	Ō	0	0	Ō	ō	Ő	0	õ	Ō	Ő	Ő
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	ō	0	ō	0	0	Ő	ō
	8ppm	0	Ō	0	Ō	õ	õ	Õ	ŏ	õ	Ő	Ő	ŏ	Ő	Ő
	20ppm	0	Ő	0	õ	õ	1	2	2	2	1	õ	o	Ő	0
ESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	ō	õ	Ő	Ő	ů	õ	õ	õ	õ	õ	õ	ŏ	ŏ	0 0
	8ppm	õ	Õ	õ	õ	õ	õ	õ	õ	õ	0	ő	Ö	Ő	Ő
	20ppm	õ	Ő	0	õ	Ő	õ	0	õ	ŏ	0	o	0	0	0
OISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0 0	ő	0	0	0 0	0 0	0	0	0	0	0	0	0	0
	8ppm	0	õ	0	0 0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	Ő	0	0	0	0	0	0	0	0	0	0	0	0
	zoppiii	v	U	U	U	U	U	U	U	U	U	U	U	U	

(HAN190)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

## SEX : MALE

PAGE : 30

Clinical sign	Group Name	Admini	stration W	eek-day											
·····	- 	71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
JLCER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	3. 2ppm	0	0	0	0	Ō	0	0	0	Ō	0	0	0	0	Ó
	8ppm	0	0	0	Ō	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	3. 2ppm	Ō	0	Ō	0	õ	0	õ	Ő	õ	õ	, O	õ	õ	Ő
	8ppm	0	Ő	Ő	õ	0 0	õ	ŏ	õ	Ő	0 0	0 0	õ	Ő	ő
	20ppm	0	1	1	1	1	2	Ő	3	2	2	4	1	2	3
ESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	õ	0	õ	õ	õ	ŏ	õ	õ	õ	0	õ	õ	õ	ő
	8ppm	Ō	Õ	0	ŏ	õ	Ő	õ	Ő	0	õ	Ő	ő	õ	Ő
	20ppm	0	0	ů 0	ō	õ	õ	õ	2	2	ŏ	1	0 0	0	0
01SY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	õ	õ	Ő	Ö	0	0 0	0	0	0	0 0	0 0	0	0 0	0
	8ppm	õ	ő	0	0	0	0	0	0 0	0	0	0	0	0	0
	20ppm	Ő	õ	0	1	1	1	0	0	0	2	2	1	1	2

(HAN190)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : MALE

linical sign	Group Name	Admini	stration W	leek-day											
		85-7	867	87-7	88-7	89-7	90-7	91-7	927	93-7	94-7	95-7	96-7	97-7	98-7
CER	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0 0	0	Ő	0	0	õ	0	0	0	õ	0	0	0	ő
	8ppm	0 0	1	1	1	1	i i	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	o o	0	ò	o	0	0	Ó	0	o	0
OSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORRHAGE	Control	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OLAPSE OF PENIS	Control	1	1	1	1	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REGULAR BREATHING	Control	0	0	1	1	1	1	1	1	1	2	2	2	2	2
	3. 2ppm	0	0	0	0	0	0	0	1	1	2	1	1	1	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	20ppm	0	1	2	3	2	1	0	2	1	2	2	1	1	3
SPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	1	2	2	1	1	0	1	1	1	1	0	0	0

## STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] REPORT TYPE : A1 104

## CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

## SEX : MALE

PAGE : 32

Clinical sign	Group Name	Admin	istration	Week-day				
orrinoar urgit	а сар намо	99-7	100-7	101-7	102-7	103-7	104-7	
ULCER	Control	0	0	0	0	0	0	
	3.2ppm	0	0	0	0	0	0	
	8ppm	1	1	0	0	0	0	
	20ppm	0	0	0	0	0	0	
EROSION	Control	1	0	0	0	0	0	
	3. 2ppm	0	0	0	0	0	0	
	8ppm	0	0	0	0	0	0	
	20ppm	0	0	0	0	0	0	
HEMORRHAGE	Control	0	0	0	0	0	0	
	3.2ppm	0	0	0	0	0	0	
	8ppm	0	0	0	0	0	0	
	20ppm	0	0	0	0	0	0	
PROLAPSE OF PENIS	Control	0	0	0	0	0	` O	
	3.2ppm	0	0	0	0	0	0	
	8ppm	0	0	0	0	0	0	
	20ppm	0	0	0	0	0	1	
IRREGULAR BREATHING	Control	2	2	2	1	1	1	
	3. 2ppm	1	õ	1	1	i	1	
	8ppm	1	1	, O	ò	1	0	
	20ppm	3	4	3	1	1	1	
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	
	3. 2ppm	0	0	0	0	0	0	
	3. 2ppm 8ppm	0	0	0	0	0		
	20ppm	0	0	0	0	0	0	
	Ζυμριιι	v	U .	U	v	U	U	
NOISY	Control	0	0	0	0	0	0	
	3.2ppm	1	1	1	1	1	0	
	8ppm	0	0	0	0	0	0	
	20ppm	2	2	0	0	Ō	0	

TABLE C2

CLINICAL OBSERVATION : FEMALE

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : FEMALE

linical sign	Group Name	Adminis	stration We	ek-day											
		1-7	27	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
EATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	õ	õ	0	0	0	Ő	0 0	õ	õ	õ	õ	Ő	ŏ	ŏ
	8ppm	õ	õ	Ő	Ő	0 0	õ	õ	Õ	Ő	õ	õ	0	ō	0
	20ppm	0	õ	õ	õ	Ő	õ	Ő	0	0	õ	õ	Ő	Õ	0
RIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
COMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
AXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
RALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Õ	õ	ō	õ	õ	ŏ	õ	Ő	Ő	õ	Õ	õ	õ	Ő
	8ppm	Ő	Ő	õ	0 0	õ	õ	0 0	Ő	ő	õ	Ő	Ő	õ	õ
	20ppm	0	Ō	0	0	0	0	õ	0	0	0	0	0	Ő	0
STING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
ILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	•	0	0
TEED TENT VENTILEIN	3. 2ppm	0	0	0	0	0	0	0		0	0	0 0	0	0	0
	3. zppm 8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

3.2ppm

8ppm

20ppm

Control

3.2ppm

8ppm

20ppm

SEX : FEMALE

SOILED PERI-GENITALIA

DEATH

Group Name Administration Week-day 15-7 18-7 19-7 20-7 21-7 22-7 23-7 24-7 25-7 26-7 27-7 28-7 16-7 17-7 Control 3. 2ppm 8ppm 

	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3, 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		-	-												

PAGE : 34

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : FEMALE

----

OLA - I CAALE															1102
Clinical sign	Group Name	Admin	istration W	leek-day											
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
EATH	Control	0	Ö	0	0	0	0	0	0	0	0	0	0	0	0
LAIN	3, 2ppm	0	0	0	0	0	0	0	0	õ	0	0	ŏ	0 0	õ
	8ppm	0	Ő	0	0	ő	0 0	0	0	0	0	Ő	0 0	õ	ŏ
	20ppm	Ő	õ	õ	õ	õ	õ	õ	õ	õ	õ	Õ	Ő	0	õ
RIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
COMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0 0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	U	0	U	U	0
AXIC GAIT	Control	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0	0 0	0 0	0 0	0 0
	3. 2ppm	0	0			0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0	0	0 0	0 0	0	0	0	0	0	0	0	0	0	0
RALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3, 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
STING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
ILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	1	1	0	0	1
	3, 2ppm	ő	0	õ	0	Ö	0	0	Ő	0	0	Ó	Ő	0	0
	8ppm	Ő	0	0	0	0 0	0	0	0	0	0	ŏ	õ	ŏ	0
	20ppm	ŏ	õ	õ	Ö	õ	õ	õ	Ő	õ	Ő	Ő	õ	Ő	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : FEMALE

															17102 1
Clinical sign	Group Name	Admin	istration W	eek-day					· · ····						
		43-7	44-7	45-7	46-7	477	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
F 4 T 1	Questions 1	•	<u>,</u>	0	•	<u>^</u>	•	0	0	0	0	0	0	0	0
EATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	1 0	1 0	1 0	1 0	1 0
ORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
COMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0	0 0	0 0	0	0 0	0 0	0	0 0	0 0	0	0 0	0 0	0 0
ARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ő	ō	ő	ŏ	0 0	0	0	0	0	õ	0	0	0	0
	8ppm	Ő	0 0	õ	ŏ	0	0 0	1	1	0	õ	0	0	ő	0
	20ppm	0	õ	0	õ	0 0	õ	0	0	õ	õ	0	Ö	õ	õ
ASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
ROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] REPORT TYPE : A1 104

### CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

## SEX : FEMALE

Clinical sign	Group Name	Admini	stration W	eek-day											
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
ATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LATH	3. 2ppm	0	0	0	0	0	ŏ	0	0	0	0	0	0	0	0
	0. 2ppm 8ppm	1	2	2	2	2	2	2	2	2	2	2	2	2	2
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
ORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	1	1	1	1	1	1	1	1	1	1	1	1	1
COMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0	0 0	0	0	0	0	0	0 0	0	0	0	0 0	0 0
	ZOPPii	U	0	U	Ū	0	U	U	0	U	U	0	U	U	0
RALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
STING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

.

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

# SEX : FEMALE

DEATH	Control	0	0	0	0	0	2	2	2	2	2	2	2	3	3
	3. 2ppm	0	Õ	ō	0	Ő	0	ō	0	ō	0	0	0	0	0
	8ppm	2	2	2	2	2	2	2	2	3	3	3	3	4	4
	20ppm	1	2	2	2	2	2	2	2	2	2	2	2	2	2
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	3. 2ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	8ppm	0	0	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	1	1	1	1	1	1	1	2	2	2	3	4	5	5
LOCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	Ō	0	0
	8ppm	õ	Ő	õ	õ	Ő	ő	Ő	Ő	õ	0 0	Ő	õ	õ	õ
	20ppm	0	0	õ	Ő	0	0 0	õ	0	Ő	ů 0	0	õ	0	õ
ATAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ő	õ	ŏ	Ő	0	õ	õ	0 0	Ő	0 0	Ő	õ	õ	õ
	8ppm	Ő	Ő	ŏ	ő	Ő	õ	ő	0 0	õ	õ	õ	õ	õ	õ
	20ppm	1	Ö	õ	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0 0	0	õ	0	0	0	0	0	0	õ
	3. 2ppm 8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	õ	0	ŏ	0	0	0	0 0	0	0	0	0	0	õ	0
	3. 2ppm 8ppm	0	0	0	0				-				-	-	-
						0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	oppin	•	-	-	•		•		0	0	0	•	•	•	

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

### CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Admini	stration W	eek-dav											
		857	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97–7	98-7
EATH	Control	3	3	3	3	3	3	3	3	3	3	A	4	4	5
LAID	3. 2ppm	0	0	0	0	0	0	0	õ	1	1	4			1
	0.2ppm 8ppm	4	4	4	4	4	5	6	6	6	6	, 6	6	6	6
	20ppm	2	3	3	3	4	5	5	6	6	6	6	6	6	6
RIBUND SACRIFICE	Control	1	1	1	1	1	1	1	1	1	2	2	2	2	3
	3.2ppm	1	1	1	1	1	2	2	2	2	3	4	6	6	6
	8ppm	2	2	3	3	3	3	3	3	4	4	4	5	5	6
	20ppm	5	5	6	6	7	7	7	7	7	7	7	7	7	7
COMOTOR MOVEMENT DECR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	1	0	0	0	0	0	0	0	0	0	0
TAXIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
ARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ō	õ	Ő	Õ	Ő	õ	õ	õ	õ	õ	õ	õ	õ	Ő
	8ppm	Ő	Ő	Ő	Õ	0	õ	Õ	õ	Õ	Ő	õ	õ	õ	0
	20ppm	0	0	0	Ō	Õ	Õ	Ō	õ	Ő	Ō	0	Ō	0	0
ASTING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	1	0	0	0	0	0	0	0	0	0	0	0	1
ILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	1	1	1	0	0	0	1	0	0	0
	20ppm	0	0	0	1	0	0	0	0	0	0	0	0	0	0

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

## CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

SEX : FEMALE

SEX · FEMALE								PAG
Clinical sign	Group Name	Admin	istration W	Yeek-day				
		99-7	100-7	101-7	102-7	103-7	104-7	
~ * 7 1 1		-	-	-		-		
EATH	Control	5	5	5	5	5	6	
	3.2ppm	1	2	2	2	2	3	
	8ppm	6	6	6 7	6	6	7	
	20ppm	6	7	/	7	7	8	
ORIBUND SACRIFICE	Control	3	3	4	4	4	5	
	3. 2ppm	6	6	6	6	6	8	
	8ppm	8	8	8	8	8	8	
	20ppm	9	9	12	13	13	13	
OCOMOTOR MOVEMENT DECR	Control	0	0	0	0	0	. 0	
	3.2ppm	0	0	0	0	1	0	
	8ppm	0	0	0	0	0	0	
	20ppm	0	0	0	0	0	0	
TAXIC GAIT	Control	0	0	•	0	0	0	
	Control	0		0	0	0	0	
	3. 2ppm	0	0	0	0	0	0	
	8ppm 20ppm	0 0	0 0	0 0	0	0 0	0 0	
	zoppiii	U	U	U	U	U	U	
ARALYTIC GAIT	Control	0	0	0	0	0	0	
	3. 2ppm	0	0	0	0	0	0	
	8ppm	0	0	0	0	0	0	
	20ppm	0	0	0	0	0	0	
ASTING	Control	0	0	0	0	0	0	
norma	3. 2ppm	0	0	0	0	0 1	0 0	
		0	0	0				
	8ppm 20ppm	0	0	0	0	0	0 0	
	zoppiii	0	v	v	U	U	v	
TLED	Control	0	0	0	0	0	0	
	3.2ppm	0	0	0	0	0	0	
	8ppm	0	0	0	Ō	0	0	
	20ppm	0	0	0	0	ō	0	
ROG BELLY	Control	0	0	0	0	0	0	
	3. 2ppm	0	0	0	0	0	0	
	8ppm	0	0	0	0	0	0	
	20ppm	0	0	0	0	0	1	
ILED PERI-GENITALIA	Control	0	0	0	0	0	0	
	3. 2ppm	0	1	1	1	1	1	
	3. 2ppm 8ppm	0	0	1	•			
	20ppm	0	0	0	0 0	0 1	0	
	zoppm	U	U	U	U	1	2	

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : FEMALE

															TAGE -
Clinical sign	Group Name		stration Wo												
		1-7	27	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
XOPHTHALMOS	Control	0	0	0	0	1	4		1		1		1	0	
AUTITIAL MUS	Control 3.2ppm	0 0	0	0	0 0	1 0	1 0	0	1	1 0	0	1 0	0	2 0	2 0
	3. 200m 800m	0	0	0	0		0	0	0	0		0	0		0
	20ppm	0	0	0	0	0 0	0	0	0 0	0	0 0	0	0	0 0	0
ATARACT	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	3. 2ppm	0	Õ	0	Ő	Ő	õ	õ	õ	õ	O	0	0 0	Ó	1
	8ppm	Ō	0	ō	õ	0	Ō	Ő	0 0	Ō	Ő	õ	õ	ō	0
	20ppm	õ	õ	Õ	Ő	õ	0	0 0	õ	0	õ	õ	õ	õ	õ
ORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	ō	õ	0	0	0	0	õ
NTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(TERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	Ó	0	0	0	0	0	0	0	0	0	0	0	0
.PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : FEMALE

-

•

Clinical sign	Group Name	Admini	stration W	eek-day											
-		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
XOPHTHALMOS	Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	2	0	0
	3. zppm 8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	ŏ	0	0	0	0	0	0	0	0	0	0	0	0
CATARACT	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3. 2ppm	1	1	1	1	i	1	1	1	1	1	2	2	2	2
	8ppm	ò	0	o	ò	0	ò	1	1	1	1	1	1	1	1
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
ORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	Ō	Ō	0	0	0	0	0	0	0	0	0
	8ppm	0	Ō	0	ō	Õ	0	ŏ	ō	Ō	ō	ō	Ō	Ō	Ō
	20ppm	0	Ō	ō	õ	Ő	Ő	Ő	õ	õ	Õ	õ	ō	0	0
NTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(TERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	. 0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] REPORT TYPE : A1 104

# SEX : FEMALE

															TAL .
Clinical sign	Group Name	Admini	stration W	leek-day											
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
					_										
XOPHTHALMOS	Control	2	2	2	2	2	1	1	1	1	1	1	1	1	1
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ATARACT	Control	1	2	2	2	2	2	3	3	3	3	3	3	3	4
	3. 2ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	8ppm	1	1	1	1	1	1	1	2	2	2	2	2	2	2
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
ORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	õ	ő	Ő	ő	õ	õ	Ő	õ	0	õ	õ	Ő	0	õ
	8ppm	õ	0	0 0	0	Ö	ŏ	Ő	0	Ő	0	0 0	Ő	Ő	õ
	20ppm	0	0 0	õ	õ	Ö	õ	0	0	Ő	0	0	0	0	o
(TERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	ŏ	ŏ	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	ŏ	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ITERNAL MASS	O and the st	<u>,</u>	<u> </u>	<u> </u>							-		-	-	
VIERINAL MIASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	õ	õ	õ	ŏ	ŏ	Ő	õ	Ő	Ő	0	Ő	Ő	Ő	Ő
	8ppm	õ	õ	õ	Ő	Ő	0	0	0	0	0	0	0	0	0
	20ppm	õ	o	0	0	0	0	0	0	0	0	0	0	0	0
PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0			-			-	
	3. 200m 800m	0	0		0			-	0	0	0	0	0	0	0
		0		0		0	0	0	0	0	0	0	0	0	0
	20ppm	U	0	0	0	0	0	0	0	0	0	0	0	0	0



STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCr] REPORT TYPE : A1 104

## SEX : FEMALE

Clinical sign	Group Name	Admini	stration W	eek-dav				·····							
······································		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
OPHTHALMOS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3. 2ppm	0	, O	0	ò	ò	, 0	0 0	ò	ò	ò	, O	0	O	0
	8ppm	Ő	Ő	Ő	õ	õ	õ	Ő	Ő	õ	õ	õ	Ő	õ	Ő
	20ppm	0	õ	õ	ŏ	õ	ő	õ	õ	õ	Ő	õ	õ	õ	Ő
TARACT	Control	4	4	4	4	4	4	4	4	4	4	4	4	4	4
	3. 2ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	8ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
RNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
XTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	3. 2ppm	ő	õ	0 0	Ő	ŏ	Ő	1	1	1	1	1	1	1	1
	8ppm	Ő	õ	Ő	ő	õ	õ	1	1	0 0	0	1	1	1	1
	20ppm	õ	õ	0	ŏ	õ	õ	0	0	Ö	õ	0	0	0	0
ITERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : FEMALE

PAGE: 45

Clinical sign	Group Name	Admini	stration W	eek-day											
-	·	57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
XOPHTHALMOS	Control	1	1	0	0	0	0	0	0	0	0	0	0	0	0
LAOPHTHALMOS	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. Zppm 8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	ŏ	0	0	0	0	0	0	o	o	0	0 0	0	ő
ATARACT	Control	4	4	4	5	5	5	5	5	5	5	5	5	5	5
	3. 2ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	8ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
ORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NTERIOR CHAMBER OPACITY	Control	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
XTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	3. 2ppm	1	1	1	1	1	1	1	1	t	1	1	1	1	2
	8ppm	1	1	1	1	1	1	1	1	1	1	2	2	2	2
	20ppm	1	1	1 -	1	1	2	2	2	3	3	3	3	4	5
NTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
.PERI-MOUTH	Control	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	ŏ	0	õ	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0 0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	õ	0	ŏ	0	0	0	0	0	0	0	0	0	0	0

 $\bigcirc$ 

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : FEMALE

															1 AGE
Clinical sign	Group Name		stration W		·····										
		71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
	0 - u t u s t		•	•	•	<u>^</u>	<u> </u>	•				<u>^</u>	•	0	0
XOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0	0	0 0	0	0	0	0	0	0 0	0	0	0	0	0 0
	20ppm	U	U	U	U	U	U	U	U	U	U	U	U	U	U
TARACT	Control	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	3. 2ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	8ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
RNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	õ	ő	õ	ů 0	0 0	0 0	0 0	õ	õ	õ	0	õ	õ	õ
	8ppm	ů 0	Ő	0	Ő	0	ŏ	õ	Ő	0	0 0	0	õ	Ő	ŏ
	20ppm	Ő	õ	õ	0	0	0	0	0	0	0	0	0	õ	õ
	zobhu		v	v	v	U	v	v	U	v	v	v	v	v	v
ITERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TERNAL MASS	Control	1	1	1	2	2	2	2	2	2	2	2	2	2	2
	3.2ppm	2	2	2	2	3	3	3	3	3	2	3	3	3	3
	8ppm	2	4	4	4	4	4	4	4	4	4	4	4	4	4
	20ppm	6	5	6	6	6	6	6	7	7	8	8	8	7	7
ITERNAL MASS	Control	0	1	1	1	1	0	0	0	0	0	0	0	0	0
	3. 2ppm	Õ	0 0	0 0	O	o o	õ	õ	õ	0 0	0 0	õ	ŏ	Ő	õ
	8ppm	ŏ	Ő	0	õ	õ	ő	õ	Ő	Ő	õ	õ	Ő	Ő	Ő
	20ppm	õ	õ	0 0	õ	ŏ	õ	0	o	0	0 0	0 0	0	0	0 0
PER1-MOUTH	Control	0	0	0	•	0	•	0	•	0	~	^	•	•	~
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. Zppm 8ppm	1	1	1			1		0	0		0	0	0	0
	8ppm 20ppm	0	0	0	1 0	1 0	0	1 0	1 0	0	0 0	0	0 0	0 0	0 0
ORAL CAVITY	Control 3.2ppm	0 0	0 0	0 0	0	0	0	0	0	0	0	0	0	0	0
			0		0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0	0	0 0	0 0	0 0	0 0	0 0	0 0	0	0	0	0 0	0 0	0 0
	20ppm	v	v	v	Ū	v	v	v	v	U	v	U	U	v	0
PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] REPORT TYPE : A1 104

Group Name

85-7

86-7

SEX : FEMALE Clinical sign

Administration Week-day 89-7 90-7 91-7 92-7 93-7 94-7 95-7 96-7 97-7 98-7 87-7 88-7

EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
CATARACT	Control	5	5	5	5	5	5	6	6	6	6	6	6	6	6	
	3.2ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
	8ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
	20ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8ppm	0	0	0	0	Ō	0	Ō	0	0	0	Ō	0	0	0	
	20ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1	
ANTERIOR CHAMBER OPACITY	Control	0	0	0	0	0	0	1	1	1	1	1	1	1	1	
	3. 2ppm	0	0	ō	Õ	0 0	0 0	0	0 0	0	0	0	0 0	0 0	ò	
	8ppm	õ	Ő	Ő	õ	õ	õ	õ	õ	õ	õ	õ	õ	Ő	ő	
	20ppm	õ	Ő	Ő	õ	Ő	õ	õ	Ő	Ő	0 0	õ	ő	Ő	ő	
	Loppin	Ŭ	Ū	v	v	Ū	v	v	Ū	Ū	U	v	v	Ū	v	
EXTERNAL MASS	Control	2	2	2	2	2	2	2	2	2	2	3	4	4	3	
	3. 2ppm	5	7	7	7	8	7	7	8	7	9	9	9	9	11	
	8ppm	4	4	5	6	7	6	7	7	7	8	9	10	14	14	
	20ppm	7	7	7	7	7	6	6	5	6	6	6	7	7	7	
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
-	3.2ppm	0	0	0	0	0	0	0	0	0	1	0	0	0	0	
	8ppm	0	0	0	0	0	0	0	1	0	0	1	0	0	0	
	20ppm	0	1	1	1	0	0	0	0	0	0	0	0	0	0	
M. PERI-MOUTH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	3. 2ppm	0	0	0	0	ō	0 0	0	0	0	Ő	Õ	Õ	Ő	ň	
	8ppm	0	Ő	Ő	Ő	1	1	1	1	1	1	1	1	1	1	
	20ppm	õ	Ő	0	õ	Ó	0	0	0	ů 0	0 0	0	0	ò	0	
M. ORAL CAVITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	3. 2ppm	Õ	õ	Ő	Õ	Ő	Ő	Ő	ŏ	Ő	0	õ	Ö	0	ñ	
	8ppm	õ	0	0	0	0	ŏ	0	0	0	0	0	0	0	0	
	20ppm	Ö	0	0	0	0	0	0	0	0	0	0	0	0	0	
M. PERI EAR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	3. 2ppm 8ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1	
	20ppm	õ	0	0	0	0	0	0	0	0	0	0	0	0	0	
	zoppm	v	v	U	v	v	U	U	v	U	U	v	U	U	v	

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

### CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

### SEX : FEMALE

PAGE : 48

\_\_\_\_\_

	Group Name	Admin	istration	Week-dav			
	a oup mune	99-7	100-7	101-7	102-7	103-7	104-7
					·····		
	Ocurture I	0	•	•	•	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0
	8ppm	0 0	0	0	0	0	0 0
	20ppm	U	U	U	U	U	U
CATARACT	Control	6	6	6	6	6	5
	3. 2ppm	2	2	2	2	2	2
	8ppm	2	2	2	2	2	2
	20ppm	1	1	- 1	- 1	1	1
		•		,	•	•	
CORNEAL OPACITY	Control	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
ANTERIOR CHAMBER OPACITY	Control	1	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
EXTERNAL MASS	Control	4	4	6	6	6	6
	3.2ppm	11	10	12	13	13	15
	8ppm	13	13	15	14	16	15
	20ppm	7	6	6	8	13	15
INTERNAL MASS	Ocution I	•	0	0	0	0	•
INTERNAL MASS	Control	0 0	0	0	0	0	0
	3. 2ppm		0	0	0	0	0
	8ppm 20opm	0	0 0	0	1	1	1
	20ppm	0	U	1	0	0	0
M. PERI-MOUTH	Control	0	0	0	0	0	0
	3. 2ppm	0	ŏ	0	0	0	0
	8ppm	1	1	1	1	1	1
	20ppm	0	0	0	0	0	0
	zoppin	v	v	v	v	v	U
M. ORAL CAVITY	Control	0	0	0	0	0	0
	3. 2ppm	õ	0	1	1	1	1
	8ppm	Ő	Ő	Ó	ò	o	0
	20ppm	Ő	0 0	0	ő	0	0 0
	~9ppm		~	~	v		v
M. PERI EAR	Control	0	0	0	0	0	0
	3. 2ppm	Ō	Ő	Ő	õ	õ	õ
	8ppm	1	1	1	1	1	1
	20ppm	Ó	O	0	0	0	ò
		-	-	-	-	•	•

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

SEX : FEMALE

Clinical sign Group Name Administration Week-day 5-7 7-7 1-7 2-7 3-7 4-7 6-7 8-7 9-7 10-7 11-7 12-7 13-7 14-7 M. NECK Control 3.2ppm 8ppm 20ppm M. BREAST Control 3.2ppm 8ppm 20ppm M. ABDOMEN Control 3.2ppm 8ppm 20ppm M. ANTERIOR. DORSUM Control 3.2ppm 8ppm 20ppm M. POSTERIOR DORSUM Control 3.2ppm 8ppm 20ppm 

M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : FEMALE

Clinical sign	Group Name	Admini	stration We	ek-day											
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
				•									•		
. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	Ō	Ō	0	õ	0 0	õ	õ	õ	Õ	ō	Ő
	8ppm	õ	Ő	õ	õ	õ	õ	õ	Ő	õ	õ	ů 0	õ	õ	õ
	20ppm	õ	0	Ő	õ	0	õ	õ	0 0	Ő	õ	õ	õ	õ	0
ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MULTION. DONOUM	3. 2ppm	ŏ	0	0	0	0	0	0	0	0	0	0 0	0	0	0
	8ppm	o	0	0	0	0	0	0	0 0	0	0	0	0	0	0
	20ppm	ŏ	0	0	0	0	0	0	0	0	0	0	0	0	0
POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0			•	0
TOSTERTOR DORSON	3. 2ppm	0	0 0	0 0	0 0	0 0	0	0 0	0	0 0	0	0 0	0	0 0	0 0
		0	0	0							-				
	8ppm 20ppm	0	0	0	0 0	0 0	0	0	0	0	0	0	0	0	0
	20ppm	0	U	U	U	U	0	0	0	0	0	0	0	0	0
HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	õ	ō	Ō	õ	õ	õ	Õ	0
	20ppm	0	0	0	0	0	Ő	Ő	Ō	õ	Ő	0	õ	ō	0 0
EMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0 0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	ŏ	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	o	0	0	0	0	0	0	0	0	0	0	0	0	0
USTA	Control	0	0	0	0	0	0	0	0	0	0	•		•	0
		0			0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm		0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : FEMALE

Clinical sign	Group Name		stration W												
		297	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
NEOK			•			•			-	-		-			-
I. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	Ō	0	Ō	ō	0	Ō	Õ	õ	Ő	õ	ō	Õ	õ	õ
	8ppm	õ	0	Ő	Ő	Ő	õ	Ő	õ	Ő	õ	õ	õ	Ő	õ
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
. ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	õ	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	ŏ	õ	0	0	0	0	0	0	0	0	0	0
	20ppm	õ	õ	õ	õ	0	õ	0	0	0	0	0	0	0	0
.POSTERIOR DORSUM	Control	0	0	0	0	0	•	0	0	0	0		0	•	0
. TOOTERTON DORSOM	Control 3.2ppm	0	0	0	0	0	0 0	0 0	0	0	0	0 0	0 0	0	0
	3. 2ppm 8ppm	0	0	0	0	0	0						-	0	0
	20ppm	0	0	0	0	0	0	0	0	0 0	0 0	0 0	0 0	0 0	0 0
	• • •					_							_	_	
. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0	0 0	0	0	0	0	0	0	0	0	0	0	0
	zohbw	U	U	U	0	U	0	0	0	0	0	0	0	0	0
. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	Ō	Ō	Ō	õ	õ	Ő	ŏ	õ	õ	õ
	8ppm	0	0	0	0	0	Õ	ō	õ	õ	õ	ŏ	õ	ŏ	ů 0
	20ppm	0	0	0	õ	0	Ő	0	õ	Ő	0	Ő	0	0	õ
RUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0 0	0	0 0	0
	8ppm	õ	0	0	0	0	0	0	0	0	0	0	0 1	1	1
	20ppm	Ő	0	0	0	0	0	0	0	0	0	0	0	0	0

.

STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] REPORT TYPE : A1 104

Group Name

SEX : FEMALE

M. NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. ANTERIOR. DORSUM	Contro I	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M. HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	1	1	0	0	Ő	Ő	0	0
	20ppm	0	0	0	0	0	0	0	0	0	õ	õ	õ	õ	0
M. GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	Ő	0 0	õ	0 0	Ő	Ő	õ	0	0 0	0	õ	ő
	8ppm	0	0	õ	õ	õ	õ	õ	õ	õ	0	Ő	0	õ	õ
	20ppm	0	ō	õ	Ő	õ	õ	õ	0	0	õ	0	õ	0	0
ANEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	Ő	0	õ	Ő	0 0	Ő	õ	0	0 0	0	õ	ů 0
	8ppm	0	õ	Õ	õ	ő	Ő	0	0	0	0 0	õ	0	õ	0
	20ppm	õ	Ő	õ	0	0	0	0	õ	0	0	0	0	o	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			1	1		-	-	-	0	•	0	0	•	0	0
	8ppm 20ppm	1 0	0	1	1	1	1	1	1	0	0	0	0	0	0
	20ppm	U	U	0	0	0	0	0	0	0	0	0	0	0	0

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

#### CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Admini	stration W	eek-day											
-	•	57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
NEOK	<b>.</b>				<u> </u>										
NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BREAST	Control	0	1	1	1	1	1	1	1	1	1	1	1	1	1
	3. 2ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	2
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	20ppm	0	0	0	0	0	1	1	1	1	1	1	1	1	1
ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	Ō	0	Ō	Ō	Ó
	8ppm	0	0	0	Ō	0	Ō	0	0	0	0	0	0	ō	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	ō	Ő	õ	õ	õ	õ	õ	Ő	õ	õ	õ
	8ppm	0	0	0	Ō	0	0	õ	õ	õ	õ	õ	õ	ŏ	Ő
	20ppm	õ	Ő	0	Ö	0	õ	Ö	ŏ	Ő	õ	õ	õ	õ	0
GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	ŏ	ő	0 0	Ő	0 0	ŏ	ő	0	0	õ	0	0 0	0	ő
	8ppm	õ	Ő	0	0	0	0	õ	0 0	0	0 0	0	0	0	0
	20ppm	1	1	1	1	1	1	1	1	2	2	2	2	3	3
IEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm 8ppm	1	0	0	0	0	0	0	0	0	0	0	0		0
	20ppm	0	0	0	0	1	0	0	0	0	0	0	0	0 0	0
USTA	Control	0	0	0	0	0	0	0	0	0	•	0	0	•	0
oun	3. 2ppm	0	0	0	0 0	0	0 0	0	0	0	0	0	0	0	0
		0	0			-		-	-	0	0	0	0	0	0
	8ppm 20ppm			0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

20ppm

Control

3. 2ppm

8ppm

20ppm

Control

3. 2ppm

8ppm

20ppm

SEX : FEMALE

ANEMIA

CRUSTA

Clinical sign Group Name Administration Week-day 74-7 75-7 77--7 78-7 79-7 80-7 81-7 82-7 83-7 84-7 71-7 72-7 73-7 76-7 M. NECK Control 3.2ppm 8ppm 20ppm M. BREAST Control 3.2ppm 8ppm 20ppm M. ABDOMEN Control 3.2ppm 8ppm 20ppm M. ANTERIOR, DORSUM Control 3.2ppm 8ppm 20ppm M. POSTERIOR DORSUM Control 3.2ppm 8ppm 20ppm M. HINDLIMB Control 3.2ppm 8ppm 20ppm M. GENITALIA Control 3. 2ppm 8ppm 

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : FEMALE

															, Auc
Clinical sign	Group Name		istration ¥												
		85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LON	3, 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	ő	Ő	0	0	0	0	0	0	0	0	0	0	0	ő
	20ppm	0	õ	0	0	1	1	1	1	1	1	1	1	1	1
BREAST	Control	2	2	2	2	2	2	2	2	2	2	3	4	4	3
	3.2ppm	3	4	4	4	4	4	4	5	5	7	7	7	7	8
	8ppm	1	1	2	2	2	2	3	3	3	3	4	4	8	8
	20ppm	3	3	3	3	3	3	3	3	4	4	4	4	4	4
ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	1	1	1	1	2	1	1	1	1	1	1	1	1	2
	8ppm	1	1	1	2	2	2	2	2	2	3	3	3	4	4
	20ppm	1	1	1	1	1	1	1	0	0	0	0	1	1	1
ANTERIOR. DORSUM	Control	0	0	0	0	0	0	0	0	0	0	1	1	1	1
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20ppm	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	1	1	1	1	1	1	1	1	Ő	0 0	õ	õ	ŏ	õ
	8ppm	Ō	0	Ó	0 0	0 0	0	0 0	0 0	0 0	Ő	0	õ	õ	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	Ō
HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	1	1	1	1	1	1	1	1	1	1	1	1	1
	8ppm	2	2	2	2	2	1	1	1	1	1	1	1	1	1
	20ppm	3	3	3	3	2	1	1	1	1	1	1	1	1	1
IEMIA	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	0
	3. 2ppm	0	0	0	0	0	0	0	0	1	1	0	0	0	0
	8ppm 20ppm	3 1	2 1	1	1	2 0	1 0	1 0	2 0	1 0	1 0	1 0	1 0	0 0	0 0
RUSTA			^	•											
001A	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm 20mm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] REPORT TYPE : A1 104

### CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Admini	stration	Week-day				
		99-7	100-7	101-7	102-7	103-7	104-7	
M. NECK	Control	0	0	0	0	0	0	
	3. 2ppm	0	0	0	0	0	0	
	8ppm	0	0	0	0	0	0	
	20ppm	2	2	2	2	2	1	
M. BREAST	Control	3	3	3	3	3	3	
	3. 2ppm	8	7	8	9	9	10	
	8ppm	8	8	8	9	10	9	
	20ppm	3	2	2	4	9	12	
M. ABDOMEN	Control	1	1	2	2	2	2	
	3.2ppm	2	2	2	2	2	3	
	8ppm	3	3	5	4	5	4	
	20ppm	1	1	1	1	1	1	
M. ANTERIOR. DORSUM	Control	1	1	1	1	1	1	
	3.2ppm	0	0	0	0	0	0	
	8ppm	0	0	0	0	0	0	
	20ppm	0	0	0	0	0	0	
M. POSTERIOR DORSUM	Control	0	0	0	0	0	0	
	3.2ppm	0	0	0	0	0	0	
	8ppm	0	0	0	0	0	0	
	20ppm	0	0	0	0	0	0	
M. HINDLIMB	Control	0	0	0	0	0	0	
	3. 2ppm	0	0	0	0	0	0	
	8ppm	0	0	0	0	0	0	
	20ppm	0	0	0	0	0	0	
M. GENITALIA	Control	0	0	1	1	1	1	
	3. 2ppm	1	1	1	2	2	2	
	8ppm	1	1	1	1	1	- 1	
	20ppm	1	1	1	1	1	2	
ANEMIA	Control	0	0	0	0	0	0	
	3. 2ppm	Ő	0	0	0	0	0	
	8ppm	Ő	Ő	2	2	1	1	
	20ppm	õ	1	1	0	0	o	
CRUSTA	Control	0	0	0	0	0	0	
	3. 2ppm	Ő	0	0	0	0	0	
	8ppm	Ő	0	0 0	0	0	0	
	20ppm	õ	0	0	0	0	0	
	zobbii	0	U	v	v	U	v	

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : FEMALE

PAGE : 57

Control 3.2ppm 8ppm 20ppm Control 3.2ppm 8ppm 20ppm	0 0 0 0 0 0 0 0 0 0	stration W 2-7 0 0 0 0 0 0 0 0 0	3-7 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0	5-7 0 0 0 0 0 0 0	6-7 0 0 0 0 0	7-7 0 0 0 0 0 0	8-7 0 0 0 0 0	9-7 0 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0	0 0 0 0 0 0	13-7 0 0 0 0 0	14-7 0 0 0 0
3.2ppm 8ppm 20ppm Control 3.2ppm 8ppm	0 0 0 0 0	0 0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	-
3.2ppm 8ppm 20ppm Control 3.2ppm 8ppm	0 0 0 0 0	0 0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	-
8ppm 20ppm Control 3.2ppm 8ppm	0 0 0 0 0	0 0 0 0	0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0	0 0	0 0	0	0 0 0	0 0 0	0 0 0	-
20ppm Control 3.2ppm 8ppm	0 0 0 0	0 0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0	0 0	0 0	-	0 0 0	0	0 0 0	-
Control 3.2ppm 8ppm	0 0 0	0 0 0	0	0 0	0	0	0	0	0	-	0	0	0	-
3.2ppm 8ppm	0	0	0	0	0	0		-		0	0		0	0
8ppm	0	0					0	0	0	0	0	0	-	~
	0	-	0	0	0				•	0	0	U	0	0
20ppm	0				•	0	0	0	0	0	0	0	0	0
	ÿ	0	0	0	0	0	0	0	0	0	0	0	0	0
Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm Control 3.2ppm 8ppm	20ppm 0 Control 0 3.2ppm 0 8ppm 0	20ppm         0         0           Control         0         0           3. 2ppm         0         0           8ppm         0         0	20ppm         0         0         0           Control         0         0         0           3.2ppm         0         0         0           8ppm         0         0         0	20ppm         0         0         0         0           Control         0         0         0         0           3.2ppm         0         0         0         0           8ppm         0         0         0         0	20ppm         0         0         0         0         0         0           Control         0 <td< td=""><td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0</td></td></td></td></td></td></td></td></td<>	20ppm         0 <td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0</td></td></td></td></td></td></td>	20ppm         0 <td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0</td></td></td></td></td></td>	20ppm         0 <td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0</td></td></td></td></td>	20ppm         0 <td>20ppm         0<td>20ppm         0<td>20ppm         0<td>20ppm         0</td></td></td></td>	20ppm         0 <td>20ppm         0<td>20ppm         0<td>20ppm         0</td></td></td>	20ppm         0 <td>20ppm         0<td>20ppm         0</td></td>	20ppm         0 <td>20ppm         0</td>	20ppm         0

(HAN190)

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

#### CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

SEX : FEMALE

PAGE : 58

Clinical sign	Group Name	Admini	istration W	leek-day											
·	-	15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	277	28-7
IEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

(HAN190)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : FEMALE

PAGE : 59

Clinical sign	Group Name	Admini	stration W	leek-day											
		29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
101SY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	Ō	0	0	0
	20ppm	0	0	0	0	0	ō	õ	ō	0	Ō	Ō	õ	õ	õ

(HAN190)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] REPORT TYPE : A1 104

### SEX : FEMALE

PAGE : 60

Clinical sign	Group Name	Admini	istration W	eek-day											
		43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
IEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	mqq8	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

(HAN190)

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

#### CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

#### SEX : FEMALE

PAGE : 61

JLA · I LMALL															PAGE .
Clinical sign	Group Name	Admini	stration W	leek-day											
		57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
HEMORRHAGE	Quarters	0		<u> </u>		<u>,</u>									•
TEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	-	-	0	0	0	0	0	0	0	0	0	0	0
	20ppm	U	0	0	0	0	0	0	0	0	0	0	0	U	0
RREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	Ō	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OISY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	Ó	0	0	0	0	0	Ō	0
	8ppm	0	0	0	0	0	0	Ō	0	0	0	ō	0	0	0
	20ppm	0	ō	0	Ő	Ő	ŏ	õ	õ	ŏ	ō	õ	õ	Ő	ŏ

(HAN190)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] REPORT TYPE : A1 104

#### SEX : FEMALE

PAGE : 62

Clinical sign	Group Name	Admini	stration W	leek-day											
		71-7	727	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
HEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	1	0	0	0	0	0
RREGULAR BREATHING	Control	0	1	0	0	0	0	0	0	0	1	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	1	0	0	0	0	0	1	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10 I SY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	Ó	0	0	0	Ō	0	0	0

(HAN190)

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 104

#### CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

## SEX : FEMALE

PAGE : 63

Clinical sign	Group Name	Admini	istration W	leek-day											
		85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
,								<u> </u>							
IEMORRHAGE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	1	1	0	0	1
	8ppm	0	1	1	1	2	1	0	1	0	0	1	0	1	1
	20ppm	1	0	0	1	0	0	0	0	0	0	0	0	1	2
ESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
01SY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8ppm	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

(HAN190)

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 104

#### CLINICAL OBSERVATION (SUMMARY) ALL ANIMALS

SEX : FEMALE

PAGE: 64

Clinical sign	Group Name	Admin	istration 1	Week-day _			
		99-7	100-7	101-7	102-7	103-7	104-7
HEMORRHAGE	Control	0	0	0	0	0	0
	3.2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	1	0	0	0	0
	3. 2ppm	1	1	1	1	1	0
	8ppm	0	0	0	0	0	0
	20ppm	3	3	1	0	0	1
RESPIRATORY SOUND ABNOR	Control	0	0	0	0	0	0
NEOL MATORY BOOMD ADNOR	3. 2ppm	0	0	0	0	0	0
	3. 2ppm 8ppm	õ	0	0	0	0	0
	20ppm	1	1	0	0	0	0
	Zuppin	1	4	U	U	U	U
NOISY	Control	0	0	0	0	0	0
	3. 2ppm	0	0	0	0	0	0
	8ppm	0	0	0	0	0	0
	20ppm	0	0	0	0	0	Ō

(HAN190)

# TABLE D1

# BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE

#### MEAN BODY WEIGHTS AND SURVIVAL

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : MALE

PAGE: 1

		Control		3. 2p	pm		8p	pm		20p	рт
	Av. Wt.	No. of	Av.Wt.	% of	No. of	Av.Wt.	% of	No. of	Av. Wt.	% of	No. of
Week on Study		Surviv. <50>		cont. <50>	Surviv.		cont. <50>	Surviv.		cont. <50>	Surviv.
		1007		1907			100/			1002	
0	120 (50		120 (50)	100	50/50	120 (50)	100	50/50	120 (50)	100	50/50
1	151 (50		150 (50)	99	50/50	151 (50)	100	50/50	141 (50)	93	50/50
2	182 (50		182 (50)	100	50/50	181 (50)	99	50/50	167 (50)	92	50/50
3	206 (50		206 (50)	100	50/50	205 (50)	100	50/50	187 (50)	91	50/50
4	227 (50	· ·	227 (50)	100	50/50	226 (50)	100	50/50	205 (50)	90	50/50
5	242 (50		243 (50)	100	50/50	242 (50)	100	50/50	222 (50)	92	50/50
6	255 (50		257 (50)	101	50/50	255 (50)	100	50/50	235 (50)	92	50/50
8	269 (50 282 (50		270 (50)	100	50/50	268 (50)	100	50/50	250 (50)	93	50/50
8 9	282 (50		283 (50)	100	50/50	281 (50)	100	50/50 50/50	259 (50) 267 (50)	92	50/50
-	292 (50		292 (50) 300 (50)	100 100	50/50 50/50	292 (50) 300 (50)	100 100	50/50	267 (50) 275 (50)	91	50/50
10 11								50/50 50/50		92	50/50
11	304 (50		305 (50) 214 (50)	100	50/50	306 (50)	101	•	279 (50) 285 (50)	92	50/50
12	312 (50 318 (50		314 (50)	101	50/50	314 (50)	101	50/50	285 (50) 292 (50)	91	50/50
13	318 (50		320 (50) 325 (50)	101	50/50 50/50	320 (50) 326 (50)	101	50/50 50/50	292 (50) 297 (50)	92	50/50 50/50
14 18	323 (50		325 (50) 341 (50)	101 101	50/50 50/50	326 (50)	101 101	50/50 50/50	297 (50) 312 (50)	92 92	50/50 50/50
22	352 (50		341 (50)	100	50/50	343 (50) 357 (50)	101	50/50 50/50	312 (50)	92 93	50/50
22	364 (50		362 (50)	99	50/50	367 (50)	101	50/50	326 (50)	93 91	50/50 50/50
30	375 (50		373 (50)	99 99	50/50	307 (50)	101	50/50 50/50	344 (50)	91	50/50
30	375 (50		373 (50)	99 99	50/50	377 (50)	100	50/50 50/50	353 (50)	92 91	50/50
34	393 (50		382 (50)	99 98	50/50	392 (50)	100	50/50 50/50	356 (50)	91	50/50 50/50
38 42	393 (50		390 (50)	98 98	50/50	392 (50) 396 (50)	99	50/50 50/50	358 (50)	90	50/50
46	405 (50		398 (50)	98 98	50/50	402 (50)	99 99	50/50 50/50	363 (50)	90 90	50/50
50	403 (50		404 (50)	99 99	50/50	402 (50)	100	50/50	371 (50)	90 90	50/50
54	413 (50		407 (50)	99	50/50	408 (50)	99	50/50	370 (50)	90 90	50/50
58	417 (50		410 (50)	98	50/50	413 (50)	99	50/50	368 (50)	88	50/50
62	419 (50		410 (50)	98	50/50	415 (50)	99 99	50/50 50/50	366 (50)	87	50/50
66	422 (50		412 (50)	98	50/50	419 (49)	99 99	49/50	368 (48)	87	48/50
70	422 (50		418 (50)	98	50/50	419 (49)	98	49/50	365 (46)	86	46/50
76	428 (50		418 (50)	98 98	50/50	419 (48)	98	48/50	364 (45)	85	40/50
74	428 (50		418 (50)	98 98	50/50 50/50	421 (47)	98 98	47/50 46/50	364 (45) 354 (41)	83	45/50 41/50
82	428 (30		419 (50)	98 98	50/50	419 (46)	98 97	46/50	354 (41)	83	41/50 31/50
86	429 (49		419 (50)	98 99	50/50	416 (46)	97	46/50	357 (31)	85	27/50
90	422 (48		417 (30)	99 99	50/50 49/50	410 (46)	99 98	46/50	347 (20)	85	27/50
94	410 (46		408 (48)	100	49/50	412 (45)	99	45/50	347 (20)	84	20/50
94 98	410 (40		408 (48) 403 (47)	100	48/50	405 (44) 399 (43)	99 99	44/50 43/50	344 (17)	83	14/50
102	396 (43		399 (45)	100	47/50 45/50	399 (43) 398 (42)	99 101	43/50 42/50	334 (14) 335 (10)	83 85	14/50
102	390 (43		395 (43)	101	43/30 44/50	398 (42)	98	42/50	315 (9)	80 80	9/50
104	534 (41	/ 41/00	094 (44)	100	44/ 30	300 (39)	90	39/90	212 ( 9)	80	9/ 90

< >:No.of effective animals, ( ):No.of measured animals

TABLE D2

# BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE

#### MEAN BODY WEIGHTS AND SURVIVAL

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : FEMALE

PAGE : 2

		Control		3. 2p	pm		8p	pm		20p	pm
Week on Study	Av. Wt.	No.of Surviv. <50>	Av.Wt.	% of cont. <50>	No.of Surviv.	Áv.Wt.	% of cont. <50>	No.of Surviv.	Av. Wt.	% of cont. <50>	No.of Surviv.
0	97 (50	) 50/50	97 (50)	100	50/50	97 (50)	100	50/50	97 (50)	100	50/50
1	112 (50		110 (50)	98	50/50	111 (50)	99	50/50	106 (50)	95	50/50
2	126 (50	) 50/50	125 (50)	99	50/50	125 (50)	99	50/50	119 (50)	94	50/50
3	136 (50	) 50/50	134 (50)	99	50/50	134 (50)	99	50/50	129 (50)	95	50/50
4	144 (50	) 50/50	144 (50)	100	50/50	143 (50)	99	50/50	137 (50)	95	50/50
5	151 (50	) 50/50	151 (50)	100	50/50	150 (50)	99	50/50	145 (50)	96	50/50
6	157 (50	) 50/50	158 (50)	101	50/50	155 (50)	99	50/50	150 (50)	96	50/50
7	161 (50		162 (50)	101	50/50	160 (50)	99	50/50	157 (50)	98	50/50
8	165 (50	) 50/50	167 (50)	101	50/50	164 (50)	99	50/50	161 (50)	98	50/50
9	168 (50		170 (50)	101	50/50	167 (50)	99	50/50	167 (50)	99	50/50
10	172 (50		174 (50)	101	50/50	172 (50)	100	50/50	170 (50)	99	50/50
11	174 (50		178 (50)	102	50/50	174 (50)	100	50/50	172 (50)	99	50/50
12	178 (50		183 (50)	103	50/50	178 (50)	100	50/50	176 (50)	99	50/50
13	180 (50		184 (50)	102	50/50	180 (50)	100	50/50	177 (50)	98	50/50
14	182 (50		186 (50)	102	50/50	181 (50)	99	50/50	180 (50)	99	50/50
18	188 (50		194 (50)	103	50/50	190 (50)	101	50/50	186 (50)	99	50/50
22	193 (50		199 (50)	103	50/50	195 (50)	101	50/50	192 (50)	99	50/50
26	197 (50		202 (50)	103	50/50	199 (50)	101	50/50	197 (50)	100	50/50
30	203 (50		209 (50)	103	50/50	205 (50)	101	50/50	201 (50)	99	50/50
34	209 (50		213 (50)	102	50/50	207 (50)	99	50/50	206 (50)	99	50/50
38	213 (50		216 (50)	102	50/50	211 (50)	99	50/50	208 (50)	98	50/50
42	213 (50		218 (50)	101	50/50	211 (50)	99 99	50/50	208 (50)	97	50/50
42	210 (50		213 (50)	101	50/50	214 (50)	100	50/50	213 (50)	97	50/50
	219 (50		223 (50)		50/50	219 (50)		50/50	213 (50)	97	50/50
50	229 (50		233 (50)	102 102	50/50	224 (50)	100 99	49/50	219 (50)	96	50/50
54											
58	234 (50		237 (50)	101	50/50	230 (48)	98	48/50	221 (48)	94	48/50
62	240 (50		245 (50)	102	50/50	235 (48)	98	48/50	225 (48)	94	48/50
66	246 (50		251 (50)	102	50/50	244 (48)	99	48/50	230 (48)	93	48/50
70	253 (50		257 (50)	102	50/50	249 (48)	98	48/50	230 (48)	91	48/50
74	259 (50		263 (50)	102	50/50	253 (47)	98	47/50	232 (47)	90	47/50
78	263 (48		267 (50)	102	50/50	256 (47)	97	47/50	234 (46)	89	46/50
82	270 (47		272 (49)	101	49/50	258 (46)	96	46/50	237 (44)	88	44/50
86	274 (46		277 (49)	101	49/50	258 (44)	94	44/50	242 (42)	88	42/50
90	279 (46		281 (48)	101	48/50	262 (42)	94	42/50	246 (38)	88	38/50
94	280 (45	) 45/50	280 (46)	100	46/50	265 (40)	95	40/50	246 (37)	88	37/50
98	283 (42	) 42/50	285 (43)	101	43/50	266 (38)	94	38/50	242 (37)	86	37/50
102	287 (41		281 (42)	98	42/50	270 (36)	94	36/50	251 (30)	87	30/50
104	287 (39	) 39/50	286 (39)	100	39/50	265 (35)	92	35/50	249 (29)	87	29/50

Since the second sec

TABLE D3

BODY WEIGHT CHANGES : MALE

up Name	Admini	istration	week					· · · ·						
574/19.071.070.077IV	0		1		2		3		4		5	·	6	
Contro I	120土	6	151±	9	182±	11	206±	11	227±	13	242±	13	255±	14
3.2ppm	120±	6	150±	8	182±	10	206±	11	<b>22</b> 7±	12	243±	12	257±	13
8ppm	120±	6	151±	8	181±	10	205±	11	226±	12	242±	13	255±	14
20ppm	120±	6	141±	7**	167±	8**	187±	9**	205±	10**	222±	10**	235±	10**

•

(HAN260)

p Name	Admin	istration	week											
	7	1111-14-W Booker	8		9		10		11		12		13	
Control	269±	15	282±	17	292±	17	299±	18	304±	18	312±	18	318±	18
3.2ppm	270±	13	283±	15	292±	15	300±	16	305±	16	314±	16	320±	17
8ppm	268±	14	281±	15	292±	16	300±	15	306±	15	314±	16	320±	17
20ppm	250±	10**	259±	11**	267±	11**	275±	11**	279±	11**	285±	11**	292±	11**

.

Name		istration												
			18		22		26		30		34		38	
Gontrol	323±	18	338±	19	352±	21	364±	21	375±	23	386±	24	<b>393</b> ±	26
3.2ppm	325±	18	341±	18	352±	19	$362\pm$	20	373±	21	382±	22	386±	22
8ppm	326±	17	343±	17	357±	18	367±	18	377±	18	386±	19	392±	19
20ppm	<b>297</b> ±	12**	312±	12**	326±	13**	333±	14**	344±	14**	353±	14**	356±	14**

up Name	ådm i n	istration	wook				<u></u>							
	42		46		50		54		58		62		66	
Control	<b>399</b> ±	27	<b>40</b> 5土	27	410±	29	413±	30	417±	31	419±	32	422±	33
3.2ppm	390±	23	398±	23	404±	23	407±	23	410±	24	412±	23	415±	24
8ppm	396±	19	402±	18	408±	19	410±	20	413±	19	415±	19	419±	19
20ppm	358±	15**	363±	15**	371±	15**	370±	16**	368±	16**	366±	22**	368±	25**

p Name	Admin	istration	week											
:	70		74		78		82		86		90		94	
Contro I	426±	33	<b>428</b> ±	35	428±	35	429±	35	422±	37	421±	35	410±	34
3. 2ppm	418土	25	418±	24	419土	25	419土	26	417±	27	416土	28	408±	29
8ppm	419±	19	421±	18	419±	17	416土	18*	416±	18	412±	18	405±	20
20ppm	365±	19**	364±	21**	354±	28**	357±	22**	357±	25**	347±	26**	344±	21**

(SUMMARY) STUDY NO. : 0794 BODY WEIGHT CHANGES ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] ALL ANIMALS UNIT : g REPORT TYPE : A1 104 SEX : MALE PAGE: 6 Group Name Administration week\_ 98 102 104 Control 396± 41 394± 37 3.2ppm 403± 32 399± 36 394± 37 8ppm 399± 26 398± 40 388± 52 20ppm 334± 24\*\* 335± 28\*\* 315士 42\*\* Significant difference : \* : P  $\leq$  0.05 \*\* : P ≦ 0.01 Test of Dunnett

(HAN260)

TABLE D4

BODY WEIGHT CHANGES : FEMALE

p Name	Admini	stration	week											
	0		1		2		3		4		5		6	
Control	97±	3	112土	4	126土	5	136±	6	144±	7	151±	7	157土	8
3.2ppm	97±	3	110土	4	125±	5	134±	6	144±	7	151±	7	158±	8
8ppm	97土	3	111±	4	125±	5	134±	6	143±	7	150±	8	155±	8
20ppm	97±	3	106±	4**	119±	5**	129土	5**	137±	7**	145±	7**	150±	8**

up Name	Admini	istration	week						<u> </u>					
	7		8		9		10		11		12		13	
Control	161±	9	165±	10	168±	11	172±	11	174土	11	178±	11	180±	11
3.2ppm	162±	9	167±	10	170±	10	174土	10	178±	11	183±	11	184±	11
8ppm	160±	9	164±	9	167土	10	172±	11	174±	10	178±	11	180±	10
20ppm	157±	9*	161±	9	167±:	11	170±	11	172±	11	176±	11	177土	11

BAIS 5

(HAN260)

•

oup Name	Admin	istration	week											
	14		18		22		26		30		34		38	
Control	182 <b>±</b>	12	188±	12	193±	13	197土	14	203±	14	209±	16	213±	16
3. 2ppm	186±	11	194±	11	199±	12	202±	12	209±	12	213±	13	216±	13
8ppm	181±	10	190±	12	195土	12	199±	12	205±	13	207±	12	211±	13
20ppm	180±	11	186±	13	192±	13	197±	14	201±	13	206±	14	208±	15

Name	Admin	istration	week				· · ·							
	42		46		50		54		58		62		66	
Control	216土	17	219±	18	225±	19	229 <i>±</i>	19	234±	20	240±	22	246±	22
3. 2ppm	218土	14	<b>223</b> ±	13	229±	15	233±	16	<b>23</b> 7±	18	245±	19	251±	21
8ppm	214±	14	219±	14	224±	15	227±	15	230±	17	235±	18	244±	24
20ppm	<b>209</b> ±	14*	213±	16	219±	17	219土	18**	221±	16**	225±	16**	230±	17**

Name	Admin	istration	week	· · · · · ·								·		
	70		74	n - N	78		82		86		90		94	
Control	253±	23	259±	23	263±	24	270±	25	274±	23	279±	24	280±	26
3.2ppm	257±	21	263±	22	267±	24	272±	24	277±	26	281±	31	280±	36
8ppm	249±	26	253±	19	256±	20	258±	21*	258±	22**	262±	23*	265±	24*
20ppm	230±	18**	232±	18**	234±	18**	237±	19**	242±	22**	246±	21**	246±	26**

STUDY NO. : 0794 ANIMAL : RAT F344/DuC UNIT : g	crlCrlj[F344/DuCrj	]			BODY WEIGHT ALL ANIMALS	CHANGES	(SUMMARY)	
REPORT TYPE : A1 104 SEX : FEMALE								PAGE : 12
Group Name	Admin	istration						· · · · · · · · · · · · · · · · · · ·
	98		102		104			
Control	283±	31	287±	33	287±	35		
3.2ppm	285±	41	281±	43	286±	43		
8ppm	266±	32	270±	34*	265±	33**		
20ppm	242±	30**	251±	26**	249±	25**		
	10419-1049-1049-10							
Significant differen	ice; *:P≦	0. 05	** : P ≦ 0.(	01			Test of Dunnett	
(HANDED)				A64				DAICE

## TABLE E1

# FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE

#### MEAN FOOD CONSUMPTION (FC) AND SURVIVAL

STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : MALE

PAGE: 1

		Control		3. 2p	pm		8p	pm		20pj	pm
	Av. FC.	No. of	Av. FC.	% of	No.of	Av. FC.	% of	No. of	Av. FC.	% of	No. of
Week-Day		Surviv.		cont.	Surviv.		cont.	Surviv.		cont.	Surviv.
on Study		<50>		<50>			<50>			<50>	
1-7	14.8 (50	) 50/5	0 14.5 (50)	98	50/50	14.3 (50)	97	50/50	12.7 (50)	86	50/50
2-7	16.7 (50			99	50/50	16.3 (50)	98	50/50	14.1 (50)	84	50/50
37	17.2 (50			101	50/50	16.9 (50)	98	50/50	14.7 (50)	85	50/50
4-7	17.1 (50			99	50/50	16.6 (50)	97	50/50	14.5 (50)	85	50/50
5-7	16.7 (50			101	50/50	16.8 (50)	101	50/50	15.7 (50)	94	50/50
6-7	17.0 (50			99	50/50	16.7 (50)	98	50/50	15.9 (50)	94	50/50
7-7	16.6 (50		• •	99	50/50	16.4 (50)	99	50/50	16.0 (50)	96	50/50
8-7	17.0 (50			99	50/50	16.8 (50)	99	50/50	16.0 (50)	94	50/50
9-7	16.7 (50			98	50/50	16.4 (50)	98	50/50	15.2 (50)	91	50/50
10-7	16.5 (50			99	50/50	16.3 (50)	99	50/50	15.3 (50)	93	50/50
11-7	15.8 (50			102	50/50	16.1 (50)	102	50/50	15.1 (50)	96	50/50
12-7	16.2 (50			100	50/50	16.2 (50)	100	50/50	14.9 (50)	92	50/50
13-7	15.9 (50	) 50/5	0 16.0 (50)	101	50/50	16.0 (50)	101	50/50	15.2 (50)	96	50/50
14-7	15.5 (50	) 50/5	0 15.7 (50)	101	50/50	15.8 (50)	102	50/50	15.1 (50)	97	50/50
18-7	15.9 (50			99	50/50	16.1 (50)	101	50/50	15.1 (50)	95	50/50
22-7	15.8 (50			99	50/50	16.1(50)	102	50/50	15.4 (50)	97	50/50
26-7	15.5 (50			100	50/50	15.7 (50)	101	50/50	14.9 (50)	96	50/50
30-7	16.1 (50			99	50/50	16.1 (50)	100	50/50	15.5 (50)	96	50/50
34-7	16.4 (50			99	50/50	16.4 (50)	100	50/50	15.9 (50)	97	50/50
38-7	16.2 (50	) 50/5		99	50/50	16.3 (50)	101	50/50	15.6 (50)	96	50/50
42-7	16.3 (50	) 50/5		97	50/50	16.0 (50)	98	50/50	15.5 (50)	95	50/50
46-7	16.2 (50	) 50/5		99	50/50	16.4 (50)	101	50/50	15.7 (50)	97	50/50
50-7	16.6 (50	) 50/5	0 16.5 (50)	99	50/50	16.8 (50)	101	50/50	16.6 (50)	100	50/50
54-7	16.4 (50	) 50/5	0 16.4 (50)	100	50/50	16.5 (50)	101	50/50	15.9 (50)	97	50/50
58-7	16.6 (50	) 50/5	0 16.2 (50)	98	50/50	16.5 (50)	99	50/50	15.7 (50)	95	50/50
62-7	16.3 (50		0 16.2 (50)	99	50/50	16.4 (50)	101	50/50	15.5 (50)	95	50/50
66-7	16.5 (50	) 50/5	0 16.3 (50)	99	50/50	16.3 (49)	99	49/50	15.3 (48)	93	48/50
70-7	16.6 (50		0 16.3 (50)	98	50/50	16.3 (48)	98	48/50	15.1 (46)	91	46/50
74-7	16.6 (50	) 50/5	0 16.2 (50)	98	50/50	16.3 (47)	98	47/50	15.3 (45)	92	45/50
78-7	16.2 (50	) 50/5	0 16.0 (50)	99	50/50	16.3 (46)	101	46/50	14.0 (41)	86	41/50
82-7	16.4 (49	) 49/5	0 16.1 (50)	98	50/50	16.2 (46)	99	46/50	15.1 (31)	92	31/50
86-7	16.0 (48	) 48/5	0 15.8 (50)	99	50/50	16.0 (46)	100	46/50	14.7 (27)	92	27/50
90-7	16.3 (47	) 47/5	0 16.3 (49)	100	49/50	16.0 (45)	98	45/50	14.8 (20)	91	20/50
94-7	16.0 (46			99	48/50	16.0 (44)	100	44/50	14.7 (17)	92	17/50
98-7	16.3 (45			101	47/50	16.2 (43)	99	43/50	15.4 (14)	94	14/50
102-7	16.3 (43			103	45/50	16.1 (42)	99	42/50	16.2 (10)	99	10/50
104-7	16.3 (41			101	44/50	15.5 (39)	95	39/50	15.4 (9)	94	9/50

< >:No.of effective animals, ( ):No.of measured animals Av.FC.:g

TABLE E2

# FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE

#### MEAN FOOD CONSUMPTION (FC) AND SURVIVAL

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : FEMALE

		Control		3. 2p	mc		8p	m		20p	pm
	Av. FC.	No. of	Av. FC.	% of	No. of	Av. FC.	% of	No. of	Av. FC.	% of	No. of
Week-Day		Surviv.		cont.	Surviv.		cont.	Surviv.		cont.	Surviv.
on Study		<50>		<50>			<50>			<50>	
1-7	11.3 (50)	) 50/50	11.2 (50)	99	50/50	11.0 (50)	97	50/50	10.1 (50)	89	50/50
2-7	12.0 (50)		12.0 (50)	100	50/50	11.7 (50)	98	50/50	10.8 (50)	90	50/50
3-7	11.8 (50)	,	11.7 (50)	99	50/50	11.7 (50)	99	50/50	10.9 (50)	92	50/50
4-7	11.7 (50)		11.7 (50)	100	50/50	11.4 (50)	97	50/50	10.4 (50)	89	50/50
5-7	11.5 (50)		11.7 (50)	102	50/50	11.5 (50)	100	50/50	11.5 (50)	100	50/50
67	11.7 (50)		11.9 (50)	102	50/50	11.7 (50)	100	50/50	11.6 (50)	99	50/50
7-7	11.0 (50)		11.3 (50)	103	50/50	11.0 (50)	100	50/50	11.3 (50)	103	50/50
8-7	11.1 (50)		11.5 (50)	104	50/50	10.7 (50)	96	50/50	11.5 (50)	104	50/50
9-7	10.6 (50)		10.8 (50)	102	50/50	10.6 (50)	100	50/50	11.0 (50)	104	50/50
10-7	10.9 (50)		11.1 (50)	102	50/50	10.8 (50)	99	50/50	11.0 (50)	101	50/50
11-7	10.5 (50		10.7 (50)	102	50/50	10.5 (50)	100	50/50	10.7 (50)	102	50/50
127	10.8 (50)		11.4 (50)	106	50/50	10.9 (50)	101	50/50	11.0 (50)	102	50/50
13-7	10.7 (50)		11.6 (50)	108	50/50	10.6 (50)	99	50/50	11.1 (50)	104	50/50
14-7	10.5 (50)		10.9 (50)	104	50/50	10.5 (50)	100	50/50	11.1 (50)	106	50/50
187	10.8 (50)		11.2 (50)	104	50/50	11.1 (50)	103	50/50	10.7 (50)	99	50/50
22-7	10.8 (50)		11.2 (50)	104	50/50	10.9 (50)	101	50/50	11.1 (50)	103	50/50
26-7	10.5 (50)		10.4 (50)	99	50/50	10.3 (50)	98	50/50	10.4 (50)	99	50/50
30-7	11.1 (50)		11.4 (50)	103	50/50	11.0 (50)	99	50/50	11.0 (50)	99	50/50
34-7	11.3 (50)		11.1 (50)	98	50/50	10.6 (50)	94	50/50	11.3 (50)	100	50/50
38-7	11.1 (50)		11.1(50)	100	50/50	11.1 (50)	100	50/50	11.3 (50)	102	50/50
42-7	11.4 (50)	•	11.2 (50)	98	50/50	11.0 (50)	96	50/50	10.9 (50)	96	50/50
46-7	11.1 (50)		11.1 (50)	100	50/50	11.2(50)	101	50/50	11.7 (50)	105	50/50
50-7	11.6 (50)		11.8 (50)	102	50/50	11.7 (50)	101	50/50	12.1(50)	104	50/50
547	11.6 (50)	•	11.9 (50)	103	50/50	11.4 (49)	98	49/50	11.5 (50)	99	50/50
58-7	11.9 (50)		11.9 (50)	100	50/50	11.4 (48)	96	48/50	11.3 (48)	95	48/50
62-7	11.7 (50)		12.0 (50)	103	50/50	11.7 (48)	100	48/50	11.6 (48)	99	48/50
66-7	12.1 (50)		12.1 (50)	100	50/50	11.7 (47)	97	48/50	11.6 (48)	96	48/50
707	12.0 (50)	) 50/50	12.2 (50)	102	50/50	12.1 (48)	101	48/50	11.4 (48)	95	48/50
74-7	12.0 (50)		12.2 (50)	102	50/50	11.7 (47)	98	47/50	11.3 (47)	94	47/50
78-7	12.0 (48)	) 48/50	12.1 (50)	101	50/50	11.7 (47)	98	47/50	11.2 (46)	93	46/50
82-7	12.6 (47)	47/50	12.5 (49)	99	49/50	11.9 (46)	94	46/50	11.8 (44)	94	44/50
86-7	12.1 (46)	) 46/50	12.3 (49)	102	49/50	11.2 (44)	93	44/50	11.3 (42)	93	42/50
90-7	12.7 (46)	46/50	12.5 (48)	98	48/50	11.7 (42)	92	42/50	11.8 (38)	93	38/50
947	12.7 (45)	) 45/50	12.4 (45)	98	46/50	12.3 (40)	97	40/50	12.0 (37)	94	37/50
98-7	12.8 (42)	) 42/50	13.2 (43)	103	43/50	11.7 (38)	91	38/50	11.9 (37)	93	37/50
102-7	13.2 (41)	41/50	12.8 (42)	97	42/50	12.6 (36)	95	36/50	12.7 (30)	96	30/50
104-7	12.8 (39)	) 39/50	12.9 (39)	101	39/50	12.4 (35)	97	35/50	12.2 (29)	95	29/50

>:No. of effective animals, ( ):No. of measured animals Av. FC. : g

PAGE : 2

TABLE E3

## FOOD CONSUMPTION CHANGES : MALE

STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)

ALL ANIMALS

PAGE: 1

3. 2ppm       14. 5±       1.1       16. 5±       1.3       17. 4±       1.5       17. 0±       1.3       16. 9±       1.2       16. 8±       1.1       16. 9±         8ppm       14. 3±       1.0       16. 3±       1.3       16. 9±       1.4       16. 6±       1.2       16. 8±       1.2       16. 7±       1.3       16. 7±       1.3       16. 7±       1.3       16. 7±       1.3       16. 9±       1.4       16. 6±       1.2       16. 8±       1.2       16. 7±       1.3       16. 7±       1.3       16. 7±       1.3       16. 7±       1.4       16. 9±       1.4       16. 9±       1.4       16. 9±       1.4       16. 9±       1.4       16. 9±       1.4       16. 9±       1.4       16. 9±       1.4       16. 9±       1.4       16. 9±       1.4       16. 9±       1.4       16. 9±       1.4       14. 9±	oup Name	Administration 1-7(7)	week-day(effective) 2-7(7)	3-7 (7)	4-7 (7)	5-7 (7)	6-7 (7)	7-7 (7)
8ppm       14.3±       1.0       16.3±       1.3       16.9±       1.4       16.6±       1.2       16.8±       1.2       16.7±       1.3       16.7±         20ppm       12.7±       0.8**       14.1±       0.8**       14.7±       0.8**       14.5±       0.8**       15.7±       1.1**       15.9±       1.0**       16.7±	Control	14.8± 1.2	16.7± 1.6	17.2± 1.5	17.1土 1.4	16.7± 1.2	17.0土 1.5	16.6± 1.5
20ppm 12.7± 0.8** 14.1± 0.8** 14.7± 0.8** 14.5± 0.8** 15.7± 1.1** 15.9± 1.0** 16.0	3.2ppm	14.5± 1.1	16.5± 1.3	17.4± 1.5	17.0± 1.3	16.9± 1.2	16.8± 1.1	16.5± 1.1
	8ppm	14.3± 1.0	16.3± 1.3	16.9± 1.4	16.6± 1.2	16.8± 1.2	16.7± 1.3	16.4± 1.2
	20ppm	12.7± 0.8**	14.1± 0.8**	14.7± 0.8**	14.5± 0.8**	15.7土 1.1**	15.9± 1.0**	16.0± 1.0
Significant difference: $* : P \le 0.05$ $** : P \le 0.01$ Test of Duppett								
	Significant difference	; * : P ≦ 0.05	** : P ≦ 0.01		Test of Dunnett			

(HAN260)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : MALE

Significant difference : \* : P  $\leq$  0.05

\*\* : P ≦ 0.01

FOOD CONSUMPTION CHANGES (SUMMARY) ALL ANIMALS

PAGE : 2

roup Name	Administration 8-7(7)	week-day(effective) 9-7(7)	10-7 (7)	11-7 (7)	12-7 (7)	13-7 (7)	14-7 (7)
Control	17.0± 1.4	16.7± 1.4	16.5± 1.4	15.8± 1.2	16.2± 1.1	15.9± 1.1	15.5± 0.9
3. 2ppm	16.8± 1.4	16.3± 1.2	16.4± 1.3	16.1± 1.1	16.2± 1.1	16.0± 1.0	15.7± 1.2
8ppm	16.8土 1.2	16.4土 1.1	16.3± 1.0	16.1± 1.0	16.2± 1.0	16.0± 1.0	15.8± 0.9
20ppm	16.0土 1.1**	15.2± 0.9**	15.3± 1.0**	15.1± 0.8**	14.9± 0.8**	15.2土 0.8**	15.1± 0.7*

Test of Dunnett

(HAN260)

\_\_\_\_\_

STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : MALE FOOD CONSUMPTION CHANGES (SUMMARY) ALL ANIMALS

PAGE : 3

oup Name	Administration	week-day(effective)					
	18–7 (7)	22-7 (7)	26-7(7)	30-7 (7)	34-7 (7)	38-7 (7)	42-7 (7)
Control	15.9± 0.9	15.8± 1.0	15.5± 0.9	16.1± 1.0	16.4± 1.0	16.2± 1.0	16.3± 1.0
3. 2ppm	15.7± 1.1	15.7± 1.0	15.5± 0.9	15.9± 1.0	16.2± 1.0	16.0± 0.9	15.8± 1.0
8ppm	16.1± 0.9	16.1± 1.1	15.7± 0.9	16.1± 0.8	16.4± 0.9	16.3± 0.8	16.0± 0.8
20ppm	15.1土 0.7**	15.4土 0.7*	14.9± 0.8**	15.5± 0.7**	15.9± 0.8*	15.6土 0.7**	15.5± 0.7**
Significant differenc	ee ; * : P ≦ 0.05 ;	** : P ≦ 0.01		Test of Dunnett			

(HAN260)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : MALE FOOD CONSUMPTION CHANGES (SUMMARY) ALL ANIMALS

PAGE: 4

up Name	Administration	week-day(effective)_					
	46-7 (7)	50-7 (7)	54-7 (7)	58–7 (7)	62–7 (7)	66-7 (7)	70–7 (7)
Control	16.2± 1.0	16.6± 1.1	16.4± 0.9	16.6± 1.1	16.3± 1.3	16.5± 1.2	16.6± 1.1
3. 2ppm	16.1± 0.9	16.5± 0.9	16.4± 0.9	16.2± 0.9	16.2± 0.9	16.3± 1.0	16.3± 1.0
8ppm	16.4± 0.8	16.8± 0.8	16.5± 1.1	16.5士 0.9	16.4± 0.7	16.3± 1.2	16.3± 0.9
20ppm	15.7± 0.8*	16.6± 0.8	15.9± 0.8*	15.7± 0.8**	15.5± 1.7**	15.3± 0.9**	15.1± 0.9**
Significant difference	; *:P≦0.05	** : P ≦ 0.01		Test of Dunnett			
AN260)							

 $\bigcirc$ 

STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : MALE

#### FOOD CONSUMPTION CHANGES (SUMMARY)

ALL ANIMALS

PAGE: 5

Administration 74–7(7)	week-day(effective) 78-7(7)	82-7 (7)	86-7(7)	90-7 (7)	94-7 (7)	98-7 (7)
16.6± 1.2	16.2± 1.3	16.4± 1.6	16.0± 1.7	16.3± 1.3	16.0± 1.2	16.3± 1.5
16.2± 1.0	16.0± 0.9	16.1± 1.0	15.8± 0.9	16.3± 1.1	15.9± 1.6	16.4± 1.3
16.3土 1.2	16.3± 0.7	16.2± 1.0	16.0± 1.0	16.0± 1.0	16.0± 1.1	16.2± 1.4
15.3± 1.0**	14.0± 2.3**	15.1± 1.0**	14.7土 1.7**	14.8± 1.2**	14.7± 1.5**	15.4± 1.2
e; *:P≦0.05 *	κ* : Ρ ≦ 0.01		Test of Dunnett			
	74-7 (7) 16. $6 \pm 1.2$ 16. $2 \pm 1.0$ 16. $3 \pm 1.2$ 15. $3 \pm 1.0 **$	$74-7(7)$ $78-7(7)$ 16. $6\pm$ 1.2       16. $2\pm$ 1.3         16. $2\pm$ 1.0       16. $0\pm$ 0.9         16. $3\pm$ 1.2       16. $3\pm$ 0.7         15. $3\pm$ 1.0**       14. $0\pm$ 2.3**	$74-7(7)$ $78-7(7)$ $82-7(7)$ 16. $6\pm$ 1.2       16. $2\pm$ 1.3       16. $4\pm$ 1.6         16. $2\pm$ 1.0       16. $0\pm$ 0.9       16. $1\pm$ 1.0         16. $3\pm$ 1.2       16. $3\pm$ 0.7       16. $2\pm$ 1.0         15. $3\pm$ 1. $0**$ 14. $0\pm$ 2. $3**$ 15. $1\pm$ 1. $0**$	$74-7(7)$ $78-7(7)$ $82-7(7)$ $86-7(7)$ 16. $6 \pm 1.2$ 16. $2 \pm 1.3$ 16. $4 \pm 1.6$ 16. $0 \pm 1.7$ 16. $2 \pm 1.0$ 16. $0 \pm 0.9$ 16. $1 \pm 1.0$ 15. $8 \pm 0.9$ 16. $3 \pm 1.2$ 16. $3 \pm 0.7$ 16. $2 \pm 1.0$ 16. $0 \pm 1.0$ 15. $3 \pm 1.0 * *$ 14. $0 \pm 2.3 * *$ 15. $1 \pm 1.0 * *$ 14. $7 \pm 1.7 * *$	$74-7(7)$ $78-7(7)$ $82-7(7)$ $86-7(7)$ $90-7(7)$ $16.6 \pm 1.2$ $16.2 \pm 1.3$ $16.4 \pm 1.6$ $16.0 \pm 1.7$ $16.3 \pm 1.3$ $16.2 \pm 1.0$ $16.0 \pm 0.9$ $16.1 \pm 1.0$ $15.8 \pm 0.9$ $16.3 \pm 1.1$ $16.3 \pm 1.2$ $16.3 \pm 0.7$ $16.2 \pm 1.0$ $16.0 \pm 1.0$ $16.0 \pm 1.0$ $15.3 \pm 1.0 * *$ $14.0 \pm 2.3 * *$ $15.1 \pm 1.0 * *$ $14.7 \pm 1.7 * *$ $14.8 \pm 1.2 * *$	$74-7(7)$ $78-7(7)$ $82-7(7)$ $86-7(7)$ $90-7(7)$ $94-7(7)$ $16.6 \pm 1.2$ $16.2 \pm 1.3$ $16.4 \pm 1.6$ $16.0 \pm 1.7$ $16.3 \pm 1.3$ $16.0 \pm 1.2$ $16.2 \pm 1.0$ $16.0 \pm 0.9$ $16.1 \pm 1.0$ $15.8 \pm 0.9$ $16.3 \pm 1.1$ $15.9 \pm 1.6$ $16.3 \pm 1.2$ $16.3 \pm 0.7$ $16.2 \pm 1.0$ $16.0 \pm 1.0$ $16.0 \pm 1.0$ $16.0 \pm 1.1$ $15.3 \pm 1.0 * *$ $14.0 \pm 2.3 * *$ $15.1 \pm 1.0 * *$ $14.7 \pm 1.7 * *$ $14.8 \pm 1.2 * *$ $14.7 \pm 1.5 * *$

(HAN260)

FOOD CONSUMPTION CHANGES (SUMMARY) STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] ALL ANIMALS UNIT : g REPORT TYPE : A1 104 PAGE: 6 SEX : MALE Administration week-day(effective)\_ Group Name 102-7 (7) 104-7(7) Control 16.3± 1.7 16.3± 1.3 3. 2ppm 16.8± 1.5 16.4 1.5 8ppm 16.1± 2.3 15.5± 2.3\* 20ppm 16.2± 0.6 15.4± 1.2 Significant difference : \* : P  $\leq$  0.05 \*\* : P ≦ 0.01 Test of Dunnett (HAN260) BAIS 5

TABLE E4

### FOOD CONSUMPTION CHANGES : FEMALE

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : FEMALE FOOD CONSUMPTION CHANGES (SUMMARY) ALL ANIMALS

PAGE: 7

p Name	Administration	week-day(effective)					
	1–7 (7)	2–7 (7)	3-7 (7)	4-7 (7)	5-7 (7)	67 (7)	7–7 (7)
Control	11.3± 0.7	12.0土 0.9	11.8土 0.8	11.7± 0.8	11.5± 0.8	11.7± 1.0	11.0± 0.9
3.2ppm	11.2± 0.7	12.0± 0.8	11.7± 0.8	11.7± 1.0	11.7± 1.0	11.9土 1.1	11.3± 0.9
8ppm	11.0± 0.6	11.7土 0.9	11.7± 0.9	11.4± 1.0	11.5± 0.9	11.7± 1.1	11.0± 1.1
20ppm	10.1± 0.6**	10.8± 0.8**	10.9± 0.7**	10.4± 0.8**	11.5± 0.9	11.6± 1.2	11.3± 1.4
Significant differenc	ce; *:P≦0.05	#* : P ≦ 0.01		Test of Dunnett			

(HAN260)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : FEMALE

PAGE: 8 Administration week-day(effective)\_ Group Name 8-7 (7) 9-7(7) 10-7(7) 11-7(7) 12-7 (7) 13-7 (7) 14-7(7) Control 11.1± 1.0 10.6± 0.9 10.9± 0.8 10.5± 0.9 10.8 ± 0.8 10.7± 0.9 10.5± 1.1 3. 2ppm 11.5± 1.0 10.8± 0.9 11.1± 1.1 10.7 ± 0.9 11.4± 0.8\*\* 11.6土 1.2\*\* 10.9 ± 0.9 10.5± 0.8 10.7± 0.9 10.6± 1.0 10.5 ± 1.0 10.9± 0.9 10.6± 0.8 8ppm 10.8± 1.1 11.1± 1.3 11.5± 1.4 11.0± 1.3 11.0± 1.1 10.7 ± 0.9 11.0± 1.1 11.1± 1.3 20ppm

FOOD CONSUMPTION CHANGES (SUMMARY)

ALL ANIMALS

Significant difference ; \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01

Test of Dunnett

(HAN260)

BAIS 5

#### - $\bigcirc$

 $\bigcirc$ 

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : FEMALE

Significant difference : \* : P  $\leq$  0.05

\*\* : P ≦ 0.01

FOOD CONSUMPTION CHANGES (SUMMARY) ALL ANIMALS

PAGE : 9

Group Name	Administration 18-7(7)	week-day(effective) 22-7(7)	26-7 (7)	30-7 (7)	34-7 (7)	38–7 (7)	42-7 (7)
Control	10.8± 0.9	10.8± 0.9	10.5± 0.8	11.1± 0.9	11.3± 1.1	11.1± 0.9	11.4± 1.0
3. 2ppm	11.2± 0.8	11.2± 1.0	10.4± 0.6	11.4± 0.9	11.1± 1.0	11.1± 0.7	11.2± 1.0
8ppm	11.1± 1.3	10.9± 1.1	10.3± 0.8	11.0± 1.1	10.6± 0.8**	11.1± 0.9	11.0± 1.2
20ppm	10.7± 1.1	11.1± 1.1	10.4± 1.1	11.0± 1.3	11.3± 1.2	11.3± 1.2	10.9± 1.0

Test of Dunnett

(HAN260)

BAIS 5

-

STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : FEMALE FOOD CONSUMPTION CHANGES (SUMMARY) ALL ANIMALS

ALL ANTMALS

PAGE : 10

oup Name	Administration	week-day(effective)					
	46-7 (7)	50-7 (7)	54-7 (7)	58-7 (7)	62-7 (7)	66-7 (7)	70–7 (7)
Control	11.1± 0.8	11.6± 0.9	11.6± 1.0	11.9± 0.9	11.7土 1.0	12.1± 0.9	12.0± 0.9
3. 2ppm	11.1± 0.8	11.8± 0.7	11.9± 1.1	11.9± 1.0	12.0± 1.0	12.1± 1.2	12.2± 1.0
8ppm	11.2± 0.9	11.7± 1.1	11.4± 1.2	11.4± 0.9*	11.7± 1.1	11.7± 0.9	12.1± 1.9
20ppm	11.7± 1.2	12.1± 1.4	11.5± 1.4	11.3± 0.9**	11.6± 0.9	11.6± 0.9*	11.4± 1.0**
Significant difference	· * · P < 0.05	** : P ≦ 0.01		Test of Dunnett			
AN260)							

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : FEMALE

PAGE : 11

oup Name	Administration	week-day(effective)					
	74–7 (7)	78-7 (7)	82–7 (7)	86-7(7)	90-7 (7)	94–7 (7)	98–7 (7)
Control	12.0± 0.8	12.0± 1.3	12.6± 0.9	12.1± 1.0	12.7± 1.1	12.7± 1.6	12.8± 1.7
3.2ppm	12.2± 1.0	12.1± 1.1	12.5± 1.2	12.3± 1.5	12.5± 1.6	12.4± 1.8	13.2± 2.0
8ppm	11.7± 0.9	11.7± 0.8	11.9± 0.8**	11.2± 1.9**	11.7土 1.1**	12.3± 1.2	11.7± 2.4*
20ppm	11.3± 0.9**	11.2± 0.7**	11.8± 1.0**	11.3± 1.5**	11.8± 1.3**	12.0± 1.7	11.9± 2.2
Significant difference	; *:P≦ 0.05	** : P ≦ 0.01		Test of Dunnett			
N260)							BA

FOOD CONSUMPTION CHANGES (SUMMARY)

ALL ANIMALS

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY) ALL ANIMALS

Group Name Administration week-day(effective)\_ 102-7 (7) 104-7(7) Control 13.2± 2.1 12.8± 2.2 3.2ppm 12.8± 2.9 12.9 生 2.7 12.6± 1.9 12.4± 2.7 8ppm 20ppm 12.7 ± 1.9 12.2± 1.7

Significant difference ;  $*: P \leq 0.05$ \*\* : P ≦ 0.01 Test of Dunnett (HAN260) BAIS 5

PAGE : 12

TABLE F1

HEMATOLOGY : MALE

oup Name	NO. of RED BLOOD CELL Animals 1 O⁵∕µℓ		HEMOGLOBIN g ⁄dl		HEMATOCRIT %		MCV f &		MCH pg		MCHC g /dl		PLATELET 1 0 <sup>3</sup> /µl		
Control	40	8.01±	1.46	12.8±	2. 3	39.0±	6. 1	49.2±	5. 3	16.1±	2.0	32.7±	1.5	920±	293
3.2ppm	44	7.59±	1. 73	11.9土	3. 1	36.8±	8.0	48.7±	2.8	15.6±	1.4	32.0±	2.2	1014±	339
8ppm	39	6.49±	2. 15**	10.3±	3. 5**	32.5±	9.0**	51.6土	7.9	16.0±	2. 2	31.1±	2. 4**	1085±	416
20ppm	9	7.79±	1.38	11.2±	2. 1	35.8±	5.6	46.1±	3. 1	14.5±	1.7	31.3±	1.9*	1077±	270

(HCL070)

EX : MALE	REPORT T	YPE : A1			PAGE : 2
roup Name	NO. of Animals	RETICUL %	OCYTE	·	
Control	40	4.6±	4. 1		
3.2ppm	44	6.0±	5.3		
8ppm	39	9.8±	7.6**		
20ppm	9	5.4±	3.4		

(HCL070)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] MEASURE. TIME : 1 SEX : MALE REPORT TYPE : A1 HEMATOLOGY (SUMMARY) ALL ANIMALS (105W)

(%) Group Name NO. of WBC Differential WBC  $10^3/\mu\ell$ Animals NEUTRO LYMPHO MONO EOSINO BASO OTHER Control 40 3.75± 1.29 54± 8 40± 8 4土 1±  $0\pm$ 1± 0 1 0 1 3. 2ppm 44  $43\pm$ 4.49± 1.63  $51\pm$ 9 9 4± 1  $1\pm$ 1 0± 0  $1\pm$ 0 39 9.80± 34.78  $52\pm$ 14 40± 13  $4\pm$ 1± 0± 4± 15 8ppm 1 1\* 0 20ppm 9 4.87± 2.22 62± 10 32士 9  $4\pm$ 1 1土 1 0± 0 2土 1\* Significant difference : \* : P  $\leq$  0.05 \*\* : P ≦ 0.01 Test of Dunnett

(HCL070)

BAIS 5

PAGE: 3

TABLE F2

HEMATOLOGY : FEMALE

ip Name	NO. of Animals	RED BLC 1 O <sup>6</sup> /J	DOD CELL	HEMOGLO g∕dl	BIN	HEMATOC %	RIT	MCV f L		MCH pg		MCHC g∕dl		PLATELE 1 O <sup>3</sup> ⁄μ	
Control	38	8.23±	0. 75	14.7±	1.2	42.5±	2. 9	51.8±	2. 6	17.9±	0.8	34.5±	0.6	652±	68
3. 2ppm	37	7.81±	1.00**	14.0±	1. 7*	40.6±	4. 2*	52.4±	3. 1	18.0±	1.0	34.3±	1.3	668±	149
8ppm	32	7.61±	1. 18**	13.7±	2. 1*	39.9±	5.2*	52.7±	3. 3	18.0±	1.4	34.1±	1.7	679±	186
20ppm	28	7.80±	1. 20*	13.9±	2.0*	40.7±	4. 7*	52.8±	4. 5	17.9±	1.1	34.0±	1.6	668±	135

ANIMAL : RAT F MEASURE. TIME : 1				ALL A	NIMALS (105W)				
SEX : FEMALE	REPORT 1	YPE : A1							PAGE : 5
Group Name	NO. of Animals	RETICULO %	OCYTE					 	
Control	38	2.4±	1.1						
3.2ppm	37	3.5±	4.0						
8ppm	32	3.6±	3.1						
20ppm	28	4.1±	6.5						
Significant o	lifference ;	* : P ≦ 0.	05	** : P ≦ 0.01	Test c	Dunnett		 	
(HCL070)							 	 	BAIS 5

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] MEASURE. TIME : 1 SEX : FEMALE REPORT TYPE : A1 HEMATOLOGY (SUMMARY) ALL ANIMALS (105W)

oup Name	NO. of Animals	WBC 1 0 <sup>3</sup> /		Di <sup>.</sup> NEUTRO	fferentia	I WBC (% Lympho	5)	MONO		EOSINO		BASO		OTHER		
Control	38	2.54±	2. 02	42±	12	52±	12	3±	1	2±	1	0±	0	1土	0	
3. 2ppm	37	3.85±	3.44*	44土	16	47土	16	3±	1	1土	1	0±	1	4土	13	
8ppm	32	3.31±	4.06	46土	13	47±	12	3±	1	2土	1	0±	1	1±	1	
20ppm	28	3.26±	2.39	47±	11	48±	12	3±	1	2土	1	0±	0	1土	1	

(HCL070)

BAIS 5

PAGE: 6

TABLE G1

BIOCHEMISTRY : MALE

STUDY NO. : 079	94
ANIMAL : RAT	F344/DuCrICrIj[F344/DuCrj]
MEASURE. TIME	1
SEX : MALE	REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY) ALL ANIMALS (105W)

roup Name	NO. of Animals	TOTAL P g ⁄dl	ROTEIN	ALBUMIN g∕dl		A/G RA1	10	T−BILII mg∕dl		GLUCOSE mg∕dl		T−CHOLES mg∕dl	STEROL	TR∣GLYCE mg∕d£	ERIDE
Control	40	6.5±	0. 3	2.8±	0. 2	0.8±	0. 1	0. 12±	0. 23	169±	31	163±	66	82±	69
3.2ppm	44	6.3±	0.3	2.8土	0.3	0.8±	0. 1	0.08±	0. 05	170±	27	151±	34	75±	54
8ppm	39	6.2土	0.5	2.6土	0.3*	0.7±	0.1	0.15±	0. 44	160±	26	145±	41	84±	86
20ppm	9	5.8±	0.8*	2.4±	0.5**	0.7±	0. 2	1.43±	4.08	130±	50*	1 <b>62</b> ±	61	49±	19

(HCL074)

X : MALE	REPORT T	YPE : A1													PAGE :
oup Name	NO. of Animals	PHOSPHC mg∕dl	DLIPID	AST U∕L		ALT U∕L		LDH U/L		ALP U∕L		G-GTP U∕L		CK U∕L	
Control	40	<b>24</b> 1±	94	89±	49	37±	11	128±	53	353±	167	6.9±	4.5	103±	35
3.2ppm	44	223±	41	102±	77	45±	54	140土	87	362±	101	7.0±	3.7	108±	34
8ppm	39	223±	56	110±	134	36±	22	144土	140	367±	159	6.2±	4. 3	114±	39
20ppm	9	275±	192	410土	992	71±	118	246±	370	566±	524	8.0±	10. 3	199±	271

(HCL074)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] MEASURE. TIME : 1 SEX : MALE REPORT TYPE : A1 BIOCHEMISTRY (SUMMARY) ALL ANIMALS (105W)

roup Name	NO. of Animals	UREA N mg∕dl	I TROGEN	CREATII mg/dl		SODIUM mEq∕£		POTASS I m Eq /		CHLORIDE mEq⁄£		CALCIU mg∕dl	A	I NORGAN mg/dl	IC PHOSPHORUS
Contro I	40	18.5±	3.5	0.37±	0.08	143±	2	3.9±	0. 4	107±	2	10.3±	0.4	3.9±	0. 6
3, 2ppm	44	19.8±	4. 7	0.35±	0.04	144±	2	4.0±	0. 3	107±	2	10.2±	0.3	4.0±	0.5
8ppm	39	20.1±	6.2	0.35±	0.06	143±	1	4.0±	0. 4	107±	1	10.2±	0.3	4.3±	0. 6**
20ppm	9	26.0±	25. 7	0.29±	0.04**	145±	3	4.2±	0. 4	108土	2	10.0±	0.3*	4.6±	1.8

(HCL074)

### BIOCHEMISTRY : FEMALE

TABLE G2

oup Name	NO. of Animals	TOTAL I g∕dl		ALBUMIN g ⁄ dl	1	A/G RAT	10	T-BILI mg∕dl		GLUCOSE mg∕dℓ		T−CHOLE mg∕dl	STEROL	TRIGLYC mg∕d£	ERIDE
Control	39	6.8±	0.6	3.5±	0.3	1.0±	0.1	0.06±	0. 02	$161\pm$	22	140±	39	72±	56
3. 2ppm	38	6.8±	0.5	3.5±	0.4	1.1±	0. 2	0.07±	0.04	156±	21	141±	47	74±	57
8ppm	35	6.7±	0.5	3.5±	0. 4	1.1±	0. 1	0.07±	0.04	158±	21	126±	22	61±	39
20ppm	28	6.4±	0.8	3.3±	0.5	1.1±	0. 1	$0.09 \pm$	0. 20	152土	33	123±	27	59土	35

X : FEMALE	REPORT T NO. of Animals	PHOSPHO mg/dl	LIPID	AST U∕L		ALT U∕L		LDH U/L		ALP U/L	, ,,	G-GTP U∕L		СК U/L	PAGE :
Control	39	247±	64	124土	74	59±	35	151±	57	205±	92	2.4±	1.3	92±	23
3.2ppm	38	250±	75	134±	85	59±	33	163±	86	228±	139	3.0±	3.3	97±	32
8ppm	35	227±	39	129±	86	54±	17	125±	47	220±	82	2.3±	1.7	94±	25
20ppm	28	227±	48	136±	79	56±	27	154土	101	248±	180	2.8±	2.6	113±	116

(HCL074)

X : FEMALE	REPORT	TYPE : A1													PAGE :
oup Name	NO. of Animals	UREA NI mg∕dl		CREATⅡ mg∕dl		SODIUM mEq∕£		POTASS mEq/		CHLORIDE mEq∕£		CALCIU mg∕dl		I NORGAN mg∕dl	IIC PHOSPHORU
Control	39	17.5±	2.5	0.30±	0. 05	143±	2	3.7±	0. 4	105±	1	10.3±	0.4	3.6±	0. 7
3.2ppm	38	17.0±	2.3	0.29±	0. 04	142土	1	3.7±	0.4	104±	2	10.5±	0.3	3.8±	0.6
8ppm	35	17.7±	4.1	0.28±	0. 04	143±	2	3.6±	0. 3	105±	2	10.2±	0.4	3.6土	0.9
20ppm	28	20.1±	9.6	0.26±	0.04**	142土	2	3.9±	0.8	105土	2	10.2±	0.3	4.2±	1.6

TABLE H1

URINALYSIS : MALE

STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] MEASURE. TIME : 1 SEX : MALE REPORT TYPE : A1 URINALYSIS

Group Name NO. of pH\_ Protein\_ Glucose\_ Ketone body Bilirubin - ± + 2+ 3+ 4+ CHI Animals 5.0 6.0 6.5 7.0 7.5 8.0 8.5 CHI - ± + 2+ 3+ 4+ CHI - ± + 2+ 3+ 4+ CHI - + 2+ 3+ CHI Control 42 0 1 4 3 15 10 9 0 0 1 21 20 0 42 0 0 0 0 0 32 8 1 1 0 0 42 0 0 0 3. 2ppm 45 0 0 2 4 22 12 5 0 0 1 16 28 0 45 0 0 0 0 0 40 5 0 0 0 0 45 0 0 0 8ppm 39 0 0 1 7 12 8 11 0 0 0 7 31 1 \* 39 0 0 0 0 0 22 14 3 0 0 0 37 1 0 1 20ppm 9 0 0 0 0 1 4 4 0 8001 \* 0 3 4 2 0 9 0 0 0 0 0 9 0 0 0 0 0 Significant difference ;  $*: P \leq 0.05$ Test of CHI SQUARE \*\* : P ≦ 0.01

(HCL101)

PAGE: 1

roup Name	NO. of Animals	Occult blood $-\pm$ + 2+ 3+ CHI	Urobilinogen ± + 2+ 3+ 4+ CHI	
Control	42	36 4 0 1 1	42 0 0 0 0	
3. 2ppm	42	40 1 2 1 1	45 0 0 0 0	
8ppm	39	34 0 2 1 2	39 0 0 0 0	
20ppm	9	6 1 1 0 1	9 0 0 0 0	

TABLE H2

URINALYSIS : FEMALE

STUDY NO. : 0794ANIMAL: RAT F344/DuCrlCrlj[F344/DuCrj]MEASURE. TIME : 1SEX : FEMALEREPORT TYPE : A1

URINALYSIS

Name	NO. of	pH_							F	rot	ein	1					Glu	1005	e				Ketor	e b	ody				Bi	irut	oin		
	Animals	5. 0	6. 0	6.5	7.0	7.5	8. 0	8.5 CHI	-	- :	<u>+</u> -	+ :	2+ 3	+ 4	+	CHI		±	+ 2	2+ 3	3+ 4+ CHI	I	- ±	+	2+	3+ 4-	+ (	CHI		+ :	2+ 3+	CHI	
Control	39	0	0	0	0	5	12	22		0	5	7 ·	1 1	6 (	)		39	0	0	0	0 0		9 27	2	1	0 0	0		39	0	0 0		
3.2ppm	41	0	2	1	3	3	11	21		1	51	1	71	7 (	)		41	0	0	0	0 0		15 23	3	0	0 (	0		40	1	0 0		
8ppm	36	0	1	2	1	3	3	26		1	41	5	7	9 (	)		36	0	0	0	0 0		13 22	1	0	0 (	0		36	0	0 0		
20ppm	30	0	2	1	2	0	9	16		1	81	1	7	3 (	)	*	30	0	0	0	0 0		9 20	0	1	0 (	0		30	0	0 0		

(HCL101)

BAIS 5

iroup Name	NO. of Animals	Occult blood $-\pm$ + 2+ 3+ CHI	Urobilinogen ± + 2+ 3+ 4+ CHI	
Control	39	36 0 0 1 2	39 0 0 0 0	
3. 2ppm	41	38 1 0 2 0	41 0 0 0 0	
8ppm	36	35 0 0 0 1	36 0 0 0 0	
20ppm	30	25 0 2 0 3	30 0 0 0 0	

TABLE I 1

GROSS FINDINGS : MALE

STUDY NO.: 0794ANIMAL: RAT F344/DuCrICrIj[F344/DuCrj]REPORT TYPE: A1SEX: MALE

#### GROSS FINDINGS (SUMMARY) ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	50	Control (%)	50	3.2ppm (%)	50	8ppm (%)	50	20ppm (%)
skin/app	nodu l e		1	(2)	8	(16)	5	(10)	8	(16)
subcutis	jaund i ce		0	( 0)	0	( 0)	0	( 0)	1	(2)
	mass		11	(22)	9	(18)	10	(20)	14	(28)
nasal cavit	white zone		0	(0)	0	( 0)	0	( 0)	1	(2)
	nodu i e		0	(0)	1	(2)	2	( 4)	14	(28)
lung	white zone		2	(4)	3	(6)	4	(8)	2	( 4)
	red zone		2	(4)	1	(2)	1	(2)	2	( 4)
	nodule		1	(2)	1	(2)	3	(6)	2	( 4)
	voluminous		0	( 0)	0	( 0)	0	( 0)	4	(8)
lymph node	enlarged		1	(2)	0	( 0)	1	(2)	3	(6)
thymus	enlarged		0	( 0)	0	( 0)	1	(2)	0	( 0)
spleen	enlarged		6	(12)	8	(16)	8	(16)	5	(10)
	white zone		0	( 0)	0	( 0)	1	(2)	1	(2)
	nodule		0	( 0)	0	( 0)	2	(4)	0	( 0)
	adhesion		0	( 0)	0	( 0)	0	( 0)	1	(2)
heart	white zone		1	(2)	0	( 0)	1	(2)	0	( 0)
oral cavity	nodule		0	( 0)	1	(2)	0	( 0)	0	( 0)
tongue	white zone		0	( 0)	1	(2)	0	( 0)	0	( 0)
stomach	gas		0	( 0)	0	( 0)	0	( 0)	4	(8)
	forestomach:nodule		0	( 0)	0	( 0)	1	(2)	2	(4)
	glandular stomach:erosion		0	( 0)	1	(2)	0	( 0)	0	( 0)
	glandular stomach:nodule		1	(2)	0	( 0)	1	(2)	0	( 0)

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

#### GROSS FINDINGS (SUMMARY) ALL ANIMALS (0-105W)

)rgan	Findings	Group Name NO. of Animals	Control 50 (%)	3.2ррт 50 (%)	8ppm 50 (%)	20ppm 50 (%)
stomach	glandular stomach:black zone		0 ( 0)	1 (2)	0 ( 0)	1 (2)
	glandular stomach:thick		1 (2)	0 ( 0)	0 ( 0)	0 ( 0)
small intes	gas		0 ( 0)	0 ( 0)	0 ( 0)	5 (10)
large intes	gas		0 ( 0)	0 ( 0)	0 ( 0)	5 (10)
liver	enlarged		2 ( 4)	1 (2)	3 (6)	2 (4)
	white zone		1 (2)	0 ( 0)	0 ( 0)	1 (2)
	nodule		0 ( 0)	2 ( 4)	2 ( 4)	1 (2)
	cyst		0 ( 0)	0 ( 0)	1 (2)	0 ( 0)
	rough		1 (2)	0 ( 0)	4 ( 8)	0 ( 0)
	herniation		7 (14)	9 (18)	5 (10)	11 (22)
ancreas	nodule		0 ( 0)	0 ( 0)	1 (2)	0 ( 0)
idney	white zone		0 ( 0)	0 ( 0)	0 ( 0)	1 (2)
	cyst		0 ( 0)	0 ( 0)	1 (2)	0 ( 0)
	granular		4 (8)	1 (2)	2 ( 4)	0 ( 0)
ırin bladd	urine:marked retention		1 (2)	1 (2)	1 (2)	1 (2)
ituitary	enlarged		6 (12)	3 (6)	4 (8)	0 ( 0)
	red zone		6 (12)	7 (14)	3 (6)	1 (2)
	nodule		3 (6)	3 (6)	3 (6)	0 ( 0)
	cyst		0 ( 0)	0 ( 0)	1 (2)	0 ( 0)
hyroid	enlarged		3 (6)	3 (6)	3 (6)	1 (2)
	red zone		0 ( 0)	0 ( 0)	1 (2)	0 ( 0)
drenal	enlarged		0 ( 0)	0 ( 0)	1 (2)	1 (2)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

#### GROSS FINDINGS (SUMMARY) ALL ANIMALS (0-105W)

0rgan	Findings	Group Name NO. of Animals	50	Control (%)	50	3.2ppm (%)	50	8ppm (%)	50	20ppm (%)
testis	nodule		39	(78)	46	( 92)	44	( 88)	24	(48)
brain	enlarged		1	(2)	0	( 0)	0	( 0)	0	( 0)
	red zone		1	(2)	0	( 0)	0	( 0)	3	(6)
	nodu l e		0	( 0)	0	( 0)	1	(2)	2	( 4)
spinal cord	red zone		0	( 0)	0	( 0)	0	( 0)	1	(2)
	black zone		0	( 0)	0	( 0)	0	( 0)	1	(2)
еуе	turbid		0	( 0)	0	( 0)	0	( 0)	4	(8)
	white		6	(12)	5	(10)	8	(16)	2	( 4)
	red		0	( 0)	0	( 0)	0	( 0)	1	(2)
Zymbal gl	nodule		1	(2)	0	( 0)	1	( 2)	0	( 0)
muscle	nodu l e		1	(2)	0	( 0)	1	(2)	1	(2)
pleura	nodu l e		0	( 0)	0	( 0)	0	( 0)	2	(4)
peritoneum	nodu l e		2	(4)	7	(14)	14	(28)	11	(22)
abdominal c	hemorrhage		1	(2)	0	( 0)	0	( 0)	0	( 0)
	ascites		0	( 0)	1	(2)	11	(22)	8	(16)
thoracic ca	pleural fluid		1	(2)	2	( 4)	1	(2)	0	( 0)
other	lip:nodule		1	(2)	1	(2)	0	( 0)	1	(2)
	eye lid:nodule		1	(2)	0	( 0)	1	(2)	0	( 0)
	ear : nodu l e		0	( 0)	0	( 0)	0	( 0)	1	(2)
	hindlimb:swollen		0	( 0)	0	( 0)	1	(2)	0	( 0)
	nose:elevated		0	( 0)	0	( 0)	0	( 0)	3	(6)
	nose : nodu l e		1	(2)	0	( 0)	0	( 0)	13	(26)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE	GROSS FINDINGS (SUMMARY) ALL ANIMALS (O-105W)				PAGE : 4
Organ Findings	Group Name NO. of Animals	Control 50 (%)	3.2ppm 50 (%)	8ppm 50 (%)	20ррт 50 (%)
whole body anemic		0 ( 0)	0 ( 0)	0 ( 0)	3 (6)
(HPT080)					BAIS 5

 $\bigcirc$ 

TABLE I 2

## GROSS FINDINGS : FEMALE

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : FEMALE

#### GROSS FINDINGS (SUMMARY) ALL ANIMALS (0-105W)

Group Name Control 3.2ppm 8ppm 20ppm Organ\_ Findings 50 (%) 50 (%) 50 (%) 50 (%) NO. of Animals skin/app nodule 0 ( 0) 1 (2) 3 (6) 0 ( 0) erosion 0 (0) 1 (2) 0 ( 0) 0 (0) scab 0 (0) 0 ( 0) 1 (2) 0 (0) subcutis jaundice 0 ( 0) 1 (2) 3 (6) 1 (2) mass 8 (16) 19 (38) 19 (38) 29 (58) nasal cavit 0 ( 0) nodule 0 (0) 1 (2) 6 (12) lung white zone 0 ( 0) 0 ( 0) 2 (4) 1 (2) red zone 1 (2) 0 ( 0) 1 (2) 0 ( 0) nodule 0 (0) 2 (4) 0 ( 0) 0 ( 0) lymph node enlarged 1 (2) 0 ( 0) 1 (2) 1 (2) thymus enlarged 1 (2) 0 (0) 0 ( 0) 0 ( 0) spleen enlarged 5 (10) 7 (14) 9 (18) 7 (14) nodule 0 ( 0) 0 (0) 1 (2) 0 ( 0) heart white zone 0 (0) 0 (0) 0 ( 0) 1 (2) tongue nodule 0 (0) 2 (4) 0 (0) 2 (4) stomach forestomach:ulcer 1 (2) 2 (4) 0 ( 0) 1 (2) forestomach:erosion 0 (0) 0 (0) 1 (2) 0 (0) forestomach:nodule 0 (0) 0 (0) 1 (2) 1 (2) glandular stomach:ulcer 0 (0) 0 ( 0) 1 (2) 0 ( 0) glandular stomach:erosion 1 (2) 0 (0) 1 (2) 1 (2) glandular stomach:nodule 0 ( 0) 0 ( 0) 1 (2) 0 ( 0) glandular stomach:black zone 0 (0) 0 ( 0) 1 (2) 0 ( 0)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 SEX : FEMALE

### GROSS FINDINGS (SUMMARY) ALL ANIMALS (0-105W)

Organ	Findings	Group Name NO. of Animals	50	Control (%)	50	3.2ppm (%)	50	8ppm (%)	50	20ppm (%)
small intes	adhesion		0	( 0)	0	( 0)	0	( 0)	1	(2)
liver	white zone		0	( 0)	0	( 0)	1	(2)	1	(2)
	red zone		0	( 0)	1	(2)	1	(2)	1	(2)
	nodule		0	( 0)	0	( 0)	1	(2)	1	(2)
	cyst		0	( 0)	1	(2)	0	( 0)	0	( 0)
	rough		0	( 0)	3	(6)	3	(6)	0	( 0)
	nodular		0	( 0)	1	(2)	0	( 0)	0	( 0)
	herniation		13	(26)	10	(20)	10	(20)	12	(24)
pancreas	nodule		0	( 0)	1	(2)	0	( 0)	0	( 0)
k i dney	sma I I		1	(2)	0	( 0)	0	( 0)	0	( 0)
	cyst		1	(2)	1	(2)	0	( 0)	0	( 0)
	deformed		0	( 0)	0	( 0)	1	(2)	0	( 0)
	granular		0	( 0)	0	( 0)	1	(2)	0	( 0)
	hydronephros i s		0	( 0)	0	( 0)	0	( 0)	1	(2)
urin bladd	urine:marked retention		0	( 0)	0	( 0)	2	(4)	2	( 4)
	urine:red		0	( 0)	0	( 0)	0	( 0)	1	(2)
pituitary	en l arged		12	(24)	15	( 30)	9	(18)	5	(10)
	red zone		12	(24)	14	(28)	6	(12)	5	(10)
	nodule		1	(2)	2	( 4)	3	(6)	3	(6)
thyroid	en l arged		0	( 0)	0	( 0)	4	(8)	1	(2)
adrenal	enlarged		1	(2)	0	( 0)	1	(2)	0	( 0)
ovary	enlarged		0	( 0)	0	( 0)	1	(2)	2	( 4)





STUDY NO. : 0794 ANIMAL : RAT F344/DuCr!Cr!j[F344/DuCr] REPORT TYPE : A1 SEX : FEMALE

GROSS FINDINGS (SUMMARY) ALL ANIMALS (O-105W)

rgan	Findings	Group Name Contr NO. of Animals 50 (%)	ol 3.2ppm 50 (%)	8ppm 50 (%)	20ppm 50 (%)
vary	cyst	2 ( 4)	1 (2)	3 (6)	0 ( 0)
terus	black zone	0 ( 0)	1 ( 2)	1 ( 2)	1 (2)
	nodule	5 (10)	4 ( 8)	4 ( 8)	11 (22)
	dilated lumen	0 ( 0)	0 ( 0)	1 ( 2)	2 (4)
agina	nodule	0 ( 0)	0 ( 0)	1 (2)	1 (2)
	prolapse	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
rain	hemorrhage	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	nodule	0 ( 0)	0 ( 0)	0 ( 0)	1 (2)
/e	turbid	0 ( 0)	0 ( 0)	0 ( 0)	1 (2)
	white	5 (10)	2 ( 4)	2 ( 4)	1 (2)
	red	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
scle	nodule	0 ( 0)	1 ( 2)	1 (2)	0 ( 0)
eura	nodule	0 ( 0)	0 ( 0)	0 ( 0)	1 (2)
eritoneum	nodule	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
etroperit	mass	0 ( 0)	0 ( 0)	1 (2)	0 ( 0)
odominal c	hemorrhage	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	ascites	0 ( 0)	0 ( 0)	1 (2)	2 (4)
noracic ca	pleural fluid	0 ( 0)	0 ( 0)	1 (2)	1 (2)
her	lip:nodule	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0)
	ear:nodule	0 ( 0)	0 ( 0)	1 (2)	0 ( 0)
	upper jaw:nodu!e	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)
	nose:elevated	0 ( 0)	0 ( 0)	0 ( 0)	1 (2)

ANIMAL REPORT TYPE	: 0794 : RAT F344/DuCrICrIj[F344/DuCrj] : A1 : FEMALE	GROSS FINDINGS (SUMMARY) ALL ANIMALS (O-105W)				PAGE : 8
Organ	Findings	Group Name NO. of Animals	Control 50 (%)	3.2ppm 50 (%)	8ppm 50 (%)	20ppm 50 (%)
other	nose: nodu l e		0 ( 0)	0 ( 0)	0 ( 0)	1 (2)
whole body	anemic		0 ( 0)	1 (2)	0 ( 0)	2 ( 4)
(HPT080)						BAIS 5

TABLE J1

ORGAN WEIGHT, ABSOLUTE : MALE

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE UNIT: g

Significant difference ; \* : P  $\leq$  0.05

\*\* : P ≦ 0.01

ORGAN WEIGHT:ABSOLUTE (SUMMARY) SURVIVAL ANIMALS (105W)

roup Name	NO. of Animals	Body Weight	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS	
Control	40	373± 28	0.077± 0.016	3.216± 1.300	1.165± 0.103	1.355± 0.103	2.649± 0.224	
3. 2ppm	44	369± 35	0.075± 0.013	3.723± 1.270	1.198土 0.109	1.455± 0.351	2.682± 0.182	
8ppm	39	363± 53*	0.080± 0.015	3.790± 1.523	1.239土 0.125*	1.439± 0.233	2.733± 0.229	
20ppm	9	295± 39**	0.105± 0.112	3.278± 1.261	1.150± 0.162	1.302± 0.166	2.583± 0.213	

Test of Dunnett

(HCL040)

BAIS 5

STUDY NO. : 0794 ANIMAL : RAT REPORT TYPE : A1 SEX : MALE	F344/DuCrICrI	j[F344/DuCrj]				N WEIGHT:ABSO IVAL ANIMALS	UTE (SUMMARY) (105W)	
UNIT: g								PAGE : 2
Group Name	NO. of Animals	SPLE	EEN	LIV	ER	BRA	N	
Control	40	1.141±	1.287	10.400±	1.679	2.065±	0. 068	
3. 2ppm	44	1.093±	0. 856	10.427±	1.539	2.057±	0. 070	
8ppm	39	1.519±	2. 386**	10.643±	1.938	2.059±	0. 058	
20ppm	9	0.729±	0. 230	8.934±	0. 871	2.005±	0. 060	
Significant	difference ;	*:P≦0.0	)5 **	: P ≦ 0.01			Test of Dunnett	

(HCL040)

BAIS 5

TABLE J2

ORGAN WEIGHT, ABSOLUTE : FEMALE

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : FEMALE UNIT: g ORGAN WEIGHT:ABSOLUTE (SUMMARY) SURVIVAL ANIMALS (105W)

Group Name	NO. of Animals	Body	Weight	ADRE	NALS	OVAR	IES	HEAR	T	LUNG	S	KIDN	EYS	
Control	39	269±	36	0.081±	0. 027	0.125±	0. 031	0.844±	0. 066	0.961±	0. 052	1.802土	0. 143	
3. 2ppm	38	265±	35	0.077±	0.014	0.141±	0. 085	0.875±	0. 073	1.010±	0. 160	1.819±	0. 180	
8ppm	35	247±	33*	0.111±	0.216	0.700±	3. 283	0.827±	0. 074	0.984±	0. 147	1.753±	0. 122	
20ppm	28	232±	25**	0.076±	0.017	0.134±	0.068	0.836±	0.063	0.995±	0. 132	1.807±	0. 129	

(HCL040)

BAIS 5

STUDY NO. : 0794 ANIMAL : RAT REPORT TYPE : A1 SEX : FEMALE	F344/DuCrICrI	j[F344/DuCrj]				N WEIGHT:ABSO IVAL ANIMALS		
UNIT: g Group Name	NO. of Animals	SPL	EEN	LIVE	ĒR	BRA	1	PAGE : 4
Control	39	0.589±	0. 217	6.759±	1. 376	1.888±	0. 082	
<b>3.</b> 2ppm	38	0.824±	0. 911	6.932±	1. 412	1.880±	0. 067	
8ppm	35	0.862±	1. 302	6.311±	0.970	1.852±	0. 081*	
20ppm	28	0.595±	0. 459	6.544±	2. 461	1.862±	0.051*	
Significant	difference ;	* : P ≦ 0.0	05 **	: P ≦ 0.01			Test of Dunnett	
(HCL040)								BAIS 5

TABLE K1

ORGAN WEIGHT, RELATIVE : MALE

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE UNIT: % ORGAN WEIGHT:RELATIVE (SUMMARY) SURVIVAL ANIMALS (105W)

oup Name	NO. of Animals	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS	
Control	40	373± 28	0.021± 0.004	0.869± 0.370	0.314± 0.030	0.365± 0.029	0.712± 0.051	
3.2ppm	44	369± 35	0.021± 0.003	1.023± 0.369	0.327± 0.039	0.396± 0.092	0.732± 0.068	
8ppm	39	363± 53*	0.022± 0.006	1.048± 0.406	0.346± 0.050**	0.404± 0.098**	0.764± 0.110**	
20ppm	9	295 <b>士 39**</b>	0.037± 0.040*	1.089± 0.335	0.393± 0.047**	0.448± 0.075**	0.887± 0.103**	

(HCL042)

BAIS 5

STUDY NO. : 0794 ANIMAL : RAT : REPORT TYPE : A1 SEX : MALE UNIT: %	F344/DuCrlCrlj	[F344/DuCrj]		EIGHT:RELATIVE (SUMMARY) L ANIMALS (105W)	
Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN	PAGE : 2
Control	40	0.304± 0.331	2.790± 0.405	0.557± 0.036	
3.2ppm	44	0.294± 0.221	2.833± 0.339	0.562± 0.052	
8ppm	39	0.435± 0.805**	2.958± 0.598	0.576± 0.068	
20ppm	9	0.247± 0.075	3.078± 0.487*	0.693± 0.114**	
Significant o	difference ;	*:P≦0.05 **:	P ≦ 0.01	Test of Dunnett	

(HCL042)

BAIS 5

TABLE K2

ORGAN WEIGHT, RELATIVE : FEMALE

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 SEX : FEMALE UNIT: % ORGAN WEIGHT:RELATIVE (SUMMARY) SURVIVAL ANIMALS (105W)

up Name	NO. of Animals	Body W (	leight (g)	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS	
Control	39	269±	36	0.030± 0.012	0.047± 0.012	0.316± 0.028	0.361± 0.041	0.675± 0.062	
3.2ppm	38	265±	35	0.029± 0.004	0.054± 0.034	0.334± 0.038	0.385± 0.065	0.693± 0.072	
8ppm	35	247±	33*	0.044± 0.082	0.267± 1.224	0.338± 0.044*	0.405± 0.089*	0.719± 0.101	
20ppm	28	232±	25**	0.033± 0.006*	0.059± 0.035*	0.363± 0.035**	0.434± 0.080**	0.783± 0.050**	

(HCL042)

BAIS 5

.

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : FEMALE UNIT: %

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN	
Control	39	0.221± 0.086	2.510± 0.364	0.711± 0.083	
3. 2ppm	38	0.309± 0.334	2.615± 0.368	0.720± 0.084	
8ppm	35	0.371± 0.613	2.570± 0.397	0.758± 0.081*	
20ppm	28	0.263± 0.233	2.861± 1.277**	0.811± 0.082**	
Significant	difference :	*:P≦0.05 **:	P ≦ 0.01	Test of Dunnett	
(HCL042)					BAIS

ORGAN WEIGHT:RELATIVE (SUMMARY)

SURVIVAL ANIMALS (105W)

TABLE L1

# HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS : MALE

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

		roup Name o. of Animals on Study	50	Contro	51			50	3. 2pj	pm		5	8 0	pm			5		ppm
rgan		rade 1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2 (9	2+	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)		1+ (%)	2+ (%)	3+ (%)	
Integumentary	y system/appandage}																		
ubcutis	inflammation	0 ( 0)	<50) 1 ( 2) (	0	0 ( 0)	0 ( 0)		<50> ) )) (	0	0 ( 0)	0 0) (	0	0> 0 (0)	0 ( 0)		0 0) (	<5 0 0)	0	( C
	inflammatory infiltration	0 ( 0)	0 ( 0) (	0 0)	0 ( 0)	0 ( 0)		) )) (	0 0)	0 ( 0)	1 2) (	0 0)	0 ( 0)	0 ( 0)		0 0) (	0 0)	0 ( 0)	( C
Respiratory s	system]																		
asal cavit	thrombus	1 ( 2)	<50) 0 ( 0) (	0	0 ( 0)	1 (2)		<50> ) )) (	0	0 ( 0)	2 4) (	0	0> 0 (0)	0 ( 0)		0 0) (	<5 0 0)	0	( C
	mineralization	41 ( 82)	0 ( 0) (	0 0)	0 ( 0)	46 (92)	( (	) )) (	0 0)	0 ( 0)	2  4) (	0 0)	0 ( 0)	0 ( 0)		22 14) (	0 0)	0 ( 0)	0 ( 0
	squamous cell hyperplasia with atypia	0 ( 0)	0 ( 0) (	0 0)	0 ( 0)	1 (2)		) )) (	0 0)	0 ( 0)	2 4) (	0 0)	0 ( 0)	0 ( 0)			16 32)	7 (14)	0 ( 0
	eosinophilic change:olfactory epitheliu		5 (10) (	0 0)	0 ( 0)	43 (86)	8 (10		0 0)	0 ( 0)	10 10) (	2 4)	0 ( 0)	0 ( 0)		17 34) (	0 0)	0 ( 0)	0 ( 0
	eosinophilic change:respiratory epithel		0 ( 0) (	0 0)	0 ( 0)	12 (24)	( (	) )) (	0 0)	0 ( 0)	1 2) (	0 0)	0 ( 0)	0 ( 0)	(	1 2) (	0 0)	0 ( 0)	0 ( 0

b : Number of animals with lesion

(c) c:b/a\*100

Significant difference ; \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (O-105W)

		up Name of Animals on Study	C( 50	ontrol				3.: 50	2ppm			50	8ppm				20 50	Oppm	
Organ	Gra Findings	-	2+	3+ (%)	4+ (%)	1+ (%)		3		1+ (%)	2+ (%)	⊦ 3			1+ (%)		3		4+ (%)
{Respiratory	system)																		
nasal cavit	inflammation:foreign body	11 ( 22)	<50> 5 ( 10) (	0	0 0)	19 (38)	7	-	0 ) ( 0)	14 (28)	4		0 ) ( 0)	(	0 (0)	< 0 ( 0)	50> 0 ( 0)		0 ** 0)
	inflammation:respiratory epithelium	9 (18)	0 ( 0) (	0 0) (	0 0)	17 (34)	0 ( 0)	0 ( 0)	0 ( 0)	9 (18)	0 ( 0)	0	0 ) ( 0)	(	6 ( 12)	0 ( 0)	0 ( 0)		0 0)
	respiratory metaplasia:olfactory epitheli		0 ( 0) (	0 0) (	0 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ) ( 0)	7 (14)	0 ( 0)	0	0 ) ( 0)		14 (28)	0 ( 0)	0 ( 0)		0 ** 0)
	respiratory metaplasia:gland	46 ( 92)	2 ( 4) (	0 0) (	0 0)	40 (80)	6 (12)	0 ( 0)	0 ) ( 0)	36 (72)	9 (18)	0	0 ) ( 0)		23 (46)	3 (6)	0 ( 0)		0 ** 0)
	squamous cell metaplasia:respiratory epit		0 ( 0) (	0 0) (	0 0)	4 (8)	0 ( 0)	0 ( 0)	0 ( 0)	8 (16)	0 ( 0)	0 ( 0	0 ) ( 0)		4 ( 8)	3 (6)	0 ( 0)		0 * 0)
	squamous cell metaplasia:olfactory epithe		0 ( 0) (	0 0) (	0 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0	0 ) ( 0)	(	2 ( 4)	1 (2)	0 ( 0)		0 0)
	ulcer:respiratory epithelium	0 ( 0)	1 (2)(	0 0) (	0 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2)	0 ( 0)	0 ( 0	0 ) ( 0)	(	5 (10)	2 ( 4)	1 (2		0 0)
	ulcer:olfactory epithelium	0 ( 0)	0 ( 0) (	0 0) (	0 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0	0 ) ( 0)	(	2 ( 4)	1 (2)	0 ( 0)		0 0)

Grade 1+: Slight 2+: Moderate 3+: Marked 4+: Severe

< a > a : Number of animals examined at the site

b b: Number of animals with lesion

(c) c:b/a\*100

Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (O-105W)

		Group Name No. of Animals on Stud	iv	5	Cont i0	rol					50	3. 2p	pm			50	8pt	om				50	20pp	m
Organ	Findings	Grade	1+ (%)	2+ (%)	3+ (%)		4+ (%)		1+ (%)	2 (%	+	3+ (%)	4+ (%)	1+ (%)		2+ %)	3+ (%)	4+ (%)		1+ (%)	2 (%	2+	3+ (%)	4+ (%)
{Respiratory s	ystem}											-												
nasal cavit	squamous cell metaplasia with atypia: ium		0 0) (	0	io> 0 (0)		0 0)	(	5 10)	0		0	0 ( 0)	10 (20)		<50) 5 0) (	0	0 ** ( 0)		2 4)	4	<50> 1 3) (	0 0) (	0* (0)
	hyperplasia:nasal gland	(	0 0) (	0 0)	0 ( 0)		0 0)	(	0 0)	0		0 0)	0 ( 0)	0 ( 0)		0 0) (	0 0)	0 ( 0)	(	3 6)	1	?) (	0 0) (	0 ( 0)
	hyperplasia:transitional epithelium	(	0 0) (	0 ( 0)	0 ( 0)		0 0)		15 30)	1 (2	) (	0 0)	0 * ( 0)	26 (52)	(1	7 4) (	2 4)	0 ** ( 0)		2 4)	0 ( 0	) )) (	0 0) (	0 ( 0)
	regeneration:respiratory epithelium	(	0 0) (	0 ( 0)	0 ( 0)		0 0)	(	0 0)	0	) (	0 0)	0 ( 0)	3 (6)	(	0 0) (	0 0)	0 ( 0)	(	0 0) (	0	)) (	0 0) (	0 ( 0)
	regeneration:olfactory epithelium	(	0 0) (	0 0)	0 ( 0)		0 0)	(	0 0)	0	) (	0 0)	0 ( 0)	2 ( 4)	(	0 0) (	0 0)	0 ( 0)	(	1 2) (	0	) )) (	0 0) (	0 ( 0)
	atrophy:olfactory epithelium	(	2 4) (	0 0)	0 ( 0)		0 0)	(	5 10)	0	) (	0 0)	0 ( 0)	10 (20)	(	4 8) (	0 0)	0** (0)		16 32) (	3 (6	; ;) (	0 0) (	0 ** ( 0)
	necrosis:olfactory epithelium	(	0 0) (	0 0)	0 ( 0)		0 0)	(	0 0)	1 (2		0 0)	0 ( 0)	7 (14)		0 0) (	0 0)	0* (0)	(	0 0) (	0		0 0) (	0 ( 0)
	necrosis:respiratory epithelium	(	0 0) (	0 0)	0 ( 0)		0 0)	(	1 2)	0		0 0)	0 ( 0)	2 ( 4)	(	0 0) (	0 0)	0 ( 0)	(	0 0) (	0 ( 0	)) (	0 0) (	0 ( 0)

Grade 1+:Slight 2+:Moderate 3+:Marked 4+:Severe

b b: Number of animals with lesion

(c) c:b/a\*100

Significant difference : \* : P  $\leq$  0.05  $\,$  \*\* : P  $\leq$  0.01  $\,$  Test of Chi Square

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (O-105W)

		Group Name No. of Animals on Stu	d.		С 50	ontro	bl				50	3. 2p	mc				50	8p	pm					50		ppm	
Organ	Findings	Grade	1+ (%)	2 (%	+	3+ (%)	4+ (%)		1+ (%)	2 (%	+	3+ (%)	4+ (%)		1+ (%)	2 (%	÷	3+ (%)		4+ %)		1+ (%)		2+ (%)	3+ (%)		4+ (%)
{Respiratory	system]																										
nasal cavit	hyperplasia:respiratory epithelium	(	0 0)	0		0 0)	0 ( 0)	(	3 6)		<50> ) (	1 2)	0 ( 0)	(	1 2)	0	<50> ) (	0 0)	(	0 D)	(	2 4)	(	<50) 2 4) (	> 0 0)	(	0 0)
larynx	inflammation cell	(	0 0)	0	<50> ) (	0 0)	0 ( 0)	(	0 0)	0	<50> ) (	0	0 ( 0)	(	2 4)	0	<50> ) (	0 0)	(	0 D)	(	0 0)	(	<50) 0 0) (	0	(	0 0)
	inflammation	. (	3 6)	0		0 0)	0 ( 0)	(	1 2)	0 ( 0	) (	0 0)	0 ( 0)	(	2 4)	0 ( 0	) (	0 0)	(	0 0)	(	1 2)	(	0 0) (	0 0)	(	0 0)
lung	congestion	(	1 2)	0	<50> ) (	0 0)	0 ( 0)	(	0 0)	0	<50> ) (	0 0)	0 ( 0)	(	1 2)	0	<50> ) (	0 0)	(	0 D)	(	1 2)	(	<50) 0 0) (	> 0 0)	(	0 0)
	hemorrhage	(	0 0)	0 ( 0)	) (	0 0)	0 ( 0)	(	1 2)	1	) (	0 0)	0 ( 0)	(	2 4)	0 ( 0	) (	0 0)	(	0 0)	(	3 6)	(	1 2) (	0 0)	(	0 0)
	edema	(	2 4)	0 ( 0)	) (	0 0)	0 ( 0)	(	0 0)	0	) (	0 0)	0 ( 0)	(	1 2)	0	) (	0 0)	( )	) )	(	3 6)	(	0 0) (	0 0)	(	0 0)
	inflammatory infiltration	(	0 0)	0 ( 0)		0 0)	0 ( 0)	(	0 0)	0		0 0)	0 ( 0)	(	0 0)	0	) (	0 0)	( )	) ))	(	0 0)		1 2) (	0 0)		0 0)

Grade 1+: Slight 2+: Moderate 3+: Marked 4+: Severe

 $\langle \, a \, \rangle \qquad \ \ a$  : Number of animals examined at the site

b b : Number of animals with lesion

(c) c:b/a\*100

Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

PAGE: 4

 $\bigcirc$ 

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (O-105W)

		Group Name No. of Animals on Study		Co 50	ntro	1				50 50	3. 2pp	om				50	8r	mqq					2 50	20pp	m
Organ	Findings	Grade 1+ (%)	2 (%)	+	3+ %)	4+ (%)		1+ (%)	2+ (%)		3+ (%)	4+ (%)		1+ (%)	2 (%	50 + )	3+ (%)	4+ (%)			1+ %)	2+ (%)	. 3	3+ 6)	4- (%)
Respiratory	system}																								
lung	lymphocytic infiltration	0 ( 0)	0	<50> ) (	0 0) (	0 0)	(	0 0) (	< 0 ( 0)	50> (	0 0)	0 ( 0)	(	0 0)	0	<50) ) (	0 0)	0 ( 0)		( ;	1 2) (	< 0 0)	(50) (	) )) (	0 ( 0)
	fibrosis:focal	1 ( 2)	0 ( 0)	) (	0 0) (	0 0)	(	0 0) (	0 ( 0)	(	0 0)	0 ( 0)	(	0 0)	0 ( 0	) (	0 0)	0 ( 0)		( (	) 0) (	0 0)	( (	)) (	0 ( 0)
	bronchiolar-alveolar cell hyperplasia	a 5 (10)	2 (4)	) (	0 0) (	0 0)	( 1	5 10) (	4 (8)	(	0 0)	0 ( 0)	(	4 8)	1 (2	) (	1 2)	0 ( 0)		( :	 2) (	2 4)	( (	)) (	0 ; 0;
	accumulation of histiocyte	0 ( 0)	0 ( 0)	) (	0 0) (	0 0)	(	1 2) (	0 ( 0)	(	0 0) (	0 ( 0)	(	0 0)	0 ( 0	) (	0 0)	0 ( 0)		( (	) )) (	0 0)	( (	) )) (	0 ( 0)
{Hematopoieti	c system}																								
bone marrow	granulation	0 ( 0)	0 ( 0)	<50> ) (	1 2) (	0 0)	(	0 0) (	< 0 ( 0)	50> (	0 0) (	0 ( 0)	(	0 0)	0 ( 0	<50> ) (	0 0)	0 ( 0)		( :	1 2) (	< 0 0)	50> C ( C	) )) (	0 ( 0)
	increased hematopoiesis	7					1	10			3	0		9	14		8	0	**	-	7	9	6	;	0

(14) (6) (6) (0) (20) (14) (6) (0) (18) (28) (16) (0) (14) (18) (12) (0) lymph node <50> <50> <50> <50> congestion 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 (0)(0)(0)(0) (0)(0)(0)(0) ( 0) ( 0) ( 0) ( 0) (2)(0)(0)(0)

Grade 1+: Slight 2+: Moderate 3+: Marked 4+: Severe

 $\langle a \rangle$  a : Number of animals examined at the site

b b : Number of animals with lesion

(c) c:b/a\*100

Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

SEX :	MALE					PAGE : 6
		Group Name No. of Animals on Study Grade 1+	Control 50 2+ 3+ 4+	3.2ppm 50 1+ 2+ 3+ 4+	8ppm 50	20ppm 50
Organ	Findings	(%)	(%) (%) (%)	1+ 2+ 3+ 4+ (%) (%) (%) (%)	1+ 2+ 3+ 4+ (%) (%) (%) (%)	1+ 2+ 3+ 4+ (%) (%) (%) (%)
{Hematopoieti	ic system)					
lymph node	inflammatory infiltration	0 ( 0)	<50> 0 0 0 ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 1 0 0 0 ( 2) ( 0) ( 0) ( 0)
spleen	congestion	0 ( 0)	<50> 0 0 0 ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 1 0 0 0 ( 2) ( 0) ( 0) ( 0)
	deposit of hemosiderin	1 ( 2)	0 0 0 ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	5 0 0 0 (10) (0) (0) (0)
	fibrosis:focal	0 ( 0)	0 0 0 ( 0) ( 0) ( 0)	1 0 0 0 (2)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)
	extramedullary hematopoiesis	17 ( 34)	3 1 0 (6)(2)(0)	9 10 4 0* (18) (20) (8) (0)	8 12 11 0 ** (16) (24) (22) (0)	7 5 10 0 *** (14) (10) (20) (0)

{Circulatory system}

heart		<50>	<50>	<50>	<50>					
	thrombus	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 (0)(0)(0)(0)(0)	1 0 0 0 (2)(0)(0)(0)	2 0 0 0 ( 4) ( 0) ( 0) ( 0)					
Grade < a > b	1+ : Slight 2+ : Moderate 3+ : Mar a : Number of animals examined at the site b : Number of animals with lesion	ed 4+ : Severe								

(c) c:b/a\*100 Significant difference ; \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

(HPT150)

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (O-105W)

		Group Name No. of Animals on Study	0 50	ontro			3. 2 50	2ppm			3ppm			Oppm
Irgan	Findings	Grade 1+ (%)	2+	3+ (%)	4+ (%)	1+ 2+ (%) (%)	- 3+		1+ 2 (%) (9	50 (+ 3+ (%)		1+ (%)	50 2+ 3+ (%) (%)	
Circulatory	system]													
leart	mineralization	1 ( 2)	<50> 0 ( 0) (	0	0 0)	<pre>     1 0     ( 2) ( 0) </pre>	(50> 0 (0)	0 ( 0)	0 ( ( 0) ( (	<50> 0 0) ( 0)	0 ( 0)	0 ( 0) (	<50> 0 0 ( 0) ( 0)	( ) ( (
	myocardial fibrosis	34 (68)	10 (20) (	0 0) (	0 0)	32 6 (64) (12)	0 ( 0)		34 11 (68) (22	0 :) ( 0)		32 (64) (	70 (14)(0)	) ( )
	subendocardial fibrosis	0 ( 0)	0 ( 0) (	0 0) (	0 0)	0 0 (0)(0)	0 ( 0)	0 ( 0)	1 ( (2) ( (	) ( 0)	0 ( 0)	0 ( 0) (	0 0 (0)(0)	)   ( )
artery/aort	mineralization	1 ( 2)	<50> 0 ( 0) (	0	0 0)	<pre></pre>	(50> 0 (0)		0 ( ( 0) ( (	<50> 0 0) ( 0)	0 ( 0)	0 ( 0) (	<50> 0 0 ( 0) ( 0)	
Digestive sy	stem}													
congue	squamous cell hyperplasia	0 ( 0)	<50> 0 ( 0) (	0	0 0)	< 0 1 ( 0) ( 2)			0 ( ( 0) ( 0	<50> 0 ) ( 0)	0 ( 0)	0 ( 0) (	<50> 0 0 ( 0) ( 0)	
	mineralization:artery	1 ( 2)	0 ( 0) (	0 0) (	0 0)	00 (0)(0)	0 ( 0)		0 ( ( 0) ( (	) ( 0)	0 ( 0)	0 ( 0) (	0 0 (0) (0)	

Significant difference ;  $\ \ *$  : P  $\leq$  0.05  $\ \ **$  : P  $\leq$  0.01  $\ \$ Test of Chi Square

(HPT150)

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCr] REPORT TYPE : A1 SEX : MALE

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

		······································																						
		Group Name No. of Animals on Study Grade 1+	Ŧ	50 2+	Contr 3+	ol 4+	1.		50 2+	3. 2p 3+	pm 4+		1+		50 2+		орт 4+		4.		50 2+	20p 3+		4+
Organ	Findings	(%)		(%)	(%)	(%)	1+ (%)		(%)	(%)	(%)		(%)		(%)	(%)	(%)		1+ (%)		2+ (%)	(%)	(9	
{Digestive sy	vstem}																							
esophagus	inflammation	0 ( 0)		<50 0 0) (	0	0 ( 0)	0 ( 0)	(	<50 0 0) (	0	0 (0)	(	0 ( 0)		<50) 0 0) (	0	0 ( 0)	(	1 2)		<50 0 0) (	> 0 0)	( (	D 0)
stomach	erosion:forestomach	0 ( 0)		<50 0 0) (	0	0 ( 0)	0 ( 0)		<50 0 0) (	0	0 ( 0)	(	0 ( 0)		<50) 0 0) (	0	0 ( 0)	(	1 2)		<50 0 0) (	> 0 0)		0 0)
	ulcer:forestomach	1 ( 2)	) (	1 2) (	0 0)	0 ( 0)	1 (2)	(	0 0) (	0 0)	0 ( 0)	(	1 ( 2)	(	0 0) (	0 0)	0 ( 0)	(	3 6)	(	2 4) (	0 0)	( (	
	hyperplasia:forestomach	1 ( 2)		0 0) (	0 0)	0 ( 0)	4 (8)	(	0 0) (	0 0)	0 ( 0)	(	3 6)	(	1 2) (	0 0)	0 ( 0)	(	5 10)	(	3 6) (	0 0)	( (	0 * 0)
	erosion:glandular stomach	0 ( 0)		0 0) (	0 0)	0 ( 0)	3 (6)	(	0 0) (	0 0)	0 ( 0)	(	0 0)	(	0 0) (	0 0)	0 ( 0)	(	1 2)		1 2) (	0 0)	( (	
	ulcer:glandular stomach	1 ( 2)		1 2) (	0 0)	0 (0)	1 (2)	(	0 0) (	0 0)	0 ( 0)	(	0 0)	(	0 0) (	0 0)	0 ( 0)	(	1 2)		1 2) (	0 0)		0 0)
	hyperplasia:glandular stomach	1 ( 2)		1 2) (	0 0)	0 (0)	3 (6)	(	0 0) (	0 0)	0 ( 0)	(	2 4)	(	0 0) (	0 0)	0 ( 0)	(	1 2)		0 0) (	0 0)		0 0)
	mineralization:glandular stomach	0 ( 0)		1 2) (	0 0)	0 ( 0)	0 ( 0)	(	0 0) (	0 0)	0 ( 0)	(	0 0)	(	0 0) (	0 0)	0 ( 0)	(	0 0)		0 0) (	0 0)		0 0)

Grade 1+: Slight 2+: Moderate 3+: Marked 4+: Severe

< a > a : Number of animals examined at the site

b b: Number of animals with lesion

(c) c:b/a\*100

Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (O-105W)

<b>.</b>																	
		Group Name No. of Animals on Study	5	Contr 50	-01		50	3. 2pp	om		50	8p;	om		50	20pp	m
Organ	Findings	Grade 1+ 	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Digestive sy	rstem]																
small intes	hyperplasia	0 ( 0)	<5 0 ( 0)	i0> 0 (0)	0 ( 0)	0 ( 0) (	<50 0 0) (	0	0 ( 0)	0 ( 0)	<50 0 ( 0)	0	0 ( 0)	0 ( 0) (	<50 1 2) (	> 0 0) (	0 ( 0)
liver	herniation	7 (14)	<5 0 ( 0)	i0> 0 (0)	0 (0)	9 (18) (	<50 0 0) (	0	0 ( 0)	5 (10)	<50 0 ( 0)	0	0 ( 0)	11 (22) (	<50 0 0) (	0	0 ( 0)
	necrosis:central	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0) (	1 2) (	0 0)	0 ( 0)	1 (2)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 4) (	0 0) (	0 0) (	0 0)
	granulation	8 (16)	0 ( 0)	0 ( 0)	0 ( 0)	6 (12) (	0 0) (	0 0)	0 ( 0)	4 (8)	1 (2)	0 ( 0)	0 ( 0)	1 (2)(	0 0) (	0 0) (	0 * ( 0)
	inflammatory cell nest	7 (14)	0 ( 0)	0 ( 0)	0 ( 0)	5 (10) (	0 0) (	0 0)	0 (0)	1 (2)	0 ( 0)	0 (0)	0 (0)	1 (2)(	0 0) (	0 0) (	0 0)
	extramedullary hematopoiesis	2 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	3 (6)(	0 0) (	0 0) (	0 (0)	2 ( 4)	0 ( 0) (	0 ( 0) (	0 ( 0)	3 (6)(	0 0) (	0 0) (	0 ( 0)
	clear cell focus	1 ( 2)	1 (2)	0 ( 0)	0 ( 0)	1 (2) (	0 0) (	0 0) (	0 (0)	0 ( 0)	0 ( 0) (	0 ( 0) (	0 (0)	0 (0)(	0 0) (	0 0) (	0 ( 0)
	acidophilic cell focus	24 ( 48)	3 (6)	1 (2)	0 ( 0)	28 (56) (	5 10) (	2 4)	0 ( 0)	32 (64)	3 (6)	0 ( 0) (	0 ( 0)	9 (18) (	0 0) (	0 0) (	0 ** 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe

< a > a : Number of animals examined at the site

b b : Number of animals with lesion

(c) c:b/a\*100

Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (O-105W)

		Group Name No. of Animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
gan	Findings	Grade 1+ (%)	2+ 3+ 4+ (%) (%) (%)	1+ 2+ 3+ 4+ (%) (%) (%) (%)	1+ 2+ 3+ 4+ (%) (%) (%) (%)	1+ 2+ 3+ 4 (%) (%) (%) (%)
igestive s	ystem]					
ver	basophilic cell focus	11 ( 22)	<50> 0 0 0 ( 0) ( 0) ( 0)	<50> 17 1 0 0 (34) (2) (0) (0)	<50> 16 1 0 0 (32) (2) (0) (0)	<50> 7 0 0 0 (14) (0) (0) (0
	spongiosis hepatis	5 (10)	0 0 0 ( 0) ( 0) ( 0)	4 0 0 0 (8)(0)(0)(0)	4 0 0 0 (8)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0
	bile duct hyperplasia	26 ( 52)	24 0 0 (48) (0) (0)	27 22 0 0 (54) (44) (0) (0)	29 20 0 0 (58) (40) (0) (0)	38 12 0 0 (76)(24)(0)(0
	biliary cyst	1 ( 2)	0 0 0 ( 0) ( 0) ( 0)	0 0 0 0 (0)(0)(0)(0)	0 0 0 0 (0) (0) (0) (0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0
ncreas	atrophy	1 ( 2)	<50> 0 0 0 ( 0) ( 0) ( 0)	<50> 6 0 0 0 (12) (0) (0) (0)	<50> 2 0 0 0 ( 4) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0
	islet cell hyperplasia	0 ( 0)	0 0 0 ( 0) ( 0) ( 0)	2 1 0 0 (4)(2)(0)(0)	0 1 0 0 (0)(2)(0)(0)	1 2 0 0 (2)(4)(0)(0
Urinary sys	tem}					
dney	cyst	0 ( 0)	<50> 0 0 0 ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 1 0 0 0 ( 2) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0

b b : Number of animals with lesion

(c) c:b/a\*100

Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

 ALL ANIMALS	(0-105W)	· NON	NEOFEROT

		Group Name No. of Animals on Study	( 50	Contro	bi		5	3. 2r	opm			5	8p	pm			50 S	20ppn	n
)rgan	Findings	Grade 1+ 		3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1 (%	+ 5)	2+ (%)	3+ (%)	4+ (%)	1 (%		+ (	3+ %)	4+ (%)
Urinary sys	tem]																		
idney	osseous metaplasia	0 ( 0)	<50) 0 ( 0) (	0	0 ( 0)	1 (2)	<5( 0 ( 0)	0	0 ( 0)	( (		<50 0 0)	0> 0 (0)	0 ( 0)	0 ( 0			0 0) (	0 0)
	chronic nephropathy	25 (50)	15 (30) (	7 14)	1 (2)	26 (52)	18 (36)	4 (8)	0 ( 0)	18 (36		25 50)	3 (6)	0 ( 0)	39 (78	3 ) ( 6			0 ** 0)
	mineralization:papilla	0 ( 0)	0 ( 0) (	0 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	( (		0 0)	0 ( 0)	0 ( 0)	1 ( 2	0 ) ( 0		D D) (	0 0)
	mineralization:pelvis	1 ( 2)	0 ( 0) (	0 0)	0 ( 0)	1 (2)	0 (0)	0 ( 0)	0 ( 0)	0 ( 0	) )) (	0 0)	0 (0)	0 ( 0)	0 ( 0	0 ) ( 0)		D D) (	0 0)
	urothelial hyperplasia:pelvis	( 0)	0 ( 0) (	0 0)	0 ( 0)	1 (2)	0 ( 0)	0 ( 0)	0 ( 0)	( (	) )) (	0 0)	0 (0)	0 ( 0)	0 ( 0	0 ( 0)		D D) (	0 0)
	atypical tubule hyperplasia	0 ( 0)	0 ( 0) (	0 0)	0 ( 0)	1	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0	) )) (	0 0)	0 (0)	0 ( 0)	0 ( 0	0 ) ( 0)	( ) ( (	) )) (	0 0)
	dilated pelvis	0 ( 0)	0 ( 0) (	0 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 2	?) (	0 0)	0 ( 0)	0 (0)	0 ( 0	0 ) ( 0)			0 0)
rin bladd	dilatation	1 ( 2)	<50) 0 ( 0) (	0	0 (0)	0 (0)	<5( 1 (2)	0	0	0 ( 0		<50 1 2)	0> 0 (0)	0 (0)	0		<50> (	-	0 0)

Grade 1+: Slight 2+: Moderate 3+: Marked 4+: Severe

- $\langle \, a \, \rangle \qquad \ \ a$  : Number of animals examined at the site
- b b: Number of animals with lesion
- (c) c:b/a\*100
- Significant difference ; \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (O-105W)

		Group Name No. of Animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
Organ	Findings	Grade 1+ (%)	2+ 3+ 4+ (%) (%) (%)	1+ 2+ 3+ 4+ (%) (%) (%) (%)	1+ 2+ 3+ 4+ (%) (%) (%) (%)	1+ 2+ 3+ 4 (%) (%) (%) (%)
{Urinary syst	:em]					
urin bladd	papillary and/or nodular hyperplasia	0 ( 0) (	<50> 0 0 0 ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	<50> 2 0 0 0 ( 4) ( 0) ( 0) ( 0)
Endocrine sy	rstem]					
ituitary	angiectasis	0 ( 0) (	<50> 0 1 0 ( 0) ( 2) ( 0)	<50> 2 1 0 0 ( 4) ( 2) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 2 0 0 0 ( 4) ( 0) ( 0) ( 0
	cyst	3 ( 6) (	0 0 0 (0)(0)(0)	2 0 0 0 (4)(0)(0)(0)	3 0 0 0 (6)(0)(0)(0)	2 0 0 0 (4)(0)(0)(0)
	hyperplasia	14 (28) (	500 (10)(0)(0)	11 3 0 0 (22) (6) (0) (0)	18 5 0 0 (36)(10)(0)(0)	15 1 0 0 (30)(2)(0)(0
	Rathke pouch	1 ( 2) (	0 0 0 (0)(0)(0)	3 0 0 0 (6)(0)(0)(0)	4 0 0 0 (8)(0)(0)(0)	4 0 0 0 (8)(0)(0)(0)
hyroid	inflammatory infiltration	1 (2)(	<50> 0 0 0 ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0

Grade 1+:Slight 2+:Moderate 3+:Marked 4+:Severe

 $\langle a \rangle$  a : Number of animals examined at the site

b b : Number of animals with lesion

(c) c:b/a\*100

Significant difference : \* : P  $\leqq$  0.05 \*\* : P  $\leqq$  0.01 Test of Chi Square

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

|                              |  |   |   |  |   |   
   |   |   |   |   
  |  
   |  |  
  |   |   |   |  
  |   |   | 1 AUL •   |
|------------------------------|--|---|---|--|---
--
---|---|---|---|--
--
--|--
---
---|---|---|---
---|---|---|
| Findings                     |  |   | 50<br>⊦   | 3+   | 4+  | 1+<br>(%)   
   |   | 2+  | 3+  | 4+  
  |  
   |  | 2+   
  | 0<br>3+   | 4+  |   | 1+<br>(%)  
  | 2+  | i0<br>3+  | ppm<br>4+<br>(%)  |
|                              |  | (7)   |   | . 707  | (70)<br>  | (70)  
   |   |   | (70)  | (07)  
  |  
   | 70/  | (70)   
  | (70/  | (78)  |   | (70)   
  | (70)  | (76/  | (78)  | | | |
| /stem}                       |  |   |   |  |   |   
   |   |   |   |   
  |  
   |  |  
  |   |   |   |  
  |   |   |   |
| follicular hyperplasia       | 0<br>( 0)  | 0   |   |  | 0<br>0)   | 0<br>( 0)   
   |   | 0   | 0   | 0<br>( 0)   
  | (  
   | 0<br>0) (  | 0  
  | 0   | 0<br>( 0)   |   |  
  | 0   | 0   | 0<br>( 0)   |
| C-cell hyperplasia           | 12<br>( 24)  | 2<br>( 4)   | (   | 1<br>2) (  | 0<br>0)   | 5<br>(10)   
   | ( (   | 3<br>6) (   | 4<br>8)   | 0<br>( 0)   
  | (1   
   | 8<br>6) (  | 1<br>2)  
  | 1<br>(2)  | 0<br>( 0)   | (   | 4<br>8)  
  | 1<br>(2)  | 1<br>(2)  | 0<br>( 0)   |
| angiectasis                  | 2<br>( 4)  | 0   |   | 0<br>0) (  | 0<br>0)   | 0<br>( 0)   
   | ( (   | 0   | 0   | 0<br>( 0)   
  | (  
   | 0<br>0) (  | <5<br>0<br>0)  
  | 0><br>0<br>( 0)   | 0<br>( 0)   | (   | 0<br>0)  
  | 0   | 0   | 0<br>( 0)   |
| peliosis-like lesion         | 0<br>( 0)  |   |   | 0<br>0) (  | 0<br>0)   | 0<br>( 0)   
   | ( (   | 0<br>0) (   | 0<br>0)   | 0<br>( 0)   
  | (  
   | 0<br>0) (  | 0<br>0)  
  | 0<br>( 0)   | 0<br>( 0)   | (   | 1<br>2)  
  | 0<br>( 0)   | 0<br>( 0)   | 0<br>( 0)   |
| fatty change                 | 0<br>( 0)  |   |   |  | 0<br>0)   | 1<br>(2)  
   | ( (   | 0<br>0) (   | 0<br>0)   | 0<br>( 0)   
  | (  
   | 1<br>2) (  | 0<br>0)  
  | 0<br>( 0)   | 0<br>( 0)   |   |  
  | 0<br>(0)  | 0<br>( 0)   | 0<br>( 0)   |
| extramedullary hematopoiesis | 1<br>( 2)  | 0<br>( 0)   | (   | 0<br>0) (  | 0<br>0)   | 0<br>( 0)   
   | ( (   | 0<br>0) (   | 0<br>0)   | 0<br>( 0)   
  | (  
   | 0<br>0) (  | 0<br>0)  
  | 0<br>( 0)   | 0<br>( 0)   | (   | 1<br>2)  
  | 0<br>( 0)   | 0<br>( 0)   | 0<br>( 0)   |
| hyperplasia:cortical cell    | 9<br>( 18)   |   |   | 0<br>0) (  | 0<br>0)   | 2<br>( 4)   
   | ( (   | 0<br>0) (   | 0<br>0)   | 0<br>( 0)   
  | (  
   | 2<br>4) (  | 0<br>0)  
  | 0<br>( 0)   | 0<br>( 0)   | (   | 2<br>4)  
  | 0<br>(0)  | 0<br>( 0)   | 0<br>( 0)   |
| hyperplasia:medulla          | 4<br>( 8)  | 2<br>( 4)   | (   | 0<br>0) (  | 0<br>0)   | 4<br>(8)  
   | ( 2   | 1<br>2) (   | 0<br>0)   | 0<br>( 0)   
  | (  
   | 4<br>8) (  | 4<br>8)  
  | 0<br>( 0)   | 0<br>( 0)   | (   | 2<br>4)  
  | 1<br>(2)  | 1<br>(2)  | 0<br>( 0)   |
|                              | follicular hyperplasia<br>C-cell hyperplasia<br>angiectasis<br>peliosis-like lesion<br>fatty change<br>extramedullary hematopoiesis<br>hyperplasia:cortical cell | No. of Animals on Study<br>Grade       1+         Findings       (%)         rstem]       0         follicular hyperplasia       0         C-cell hyperplasia       12         angiectasis       2         peliosis-like lesion       0         fatty change       0         extramedullary hematopoiesis       1         hyperplasia:cortical cell       9         hyperplasia:medulla       4 | No. of Animals on Study<br>Grade       1+       2-         Findings | No. of Animals on Study<br>Grade50<br>(radeFindings1+2+Findings(%)(%)rstem] $\langle 50 \rangle$ follicular hyperplasia00C-oell hyperplasia122anglectasis122(4)(4)(0)peliosis-like lesion00(50)(0)(10)fatty change00(2)(0)(10)extramedullary hematopolesis10(18)(0)(18)hyperplasia:medulla42 | No. of Animals on Study<br>Grade       50<br>1+       2+       3+         Findings       (%)       (%)       (%)       (%)       (%)         rstem] $(50)$ 0       0       0       0       0       0       0         follicular hyperplasia       12       2       1       (24)       (4)       (22)       (4)       (22)       (50)         angiectasis       2       0       0       (4)       (20)       (2 | No. of Animals on Study       50         Grade       1+       2+       3+       4+         Findings       (%)       (%)       (%)       (%)       (%)         rstem) $(50)^{\circ}$ $(0)^{\circ}$ $(0)^{\circ}$ $(0)^{\circ}$ $(0)^{\circ}$ $(0)^{\circ}$ follicular hyperplasia $(2)^{\circ}$ $(2)^{\circ}$ $(0)^{\circ}$ $(0)^{\circ}$ $(0)^{\circ}$ C-cell hyperplasia $12^{\circ}$ $2^{\circ}$ $1^{\circ}$ $(24)^{\circ}$ $(2)^{\circ}$ $(0)^{\circ}$ anglectasis $2^{\circ}$ $0^{\circ}$ $0^{\circ}$ $(0)^{\circ}$ $(0)^{\circ}$ $(0)^{\circ}$ $(0)^{\circ}$ peliosis-like lesion $0^{\circ}$ $0^{\circ}$ $0^{\circ}$ $(0)^{\circ}$ <td>No. of Animals on Study       50         Grade       1+       2+       3+       4+       1+         Findings       (\$\$)       (\$\$)       (\$\$)       (\$\$)       (\$\$)       (\$\$)         rstem)       <math>(\$0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \</math></td> <td>No. of Animals on Study       50         Grade       1+       2+       3+       4+       1+         Findings       (\$)       (\$)       (\$)       (\$)       (\$)       (\$)         rstem]       <math>(\$0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \</math></td> <td>No. of Animals on Study       50       50         Grade       1+       2+       3+       4+       1+       2+         Findings       (%)       (%)       (%)       (%)       (%)       (%)       (%)         rstem]       <math>(50)</math>       0       0       0       0       0       0       0         follicular hyperplasia       <math>(20)</math>       (0)       (0)       (0)       (0)       (0)       (0)       (0)         C-oell hyperplasia       12       2       1       0       5       3         (24)       (4)       (2)       (0)       (10)       (6)       (10)         anglectasis       2       0       0       0       0       0       0         grade       0       0       0       0       0       0       0       0       0         anglectasis       2       0       0       0       0       0       0       0       0       0         grade       0       0       0       0       0       0       0       0       0       0         anglectasis       2       0       0       0       0</td> <td>No. of Animals on Study<br/>Grade       50<br/>(%)       50<br/>(%)</td> <td>No. of Animals on Study<br/>Grade         50         50         50           Findings         1+         2+         3+         4+         1+         2+         3+         4+           Findings         (\$)<td>No. of Animais on Study       50       50         Grade       1+       2+       3+       4+       1+       2+       3+       4+         Findings       (%)</td><td>No. of Animals on Study       50       50         Grade       1+       2+       3+       4+       1+       2+       3+       4+       1+         Findings       (%)       <t< td=""><td>No. of Animals on Study       50</td><td>No. of Animais on Study       50</td><td>No. of Animals on Study         50         50         50         50         50           Findings         (%)</td><td>No. of Animals on Study       50       50       50       50       50         Findings       (%)       <th< td=""><td>No. of Animals on Study<br/>Grade         50<br/>(x)         60<br/>(x)         60<br/>(x)<!--</td--><td>No. of Animals on Study       50</td><td>No. of Animals on Study         50</td></td></th<></td></t<></td></td> | No. of Animals on Study       50         Grade       1+       2+       3+       4+       1+         Findings       (\$\$)       (\$\$)       (\$\$)       (\$\$)       (\$\$)       (\$\$)         rstem) $($0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \$ | No. of Animals on Study       50         Grade       1+       2+       3+       4+       1+         Findings       (\$)       (\$)       (\$)       (\$)       (\$)       (\$)         rstem] $($0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \ 0 \$ | No. of Animals on Study       50       50         Grade       1+       2+       3+       4+       1+       2+         Findings       (%)       (%)       (%)       (%)       (%)       (%)       (%)         rstem] $(50)$ 0       0       0       0       0       0       0         follicular hyperplasia $(20)$ (0)       (0)       (0)       (0)       (0)       (0)       (0)         C-oell hyperplasia       12       2       1       0       5       3         (24)       (4)       (2)       (0)       (10)       (6)       (10)         anglectasis       2       0       0       0       0       0       0         grade       0       0       0       0       0       0       0       0       0         anglectasis       2       0       0       0       0       0       0       0       0       0         grade       0       0       0       0       0       0       0       0       0       0         anglectasis       2       0       0       0       0 | No. of Animals on Study<br>Grade       50<br>(%)       50<br>(%) | No. of Animals on Study<br>Grade         50         50         50           Findings         1+         2+         3+         4+         1+         2+         3+         4+           Findings         (\$) <td>No. of Animais on Study       50       50         Grade       1+       2+       3+       4+       1+       2+       3+       4+         Findings       (%)</td> <td>No. of Animals on Study       50       50         Grade       1+       2+       3+       4+       1+       2+       3+       4+       1+         Findings       (%)       <t< td=""><td>No. of Animals on Study       50</td><td>No. of Animais on Study       50</td><td>No. of Animals on Study         50         50         50         50         50           Findings         (%)</td><td>No. of Animals on Study       50       50       50       50       50         Findings       (%)       <th< td=""><td>No. of Animals on Study<br/>Grade         50<br/>(x)         60<br/>(x)         60<br/>(x)<!--</td--><td>No. of Animals on Study       50</td><td>No. of Animals on Study         50</td></td></th<></td></t<></td> | No. of Animais on Study       50       50         Grade       1+       2+       3+       4+       1+       2+       3+       4+         Findings       (%) | No. of Animals on Study       50       50         Grade       1+       2+       3+       4+       1+       2+       3+       4+       1+         Findings       (%) <t< td=""><td>No. of Animals on Study       50</td><td>No. of Animais on Study       50</td><td>No. of Animals on Study         50         50         50         50         50           Findings         (%)</td><td>No. of Animals on Study       50       50       50       50       50         Findings       (%)       <th< td=""><td>No. of Animals on Study<br/>Grade         50<br/>(x)         60<br/>(x)         60<br/>(x)<!--</td--><td>No. of Animals on Study       50</td><td>No. of Animals on Study         50</td></td></th<></td></t<> | No. of Animals on Study       50 | No. of Animais on Study       50 | No. of Animals on Study         50         50         50         50         50           Findings         (%) | No. of Animals on Study       50       50       50       50       50         Findings       (%) <th< td=""><td>No. of Animals on Study<br/>Grade         50<br/>(x)         60<br/>(x)         60<br/>(x)<!--</td--><td>No. of Animals on Study       50</td><td>No. of Animals on Study         50</td></td></th<> | No. of Animals on Study<br>Grade         50<br>(x)         60<br>(x)         60<br>(x) </td <td>No. of Animals on Study       50</td> <td>No. of Animals on Study         50</td> | No. of Animals on Study       50 | No. of Animals on Study         50 |

Grade 1+: Slight 2+: Moderate 3+: Marked 4+: Severe

< a > a : Number of animals examined at the site

b b : Number of animals with lesion

(c) c:b/a\*100

Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (O-105W)

		Group Name No. of Animals on Study	( 50	Contr	01				50	3. 2p	pm				50	8pp	m				50	20p	pm	
an	Findings	Grade 1-	2+ %)	3+ (%)	4+ (%)		1+ (%)	2 (%)	÷	3+ (%)	4+ (%)		1+ (%)	2+ (%)	-	3+ (%)	4+ (%)		1+ (%)	2- (%)	+	3+ (%)		4 (%
docrine sys	tem]																							
enal	accesory cortical nodule	1 ( 2)	<50) 0 0) (	0	0 ( 0)	(	0 0)	0	<50> ) (	0	0 ( 0)		0 0)	0	(50) (	0 0) (	0 ( 0)	(	2 4)	0 ( 0)		0		0
	focal fatty change:cortex	3 ( 6)	0 0) (	0 0)	0 ( 0)	(	6 12)	1 ( 2)		0 0)	0 (0)		7  4)	1 (2)		0 0) (	0 ( 0)	(	7 14)	0 ( 0)		0 0)		C
oroductive	system}																							
is	mineralization	1 ( 2)	<50) 0 0) (	0	0 ( 0)	(	2 4)	0		0	0 (0)	(	3 6)	0		0 0) (	0 ( 0)	(	1 2)	0 ( 0)		0		0
	inflammation	1 ( 2)	0 0) (	0 0)	0 ( 0)	(	0 0)	0 ( 0)	) (	0 0)	0 ( 0)	(	1 2)	0 ( 0)	(	0 0) (	0 ( 0)	(	0 0)	0 ( 0)		0 0)		0
	interstitial cell hyperplasia	4 ( 8)	0 0) (	0 0)	0 ( 0)	(	2 4)	1 (2)		0 0)	0 ( 0)		0 0) (	0 ( 0)		0 0) (	0 ( 0)	(	5 10)	0 ( 0)		0 0)		0
in ves	inflammation	0 ( 0)	<50) 0 0) (	0	0 ( 0)	(	0 0)	0		0	0 ( 0)		1 2)	0		0 0) (	0 ( 0)	(	1 2)	0		0 0)		c c

b b: Number of animals with lesion

(c) c:b/a\*100

Significant difference ; \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

(HPT150)

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

		Group Name No. of Animals on Study	Control 50	3.2ppm	8ppm	20ppm
Irgan	Findings	Grade 1+ 	2+ 3+ 4+ (%) (%) (%)	50 1+ 2+ 3+ 4+ (%) (%) (%) (%)	50 1+ 2+ 3+ 4+ (%) (%) (%) (%)	50 1+ 2+ 3+ 4+ (%) (%) (%) (%)
Reproductive	e system}					
prostate	inflammation	9 (18)	<50> 2 0 0 ( 4) ( 0) ( 0)	<50> 8 0 0 0 (16) (0) (0) (0)	<50> 20 0 0 0 * (40) (0) (0) (0)	<50> 2 0 0 0 * ( 4) ( 0) ( 0) ( 0)
	hyperplasia	7 (14) (	1 0 0 (2)(0)(0)	7 1 0 0 (14) (2) (0) (0)	8 2 0 0 (16) (4) (0) (0)	6 0 0 0 (12) (0) (0) (0)
ammary gl	galactocele	2 ( 4) (	<50> 1 0 0 ( 2) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 1 0 0 ( 0) ( 2) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)
rep∕cli gl	hyperplasia	0 ( 0) (	<50> 0 0 0 ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 1 0 0 ( 0) ( 2) ( 0) ( 0)
Vervous syst	.em}					
rain	hemorrhage	1 (2)(	<50> 0 0 0 ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<pre> &lt;50&gt; 2 0 0 0 ( 4) ( 0) ( 0) ( 0)</pre>
	gliosis	0 ( 0) (	0 0 0 ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	3 0 0 0 (6)(0)(0)(0)

< a > a : Number of animals examined at the site

b b: Number of animals with lesion

(c) c:b/a\*100

Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

## HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)

HISTOPATHOLOGICAL FINDINGS	NUN-NEUPLASTIC LESTUNS	(201
ALL ANIMALS (0-105W)		

		Group Name No. of Animals on Study	50	Contr	ol		5	3. 2j	mqq			5	8p	pm			50	20p	,om
Organ	Findings	Grade 1+ 	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)		1+ (%)	2+ (%)	3+ (%)	4+ (%)	(9		2+ (%)	3+ (%)	4+ (%)
{Special se	nse organs/appendage}																		
еуе	cataract	6 (12)	<50 2 ( 4) (	0	0 ( 0)	2 ( 4)	<5 4 (8)	0	0 ( 0)		3 6) (	<5 5 10)	0> 0 ( 0)	0 ( 0)	( (		<50) 0 0) (	> 0 0)	0* (0)
	retinal atrophy	0 ( 0)	2 ( 4) (	5 (10)	0 ( 0)	1 (2)	1 (2)	5 (10)	0 ( 0)		1 2) (	2 4)	6 (12)	0 ( 0)			1 2) (	0 0)	0 ( 0)
	keratitis	2 ( 4)	0 ( 0) (	0 ( 0)	0 ( 0)	1 (2)	0 (0)	0 (0)	0 ( 0)	(	3 6) (	0 0)	0 ( 0)	0 ( 0)	1: ( 20		7 4) (	1 2)	0 ** (0)
	iritis	2 ( 4)	3 (6)(	0 ( 0)	0 ( 0)	5 (10)	0 ( 0)	0 ( 0)	0 ( 0)	(	3 6) (	2 4)	0 ( 0)	0 ( 0)	{ (16	; ;) (	4 8) (	0 0)	0 ( 0)
	degeneration:cornea	0 ( 0)	0 ( 0) (	0 ( 0)	0 ( 0)	0 ( 0)	0 (0)	0 ( 0)	0 ( 0)	(	0 0) (	0 0)	0 ( 0)	0 (0)	( 2	2) (	0 0) (	0 0)	0 ( 0)
	ulcer:cornea	0 ( 0)	1 (2)(	0 ( 0)	0 ( 0)	0 ( 0)	0 (0)	0 (0)	0 ( 0)		0 0) (	0 0)	0 (0)	0 ( 0)	( (	i i) (1	6 2) (	1 2)	0* (0)
Harder gl	lymphocytic infiltration	0 ( 0)	<50 0 ( 0) (	0	0 (0)	2 ( 4)	<5 0 ( 0)	0	0 ( 0)		1 2) (	<50 0 0)	0> 0 (0)	0 ( 0)	( (		<50) 0 0) (	> 0 0)	0 ( 0)
	hyperplasia	0 ( 0)	0 ( 0) (	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	(	2 4) (	0 0)	0 ( 0)	0 ( 0)	( (		0 0) (	0 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe

< a > a : Number of animals examined at the site

b : Number of animals with lesion b

(c) c:b/a\*100

Significant difference ;  $*: P \leq 0.05$   $**: P \leq 0.01$  Test of Chi Square

## HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (O-105W)

		Group Name No. of Animals on Stud		50	Cont	rol					2ppm			F		ppm					20pp	m
rgan	_ Findings	Grade	y 1+ (%)	2+ (%)	3+ (%)	4+ (%)		1+ (%)	2+ (%)	:0 3 (%			1+ (%)	5) 2+ (%)	3+ (%)			1+ (%)	2+ (%)		3+ (%)	4 (%
usculosk	əletal system)																					
ine	fracture	(	0 0) (	<50 0 0) (	0	0 ( 0)	(	0 0) (	0	io> 0 ( 0	0 ) ( 0)	(	1 2) (	<5( 0 0)	0	0 ( 0)	(	0 0)	0	50> (	0 0) (	0
	ostitis fibrosa	(	0 0) (	0 0) (	0 0)	0 ( 0)		0 0) (	0 0)	0	0 ) ( 0)		0 0) (	0 0)	0 ( 0)	0 ( 0)	(	1 2)	0 ( 0)		0 0) (	0

(HPT150)

BA1S5

TABLE L2

# HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS : FEMALE

# STUDY NO. : 0794 HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ANIMAL : RAT F344/DuCrij[F344/DuCrj] ALL ANIMALS (0-105W) REPORT TYPE : A1 SEX : FEMALE

		Group Name Control	3.2ppm	8ppm	20ppm
Organ	Findings	No. of Animals on Study 50 Grade 1+ 2+ 3+ 4+ (%) (%) (%) (%)	50 1+ 2+ 3+ 4+ (%) (%) (%) (%)	50 1+ 2+ 3+ 4+ (%) (%) (%) (%)	50 1+ 2+ 3+ 4+ (%) (%) (%) (%)
{Integumentar	y system/appandage}				
skin/app	erosion	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 1 0 0 0 ( 2) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)
	inflammation	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	1 0 0 0 (2)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)
	scab	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	1 0 0 0 (2)(0)(0)(0)	0 0 0 0 (0)(0)(0)(0)
{Respiratory :	system]				
nasal cavit	thrombus	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 1 0 0 0 ( 2) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)
	mineralization	20 0 0 0 (40) (0) (0) (0)	34 0 0 0 ** (68) (0) (0) (0)	26 0 0 0 (52) (0) (0) (0)	30 0 0 0 (60) (0) (0) (0)
	hyperplasia:gland	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 (0)(0)(0)(0)	0 1 0 0 ( 0) ( 2) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)
	squamous cell hyperplasia with atypia	a 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 (0)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	4 7 2 0 ** (8) (14) (4) (0)

Grade 1+: Slight 2+: Moderate 3+: Marked 4+: Severe

b b: Number of animals with lesion

(c) c:b/a\*100

Significant difference ; \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### STUDY NO. : 0794 : RAT F344/DuCrICrIj[F344/DuCrj] ANIMAL REPORT TYPE : A1 : FEMALE SEX

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

		up Name of Animals on Study	0 50	ontro	I			3. 2p	pm			8pt	om			20p	mc
gan	Gra Findings	· · · · · · · · · · · · · · · · · · ·	2+	3+ (%)	4+ (%)	1+ (%)	5 2+ (%)	3+ (%)	4+ (%)	1+ (%)	50 2+ (%)	, 3+ (%)	4+ (%)	1+ (%)	50 2+ (%)	3+ (%)	4+ (%)
espiratory	system]																
nsal cavit	eosinophilic change:olfactory epithelium	16 (32)	<50> 29 (58) (	3	0 0)	25 (50)	<5 25 (50)	0	0 ( 0)	29 (58)	<50 19 (38) (	0	0* (0)	37 (74)	<50 7 (14) (	0	0 * ( 0)
	eosinophilic change:respiratory epitheliu		0 ( 0) (	0 0) (	0 0)	35 (70)	0 ( 0)	0 ( 0)	0 ( 0)	22 ( 44)	0 (0)(	0 ( 0)	0* (0)	9 (18)	0 ( 0) (	0 (0)	(0)
	inflammation:foreign body	0 ( 0)	0 ( 0) (	0 0) (	0 0)	3 (6)	0 ( 0)	0 (0)	0 ( 0)	3 (6)	0 ( 0) (	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0) (	0 ( 0)	0 ( 0)
	inflammation:respiratory epithelium	7 (14)	0 ( 0) (	0 0) (	0 0)	3 (6)	0 ( 0)	0 (0)	0 ( 0)	22 ( 44)	0 ( 0) (	0 ( 0)	0 ** ( 0)	30 (60)	0 ( 0) (	0 ( 0)	0 ( 0)
	respiratory metaplasia:olfactory epitheli		0 (0)(	0 0) (	0 0)	0 ( 0)	0 ( 0)	0 (0)	0 ( 0)	1 (2)	0 ( 0) (	0 ( 0)	0 ( 0)	15 (30)	0 (0)(	0 ( 0)	0 (0)
	respiratory metaplasia:gland	49 ( 98)	0 ( 0) (	0 0) (	0 0)	47 (94)	1 (2)		0 ( 0)	41 (82)	3 (6)(	0 ( 0)	0* (0)	39 (78)	6 (12) (	0 ( 0)	0 (0)
	squamous cell metaplasia:respiratory epit		0 ( 0) (	0 0) (	0 0)	6 (12)	0 ( 0)	0 (0)	0* (0)	21 ( 42)	7 (14) (	0 ( 0) (	0 ** ( 0)	13 (26)	5 (10) (	0 ( 0) (	0 (0)
	squamous cell metaplasia:olfactory epithe		0 ( 0) (	0 0) (	0 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 (2) (	0	0 ( 0)	0 ( 0)	0 (0)(	0	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe

< a > a : Number of animals examined at the site

b b : Number of animals with lesion

(c) c:b/a\*100

Significant difference ; \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

																				PAG	ae : 20
		Group Name No. of Animals on Study	,	50	Contr	rol			3 50	l. 2pp	m			50	8pj	pm			20 50	Oppm	
Organ		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	ŀ	3+ (%)	4+ (%)	1 <sup>.</sup> (%)		2+	3+ (%)	4+ (%)	1+ (%)	- 2+	3-		4+ (%)
{Respiratory	system]																				
nasal cavit	squamous cell metaplasia with atypia:re ium		0 0) (	<50 0 0) (	0	0 ( 0)	1 (2)	1		0 0) (	0 0)	0 ( 0)		<50> 0 0) (	0	0 ( 0)	7 (14)	<br 9 (18)	50> 2 ( 4)		0 ** 0)
	hyperplasia:nasal gland		0 0) (	0 0) (	0 (0)	0 ( 0)	0 ( 0)	0 ( 0)	(	0 0) (	0 0)	1 (2)		0 0) (	0 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)		0 0)
	hyperplasia:transitional epithelium		0 0) (	0 0) (	0 (0)	0 ( 0)	4 (8)	4 (8)	(	0 0) (	0 * 0)	23 (46)	1 ) (3	5 0) (	0 0)	0 ** ( 0)	13 (26)	20 (40)	0 ( 0)		0 ** 0)
	regeneration:respiratory epithelium		0 0) (	0 0) (	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	(	0 0) (	0 0)	0 ( 0)	) (	0 0) (	0 0)	0 ( 0)	1 (2)	0 ( 0)	0 ( 0)		0 0)
	regeneration:olfactory epithelium		0 0) (	0 0) (	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	(	0 0) (	0 0)	0 ( 0)	) (	0 0) (	0 0)	0 ( 0)	10 (20)	0 ( 0)	0 ( 0)		0 ** 0)
	atrophy:olfactory epithelium		0 0) (	0 0) (	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	(	0 0) (	0 0)	7 (14)		3 6) (	0 0)	0 ** ( 0)	21 (42)	24 (48)	0 ( 0)		0 ** 0)
	necrosis:olfactory epithelium		0 0) (	0 0) (	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	(	0 0) (	0 0)	5 (10)	) (	0 0) (	0 0)	0 ( 0)	4 (8)	0 ( 0)	0 ( 0)		0 0)
	necrosis:respiratory epithelium		0 0) (	0 0) (	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)		0 0) (	0 0)	2 ( 4)	) (	0 0) (	0 0) (	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)		0 0)

Grade1+: Slight2+: Moderate3+: Marked4+: Severe< a >a : Number of animals examined at the site

- b b: Number of animals with lesion
- (c) c:b/a \* 100

Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

		Group Name			Contr					3. 2p														ppm	
gan	Findings	No. of Animals on Study Grade	( 1+ (%)	5( 2+ (%)			1+ (%)		50 2+	3. 2µ 3+ (%)		4+ %)		1+ (%)	2 (%)		3+ (%)	4+ (%)		1+ (%)	: (9	50 2+ 6)	3+ (%)		4+ (%)
Respiratory s	ystem}																								
asal cavit	hyperplasia:respiratory epithelium		0 0) (	<50 0 0)	0	0 ( 0)	3 (6)	(	<50) 1 2) (		( (	0 0)	(	2 4)	0	<50> ) (	0	0 ( 0)	(	3 6)	( (	<50) ) )) (	1	(	0 0)
irynx	inflammation	(	1 2) (	<50 0 0) (	0	0 ( 0)	1 (2)	(	<50) 0 0) (	0	( (	0 0)	(	0 0)	0	<50> ) (	0	0 ( 0)	(	0 0)	( (	<50) ) )) (	0		0 0)
ng	congestion		0 0) (	<50 0 0) (	0	0 ( 0)	2 ( 4)	(	<50) 0 0) (	0	( (	0 0)		1 2)	0	<50> ) (	0	0 ( 0)	(	2 4)	( (	<50) ) )) (	0		0 0)
	hemorrhage		0 0) (	1 2)	0 ( 0)	0 ( 0)	1 (2)	(	0 0) (	0 0)	( (	D D)	(	0 0)	0 ( 0)	) (	0 0)	0 ( 0)	(	0 0)	( (	) )) (	0 0)	(	0 0)
	edema	(	1 2) (	0 0) (	0 ( 0)	0 ( 0)	2 ( 4)	(	0 0) (	0 0)	( (	) )	(	1 2) (	0 ( 0)	) (	0 0)	0 ( 0)	(	3 6)	( (	' )) (	0 0)	( (	0 0)
	inflammatory infiltration	(	1 2) (	0 0) (	0 ( 0)	0 ( 0)	0 ( 0)	( )	0 0) (	0 0)	( (	) )	(	0 0) (	0 ( 0)	) (	0 0)	0 ( 0)	(	0 0)	( ( (	' i) (	0 0)		0 0)
	accumulation of foamy cells	(	0 0) (	0 0) (	0 ( 0)	0 ( 0)	1 (2)	( (	0 0) (	0 0)	( (	) )		0 0) (	0 ( 0)		0 0)	0 ( 0)	(	0 0)	( (		0 0)	( (	

Grade 1+: Slight 2+: Moderate 3+: Marked 4+: Severe

< a > a : Number of animals examined at the site

b b: Number of animals with lesion

(c) c:b/a\*100

Significant difference :  $*: P \leq 0.05$   $**: P \leq 0.01$  Test of Chi Square

#### STUDY NO. : 0794 : RAT F344/DuCriCrij[F344/DuCrj] ANIMAL REPORT TYPE : A1 : FEMALE

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)

ALL ANIMALS (0-105W)

		Group Name No. of Animals on Study		50	Cont	rol						3. 2	ppm							Bobw					<b>F ^</b>	20p	opm	
Organ	Findings	Grade	1+	2+ (%)	3+ (%)				1+ (%)	2 (%		3+ (%)		4+ (%)		1+ (%)		50 2+ %)	, 3+ (%)		4+ (%)		1+ (%)	2+ (%)		3+ (%)		4+ (%)
Respiratory s	ystem}																											
lung	bronchiolar-alveolar cell hyperplasia			<50) 0 0) (	0	0 ( 0)		(	0 0)	0 ( 0	<50>	0 0)	(	0 0)	(	1 2)	(	<50 0 0) (	)> 0 ( 0)	(	0 0)	(	2 4)		<50>		( (	0 0)
{Hematopoietic	system]																											
oone marrow	congestion	(		<50) 0 0) (	0	0 ( 0)		(	0 0)	0	<50> ) (	) 0 0)	(	0 0)	(	0 0)	(	<50 0 0) (	)> 0 ( 0)	(	0 0)	(	1 2)	< 0 ( 0)	<50>		( (	0 0)
	granulation	(	1 2) (	0 0) (	0 0)	0 ( 0)	I	(	0 0)	1 (2	) (	0 0)	(	0 0)	(	0 0)	(	) 0) (	0 ( 0)	(	0 0)	(	0 0)	0 ( 0)	(	0 0)	( (	0 0)
	increased hematopoiesis	( 1)	5 0) (	1 2) (	0 0)	0 ( 0)	I	(	3 6)	5 (10	) (	2 4)	(	0 0)	(	5 10)	(1)	5 0) (	2 ( 4)	(	0 0)	(	1 2)	9 (18)	(	2 4)	(	0 ** 0)
ymph node	deposit of hemosiderin			<50) 0 0) (	0	0 ( 0)	I		0 0) (	1	<50> ) (	0		0 0)	(	0 0)	(	<50) 0 0) (	) 0 ( 0)	(	0 0)	(	1 2)	< 0 ( 0)	(50> (	0		0 0)
pleen	congestion			<50) 0 0) (	0	0			0 0) (	0	<50> ) (	0	(	0 0)	(	1 2)	(	<50) 0 0) (	0	(	0 0)		1 2)			0		0 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe

<a>> a : Number of animals examined at the site

b b : Number of animals with lesion

(c) c:b/a\*100

Significant difference ; \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

REPORT TYPE	: RAT F344/DuCrlCrlj[F344/DuCrj] : A1 : FEMALE	ALL ANIMALS (O-105W)			PAGE : 23
Organ	Findings	Group Name Control No. of Animals on Study 50 Grade 1+ 2+ 3+ 4+ (%) (%) (%) (%)	3.2ppm 50 1+ 2+ 3+ 4+ (%) (%) (%) (%)	8ppm 50 1+ 2+ 3+ 4+ (%) (%) (%) (%)	20ppm 50 1+ 2+ 3+ 4+ (%) (%) (%) (%)
{Hematopoiet	ic system)				
spleen	deposit of hemosiderin	<50> 8 0 0 0 (16) (0) (0) (0)	<50> 4 0 0 0 (8) (0) (0) (0)	<50> 5 0 0 0 (10) (0) (0) (0)	<50> 7 1 0 0 (14) (2) (0) (0)
	extramedullary hematopoiesis	23 8 1 0 (46) (16) (2) (0)	16 8 3 0 (32)(16)(6)(0)	20 10 3 0 (40)(20)(6)(0)	11 6 9 0 ** (22) (12) (18) (0)
{Circulatory	system]				
heart	thrombus	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 2 0 0 0 ( 4) ( 0) ( 0) ( 0)
	mineralization	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 (0)(0)(0)(0)	1 0 0 0 (2)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)
	inflammatory infiltration	1 0 0 0 (2) (0) (0) (0)	1 0 0 0 (2)(0)(0)(0)	2 0 0 0 ( 4) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)
	myocardial fibrosis	33 3 0 0 (66)(6)(0)(0)	29 2 0 0 (58) (4) (0) (0)	25 3 0 0 (50)(6)(0)(0)	28 4 0 0 (56)(8)(0)(0)
	subendocardial fibrosis	1 0 0 0 (2)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	1 0 0 0 (2)(0)(0)(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe <a> a : Number of animals examined at the site

- b b: Number of animals with lesion
- (c) c:b/a\*100
- Significant difference ; \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (O-105W)

SEX :	FEMALE					 	-11																F	PAGE :
		Group Name No. of Animals on Study		Cont 50	trol			5		2ppn	n				50		ppm					50	20pp	m
)rgan	Findings	Grade 1+ (%)				1 (%	+ 5)	2+ (%)	3 (%)		4+ (%)		1+ (%)		2+ %)	3+ (%)		4+ (%)		1+ (%)	2+ (%)		3+ (%)	4+ (%)
Circulatory s	system)																							
artery/aort	mineralization	0 ( 0)	0	50> 0 (0)		0	) )) (	<5 0 0)	0> 0 ( 0)	) (	0 0)	(	1 2)	(	<50 0 0) (	> 0 0)	(	0 0)	(	0 0)	< 0 ( 0)		0 0)	0 ( 0)
Digestive sys	stem}																							
ral cavity	inflammation	0 ( 0)	0	50> 0 (0)		0 ( 0	)) (	<5 0 0)	0> 0 ( 0)	) (	0 0)		1 2)	(	<50 0 0) (	> 0 0)	(	0 0)	(	0 0)	< 0 ( 0)		0 0)	0 ( 0)
tomach	erosion:forestomach	0 ( 0)	0			1 (2	) (	<5 0 0)	0> 0 ( 0)	) (	0 0)	(	0 0)	(	<50 0 0) (		(	0 0)	(	0 0)	< 0 ( 0)		0 0)	0 ( 0)
	ulcer:forestomach	1 ( 2)	1 (2)			2 ( 4	) (	1 2)	1 (2)	) (	0 0)	(	0 0)	(	4 B) (	0 0)	(	0 0)	(	3 6)	3 (6)	(	0 0) (	0 ( 0)
	hyperplasia:forestomach	1 ( 2)	0 ( 0)	0 ( 0)		4 (8	) (	0 0)	0 ( 0)	) (	0 0)	(	1 2)	(	2 4) (	1 2)	(	0 0)		10 20)	2 (4)		0 0) (	0*× (0)
	erosion:glandular stomach	1 ( 2)	0 ( 0)	0 ( 0)		2 (4	) (	0 0)	0 ( 0)	) (	0 0)	(	3 6)	(	2 4) (	0 0)		0 0)	(	2 4)	0 (0)	(	0 0) (	0 (0)

(HPT150)

STUDY NO. ANIMAL REPORT TYPE SEX	: 0794 : RAT F344/DuCrICrIj[F344/DuCrj] : A1 : FEMALE	HISTOPATHOLOGICAL FINDING ALL ANIMALS (O-105W)	S :NON-NEOPLASTIC LESIONS (SUMMAN	RY)	PAGE : 25
Organ	Findings	Group Name Control No. of Animals on Study 50 Grade 1+ 2+ 3+ 4+ (%) (%) (%) (%)	3.2ppm 50 1+ 2+ 3+ 4+ (%) (%) (%) (%)	8ppm 50 1+ 2+ 3+ 4+ (%) (%) (%) (%)	20ppm 50 1+ 2+ 3+ 4+ (%) (%) (%) (%)
{Digestive s	system}				
stomach	ulcer:glandular stomach	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 1 1 0 0 ( 2) ( 2) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)
	hyperplasia:glandular stomach	0 0 0 0 (0)(0)(0)(0)	1 0 0 0 (2)(0)(0)(0)	1 0 0 0 (2)(0)(0)(0)	1 0 0 0 (2)(0)(0)(0)
	mineralization:glandular stomach	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 1 0 0 ( 0) ( 2) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)
liver	herniation	<50> 13 0 0 0 (26) (0) (0) (0)	<50> 11 0 0 0 (22) (0) (0) (0)	<50> 11 0 0 0 (22) (0) (0) (0)	<50> 12 0 0 0 (24) (0) (0) (0)
	peliosis-like lesion	1 0 0 0 (2)(0)(0)(0)	1 0 0 0 (2)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)
	necrosis:focal	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	1 0 0 0 (2)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)
	inflammatory infiltration	1 0 0 0 (2)(0)(0)(0)	1 0 0 0 (2)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)
	lymphocytic infiltration	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 1 0 0 ( 0) ( 2) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe

< a > a : Number of animals examined at the site

b b: Number of animals with lesion

(c) c:b/a\*100

Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

STUDY NO. ANIMAL REPORT TYPE SEX	: 0794 : RAT F344/DuCrICrIj[F344/DuCrj] : A1 : FEMALE	HISTOPATHOLOGICAL FINDI ALL ANIMALS (O-105W)	NGS :NON-NEOP	LASTIC LESIONS (SUMMAR	Y)	PAGE : 26
Organ	Findings	Group Name Control No. of Animals on Study 50 Grade 1+ 2+ 3+ (%) (%) (%) (%	4+ 1 %) (%)		8ppm 50 1+ 2+ 3+ 4+ (%) (%) (%) (%)	20ppm 50 1+ 2+ 3+ 4+ (%) (%) (%) (%)
{Digestive	system}					
liver	granulation	<50> 17 1 0 (34) (2) (0) (6	D 7 D) (14)	<50> 1 0 0 ) ( 2) ( 0) ( 0)	<50> 10 1 0 0 ( 20) ( 2) ( 0) ( 0)	<50> 4 1 0 0 *** ( 8) ( 2) ( 0) ( 0)
	inflammatory cell nest	6 0 0 ( (12) ( 0) ( 0) (	) 6 )) (12)	0 0 0 ( 0) ( 0) ( 0)	6 1 0 0 (12) (2) (0) (0)	5 1 0 0 (10) (2) (0) (0)
	extramedullary hematopoiesis	1 0 0 ( ( 2) ( 0) ( 0) ( (	) 5 )) (10)	0 0 0 ( 0) ( 0) ( 0)	2 0 0 0 (4)(0)(0)(0)	1 0 0 0 (2)(0)(0)(0)
	clear cell focus	0 0 0 0 ( 0) ( 0) ( 0) ( 0		0 0 0 (0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)
	acidophilic cell focus	4 3 2 ( (8) (6) (4) (6)	) 6 )) (12)	2 0 0 ( 4) ( 0) ( 0)	4 0 0 0 (8)(0)(0)(0)	1 0 0 0 (2)(0)(0)(0)
	basophilic cell focus	36 2 0 ( (72) (4) (0) (6	) 41 )) (82)	1 0 0 (2)(0)(0)	40 0 0 0 (80) (0) (0) (0)	40 1 0 0 (80) (2) (0) (0)
	bile duct hyperplasia	14 0 0 ( (28) (0) (0) (	) 22 )) (44)	3 0 0* (6)(0)(0)	19 3 0 0 (38) (6) (0) (0)	18 1 0 0 (36)(2)(0)(0)
	bile ductular proliferation	0 0 0 0 ( 0) ( 0) ( 0) ( 0		0 0 0 ( 0) ( 0) ( 0)	1 0 0 0 (2)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)

#### STUDY NO. : 0794 HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] ALL ANIMALS (0-105W) REPORT TYPE : A1 SEX : FEMALE Group Name Control 3.2ppm No. of Animals on Study 50 50 Grade 1+ 2+ 3+ 4+ 2+ 3+ 4+

Organ\_

Findings\_

liver		<50>	<50>	<50>	<50>
	cholangiofibrosis	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 1 0 0 ( 0) ( 2) ( 0) ( 0)	0 0 0 0 (0)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)
	biliary cyst	0 0 0 0 (0)(0)(0)(0)(0)	1 0 0 0 (2)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)
pancreas	atrophy	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 1 0 0 0 ( 2) ( 0) ( 0) ( 0)
	inflammatory infiltration	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	1 0 0 0 (2)(0)(0)(0)	0 0 0 0 (0)(0)(0)(0)

(%)

(%)

(%)

(%)

1+

(%)

(%)

(%)

(%)

{Urinary system}

k i dney		<50>	<50>	<50>	<50>
	aplasia	0 1 0 0	0 0 0 0	0 0 0 0	0 0 0 0
		(0)(2)(0)(0)	(0)(0)(0)(0)	( 0) ( 0) ( 0) ( 0)	( 0) ( 0) ( 0) ( 0)
	angiectasis	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 (0)(0)(0)(0)	1 0 0 0 (2)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe <a>> a : Number of animals examined at the site

b b : Number of animals with lesion

(c) c:b/a\*100

Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

(HPT150)

PAGE : 27

4+

(%)

20ppm

3+

(%)

50

2+

(%)

1+

(%)

8ppm

4+

(%)

3+

(%)

50

2+

(%)

1+

(%)

# STUDY NO. : 0794 HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] ALL ANIMALS (0-105W) REPORT TYPE : A1 SEX : FEMALE

		oup Name	-	Contr	bl		-	3. 2	ppm				8ppm				20ppn	n
Organ		o of Animals on Study ade 1+ (%)	5) 2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	50 3+ (%)	4+ (%)	1+ (%)	2: (%)			1+ (%)			3+ %)	4+ (%)
{Urinary syst	em}																	
kidney	cyst	0 ( 0)	<50 1 (2)	0	0 ( 0)	1 (2)	0	50> 0 (0)	0 ( 0)	0 ( 0)	0		0 ) ( 0)	0 ( 0)	0		D D) (	0 0)
	hyaline droplet	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 (2)	0 ( 0)		0 ) ( 0)	1 (2)	1 (2)		) ) (	0 0)
	chronic nephropathy	25 (50)	5 (10)	2 (4)	0 ( 0)	23 (46)	4 (8)	1 (2)	0 ( 0)	30 (60)	1 (2)	1 ) ( 2	0 ) ( 0)	19 (38)	1 (2)	( (	) ) (	0 * 0)
	hydronephros i s	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 (0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ) ( 0	0 ) ( 0)	0 ( 0)	1 (2)		) ) (	0 0)
	mineralization:cortico-medullary junctio	n 0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 (2)	0 ( 0)	0 ) ( 0	0 ) ( 0)	0 ( 0)	0 ( 0)		) )) (	0 0)
	mineralization:papilla	1 ( 2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ) ( 0	0 ) ( 0)	0 ( 0)	0 ( 0)	(	) )) (	0 0)
	dilatation:tubular lumen	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 (2)	0 ( 0)	0 ) ( 0	0 ) ( 0)	0 ( 0)	0 ( 0)	( (	) )) (	0 0)
	dilated pelvis	0 ( 0)	0 (0)	0 ( 0)	0 ( 0)	0 ( 0)	0 (0)	0 ( 0)	0 ( 0)	1 (2)	0 ( 0)	0) ( 0)	0 ) ( 0)	2 ( 4)	1 (2)		) )) (	0 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe

 $\langle \, a \, \rangle \qquad \ \ a$  : Number of animals examined at the site

b b: Number of animals with lesion

(c) c:b/a\*100

Significant difference ; \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (O-105W)

		Group Name No. of Animals on Study	50	Contro	01		5	3. 2pp	pm			50	8pp	m			50	20p	pm
rgan		Grade 1+ (%)	2+ (%)	, (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	(9	2+	3+ (%)	4+ (%)	1 (%		50 2+ %)	3+ (%)	4 (%
Irinary syst	em}																		
idney	squamous cell metaplasia:pelvis	0 ( 0)	<50 0 ( 0) (	0	0 ( 0)	0 ( 0)	<50 0 ( 0)	0> 0 (0)	0 ( 0)	0 ( 0)	( :	<50> 1 2) (	0 0) (	0 ( 0)	0 ( 0	) (	<50) 0 0) (	0	0 ( 0)
in bladd	dilatation	0 ( 0)	<50 0 ( 0) (	0	0 ( 0)	0 ( 0)	<5( 0 ( 0)	0	0 ( 0)	0 ( 0)	( 2	<50> 1 2) (	0 0) (	0 ( 0)	0 ( 0	) ( :	<50) 1 2) (	0	0 ( 0)
	simple hyperplasia:transitional epithe		0 ( 0) (	0 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0) (	0 ( 0)	1 (2)	( (	) )) (	0 0) (	0 0)	0	) ( )	D D) (	0 0)	0 ( 0)
	papillary and/or nodular hyperplasia	1 ( 2)	0 ( 0) (	0 0)	0 (0)	0 ( 0)	0 (0)	0 ( 0) (	0 ( 0)	0 ( 0)	( (	) )) (	0 0) (	0 0)	0 ( 0)	) ( )	D D) (	0 0)	0
indocrine sys	stem)																		
tuitary	angiectasis		<50 1 ( 2) (	0	0 ( 0)	3 (6)	<50 2 ( 4)	0	0 ( 0)	3 (6)			0 0) (	0 0)	3 ( 6)	;	<50) 2 4) (	0	0 ( 0)
	cyst	18 (36)	2 ( 4) (	0 0)	0 ( 0)	13 (26)	2 (4)	0	0 ( 0)	17 (34)	2	2 4) (	0 0) (	0 0)	21 (42)	;	2 4) (	0 0)	0

(c) c:b/a\*100

Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

|                        | Group Name<br>No. of Animals on Study   |           |  | Contr  | ol  |  |  |   
   
  | 3. 2p;   
  | n  |     
   |  | F  |  | 8ppn  | n  
  |  |   
   |   | 50   | 20pj   
           | om   |
|------------------------|---|-----------|--|--|---|--|--
--
--
--
---|--
---|--|--|--|---
---|--
---
---|--|--
--|
| Findings               | Grade 1   | +<br>6) ( | 2+   | 3+<br>(%)  | 4+<br>(%)   | 1+<br>(%)  | 2+   | ۲   
   
  | 3+<br>(%)  
  | 4+<br>(%)  |     
   | 1+<br>(%)  |  | 3  |   | 4+<br>(%)  
  |  |   
   | 2+  | •  | 3+<br>(%)  
           | 4+<br>(%)  |
| stem)                  |   |           |  |  |   |  |  |   
   
  |  
  |  |     
   |  |  |  |   |  
  |  |   
   |   |  |  
           |  |
| hyperplasia            |   |           | 2  | 0  | 0<br>( 0)   | 14<br>(28)   | 1  |   
   
  | 0  
  | 0<br>( 0)  | 1   
   | 13<br>26) (  | 3  | 0  | ) (   | 0<br>0)  
  |  |   
   | 0   |  | 0  
           | 0<br>( 0)  |
| Rathke pouch           | 2<br>( 4  | ) (       | 0<br>0) (  | 0<br>0)  | 0<br>(0)  | 0<br>( 0)  | 0<br>( 0)  | (   
   
  | 0<br>0)  
  | 0<br>(0)   | (   
   | 0<br>0) (  | 0<br>0)  | 0<br>( 0   | ) (   | 0<br>0)  
  | (  | 1<br>2)   
   | 0<br>( 0)   | (  | 0<br>0)  
           | 0<br>( 0)  |
| follicular hyperplasia |   |           | 0  | 0  | 0<br>( 0)   | 0<br>( 0)  | 0  |   
   
  | 0<br>0)  
  | 0<br>( 0)  |     
   |  | 0  | 0  |   | 0<br>0)  
  |  |   
   | 0   |  | 0  
           | 0<br>( 0)  |
| C-cell hyperplasia     |   |           |  | 0<br>0)  | 0<br>( 0)   | 13<br>(26)   | 4<br>(8)   | (   
   
  | 0<br>0)  
  | 0<br>( 0)  | (1  
   | 8<br>6) (  | 1<br>2)  | 0<br>( 0   | ) (   | 0 *<br>0)  
  | ( -  | 9<br>8)   
   | 2<br>(4)  | (  | 0<br>0)  
           | 0<br>( 0)  |
| angiectasis            |   |           | 0  | 0  | 0<br>( 0)   | 2<br>( 4)  | 0  |   
   
  | 0<br>0) (  
  | 0<br>( 0)  | (   
   | 0<br>0) (  | 0  | 0  | ) (   | 0<br>0)  
  | (  |   
   | 1   |  | 0  
           | 0<br>( 0)  |
| hemorrhage             |   |           | D<br>D) (  | 0<br>0)  | 0<br>( 0)   | 0<br>( 0)  | 0<br>( 0)  | (   
   
  | 0<br>0) (  
  | 0<br>( 0)  | (   
   | 0<br>0) (  | 0<br>0)  | 0  | ) (   | 0<br>0)  
  | (  | 1<br>2)   
   | 0<br>( 0)   | (  | 0<br>0)  
           | 0<br>( 0)  |
| peliosis-like lesion   |   |           |  | 0<br>0)  | 0<br>( 0)   | 2<br>( 4)  | 0<br>(0)   | (   
   
  | 0<br>0) (  
  | 0<br>( 0)  |     
   |  | 0<br>0)  |  |   | 0<br>0)  
  | (  | 2<br>4)   
   | 0<br>(0)  | (  | 0<br>0) (  
           | 0<br>( 0)  |
|                        | stem)<br>hyperplasia<br>Rathke pouch<br>follicular hyperplasia<br>C-cell hyperplasia<br>angiectasis<br>hemorrhage | Findings  | Grade       1+         Findings       1+         hyperplasia       14         hyperplasia       14         (28)       (         Rathke pouch       2         (4)       (         follicular hyperplasia       1         (2)       (         C-cell hyperplasia       17         (34)       (         angiectasis       4         hemorrhage       0         (0)       (         peliosis-like lesion       3 | Grade         1+         2+           Findings         (%)         (%)           stem]         (28)         (4)           hyperplasia         (28)         (4)           Rathke pouch         (4)         (0)           follicular hyperplasia         (50)           follicular hyperplasia         (2)         (0)           Grade         (2)         (0)           follicular hyperplasia         (34)         (8)           angiectasis         (8)         (0)           hemorrhage         (0)         (0)           peliosis-like lesion         3         0 | Grade         1+         2+         3+           Findings | Grade       1+       2+       3+       4+         Findings | Grade $1+$ $2+$ $3+$ $4+$ $1+$ Findings       (%)       (%)       (%)       (%)       (%)       (%)         stem] $(28)$ $(4)$ $2$ $0$ $0$ $14$ $2$ $0$ $0$ $14$ hyperplasia $(28)$ $(4)$ $(0)$ $(0)$ $(28)$ Rathke pouch $2$ $0$ $0$ $0$ $0$ $0$ follicular hyperplasia $(550)$ $1$ $0$ $0$ $0$ $0$ C-cell hyperplasia $17$ $4$ $0$ $0$ $13$ angiectasis $4$ $0$ $0$ $0$ $(4)$ hemorrhage $0$ $0$ $0$ $(0)$ $(0)$ $(0)$ | Grade       1+       2+       3+       4+       1+       2+         Findings       (%) <td< td=""><td>Grade       1+       2+       3+       4+       1+       2+         Findings       (\$)       (\$)       (\$)       (\$)       (\$)       (\$)         stem]       <math>(50&gt;</math> <math>(50&gt;</math> <math>(50&gt;</math> <math>(50&gt;</math> <math>(50)</math>         hyperplasia       14       2       0       0       14       1         Rathke pouch       2       0       0       0       0       0       (0)<td>Grade       <math>1 + 2 + 3 + 4 + (3) + 4 + (3) + 2 + 3 + 4 + (3) + 2 + 3 + 4 + (3) + 2 + 3 + 4 + (3) + 2 + 3 + (3) + (3</math></td><td>Grade       1+       2+       3+       4+       1+       2+       3+       4+         Findings       (\$)       (</td><td>Grade       1+       2+       3+       4+       1+       2+       3+       4+         Findings</td><td>Grade       1+       2+       3+       4+       1+       2+       3+       4+       1+       1+       2+</td><td>Grade       1+       2+       3+       4+       1+       2+       3+</td><td>Grade       <math>1+</math> <math>2+</math> <math>3+</math> <math>4+</math> <math>1+</math> <math>2+</math> <math>3+</math> <math>4+</math></td><td>Grade       <math>(+ 2^+ 3^+ 4^+)</math> <math>(+ 3^+ 4^+)</math> <math>(+ 3^+ 4^+)</math> <math>(- 3^+ 4^+)</math><!--</td--><td>Grade       1+       2+       3+       4+       1+       2-       3+       4+       1+       2+       3+       4+         Findings</td><td>Grade         1+         2+         3+         4+         1+         2-         3+         3+         <th< td=""><td>Grade         1+         2+         3+         4+         1+         2+         3+         3+         <th< td=""><td>Grade       <math>1 + 2 + 3 + 4 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 1 + 2 + 3 + </math></td><td>Grado       <math>1+2+3+4+</math> <math>1+2+3+4+4+</math> <math>1+2+3+4+</math></td><td>Grade       <math>1+2+3+4+</math> <math>1+2+3+4+</math></td></th<></td></th<></td></td></td></td<> | Grade       1+       2+       3+       4+       1+       2+         Findings       (\$)       (\$)       (\$)       (\$)       (\$)       (\$)         stem] $(50>$ $(50>$ $(50>$ $(50>$ $(50)$ hyperplasia       14       2       0       0       14       1         Rathke pouch       2       0       0       0       0       0       (0) <td>Grade       <math>1 + 2 + 3 + 4 + (3) + 4 + (3) + 2 + 3 + 4 + (3) + 2 + 3 + 4 + (3) + 2 + 3 + 4 + (3) + 2 + 3 + (3) + (3</math></td> <td>Grade       1+       2+       3+       4+       1+       2+       3+       4+         Findings       (\$)       (</td> <td>Grade       1+       2+       3+       4+       1+       2+       3+       4+         Findings</td> <td>Grade       1+       2+       3+       4+       1+       2+       3+       4+       1+       1+       2+</td> <td>Grade       1+       2+       3+       4+       1+       2+       3+</td> <td>Grade       <math>1+</math> <math>2+</math> <math>3+</math> <math>4+</math> <math>1+</math> <math>2+</math> <math>3+</math> <math>4+</math></td> <td>Grade       <math>(+ 2^+ 3^+ 4^+)</math> <math>(+ 3^+ 4^+)</math> <math>(+ 3^+ 4^+)</math> <math>(- 3^+ 4^+)</math><!--</td--><td>Grade       1+       2+       3+       4+       1+       2-       3+       4+       1+       2+       3+       4+         Findings</td><td>Grade         1+         2+         3+         4+         1+         2-         3+         3+         <th< td=""><td>Grade         1+         2+         3+         4+         1+         2+         3+         3+         <th< td=""><td>Grade       <math>1 + 2 + 3 + 4 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 1 + 2 + 3 + </math></td><td>Grado       <math>1+2+3+4+</math> <math>1+2+3+4+4+</math> <math>1+2+3+4+</math></td><td>Grade       <math>1+2+3+4+</math> <math>1+2+3+4+</math></td></th<></td></th<></td></td> | Grade $1 + 2 + 3 + 4 + (3) + 4 + (3) + 2 + 3 + 4 + (3) + 2 + 3 + 4 + (3) + 2 + 3 + 4 + (3) + 2 + 3 + (3) + (3$ | Grade       1+       2+       3+       4+       1+       2+       3+       4+         Findings       (\$)       ( | Grade       1+       2+       3+       4+       1+       2+       3+       4+         Findings | Grade       1+       2+       3+       4+       1+       2+       3+       4+       1+       1+       2+ | Grade       1+       2+       3+       4+       1+       2+       3+ | Grade $1+$ $2+$ $3+$ $4+$ | Grade $(+ 2^+ 3^+ 4^+)$ $(+ 3^+ 4^+)$ $(+ 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ $(- 3^+ 4^+)$ </td <td>Grade       1+       2+       3+       4+       1+       2-       3+       4+       1+       2+       3+       4+         Findings</td> <td>Grade         1+         2+         3+         4+         1+         2-         3+         3+         <th< td=""><td>Grade         1+         2+         3+         4+         1+         2+         3+         3+         <th< td=""><td>Grade       <math>1 + 2 + 3 + 4 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 1 + 2 + 3 + </math></td><td>Grado       <math>1+2+3+4+</math> <math>1+2+3+4+4+</math> <math>1+2+3+4+</math></td><td>Grade       <math>1+2+3+4+</math> <math>1+2+3+4+</math></td></th<></td></th<></td> | Grade       1+       2+       3+       4+       1+       2-       3+       4+       1+       2+       3+       4+         Findings | Grade         1+         2+         3+         4+         1+         2-         3+         3+ <th< td=""><td>Grade         1+         2+         3+         4+         1+         2+         3+         3+         <th< td=""><td>Grade       <math>1 + 2 + 3 + 4 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 1 + 2 + 3 + </math></td><td>Grado       <math>1+2+3+4+</math> <math>1+2+3+4+4+</math> <math>1+2+3+4+</math></td><td>Grade       <math>1+2+3+4+</math> <math>1+2+3+4+</math></td></th<></td></th<> | Grade         1+         2+         3+         4+         1+         2+         3+         3+ <th< td=""><td>Grade       <math>1 + 2 + 3 + 4 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 1 + 2 + 3 + </math></td><td>Grado       <math>1+2+3+4+</math> <math>1+2+3+4+4+</math> <math>1+2+3+4+</math></td><td>Grade       <math>1+2+3+4+</math> <math>1+2+3+4+</math></td></th<> | Grade $1 + 2 + 3 + 4 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 2 + 3 + 1 + 1 + 2 + 3 + $ | Grado $1+2+3+4+$ $1+2+3+4+4+$ $1+2+3+4+$ | Grade $1+2+3+4+$ |

Grade 1+: Slight 2+: Moderate 3+: Marked 4+: Severe

 $\langle \, a \, \rangle \qquad a$  : Number of animals examined at the site

b b: Number of animals with lesion

(c) c:b/a\*100

Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study Grade 1+ 	Control 50 2+ 3+ 4+ (%) (%) (%)	3.2ppm 50 1+ 2+ 3+ 4+ (%) (%) (%) (%)	8ppm 50 - 1+ 2+ 3+ 4+ (%) (%) (%) (%)	20ppm 50 1+ 2+ 3+ 4
Si Buli			(70) (70)	(%) (%) (%)	(%) (%) (%) (%)	(%) (%) (%) (9
{Endocrine s	ystem]					
adrena I	cyst	0 ( 0) (	<50> 0 0 0 ( 0) ( 0) ( 0)	<50> 1 0 0 0 ( 2) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0
	extramedullary hematopoiesis	0 ( 0) (	0 0 0 ( 0) ( 0) ( 0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 (0)(0)(0)(0)	1 0 0 ( (2) (0) (0) (
	hyperplasia:cortical cell	9 (18) (	0 1 0 ( 0) ( 2) ( 0)	6 1 0 0 (12) (2) (0) (0)	5 0 0 0 (10) (0) (0) (0)	12 0 0 ( (24) (0) (0) (0)
	hyperplasia:medulla	1 ( 2) (	0 0 0 0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	3 0 0 0 (6)(0)(0)(0)	1 1 0 (2)(2)(0)(
	focal fatty change:cortex	5 (10) (	0 0 0 0) ( 0) ( 0)	4 0 0 0 (8)(0)(0)(0)	11 1 1 0 (22) (2) (2) (0)	12 1 0 (24) (2) (0) (
	necrosis:cortex	0 ( 0) (	0 0 0 0)(0)(0)	1 0 0 0 (2)(0)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 (0)(0)(0)(
(Reproductiv	e system}					
vary	cyst	2 ( 4) (	<50> 1 0 0 2) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 2 3 0 0 ( 4) ( 6) ( 0) ( 0)	<50> 1 0 0 ( ( 2) ( 0) ( 0) ( 0

- b b : Number of animals with lesion
- (c) c:b/a\*100
- Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

		Group Name No. of Animals on Study	Co 50	ntrol		F	3. 2r	opm					mqq			-		)ppm
rgan	Findings	Grade 1+ 	2+	3+ 4- %) (%)		5 2+ (%)	0 3+ (%)	4+ (%)	1 (%	+	5 2+ (%)	3+ (%)	4+ (%)		1+ %)	5 2+ (%)	0 3+ (%)	
Reproductiv	re system]																	
vary	inflammatory infiltration	0 ( 0)	<50> 0 ( 0) (	00 0)(0)	0 ( 0)	<5 0 ( 0)	0	0 ( 0)	1 ( 2		<5 0 0)	0	0 ( 0)		0 0) (	<50 0 0)	0	( ( (
	lymphocytic infiltration	0 ( 0)	0 ( 0) (	00 0)(0)	0 ( 0)	0 ( 0)	0 (0)	0 ( 0)	1 (2	) (	0 0)	0 ( 0)	0 ( 0)	(	1 2) (	0 0)	0 ( 0)	( (
	hyperplasia	0 ( 0)	0 ( 0) (	0 0 0) ( 0)	1 (2)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0		0 0)	0 ( 0)	0 ( 0)		0 0) (	0 0)	0 ( 0)	( (
erus	cystic endometrial hyperplasia	1 ( 2)	<50> 0 ( 0) (	00 ) (0)	5 (10)	<5) 1 (2)	0	0 ( 0)	4 ( 8		<50 1 2)	0	0 ( 0)		6 2) (	<5( 1 2)	0	( (
mmary gl	hyperplasia	0 ( 0)	<50> 0 ( 0) (	0 0 0) ( 0)	1 ( 2)	<5( 0 ( 0)	0	0 ( 0)	0 ( 0		<5( 0 0)	0	0 ( 0)		0 0) (	<50 0 0)	0	0 ( 0
lervous sys	tem}																	
rain	necrosis:focal	0 ( 0)	<50> 0 ( 0) ( 0	0 0 0)(0)	0 ( 0)	<50 0 ( 0)	0> 0 (0)	0 ( 0)	0		<50 0 0)	)> 0 ( 0)	0 ( 0)		1 2) (	<50 0 0)	0	0 ( 0

(c) c:b/a\*100

Significant difference : \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (O-105W)

		Group Name No. of Animals on Study		0 50	ontro	51				3 50	. 2pp	m			5		opm			,	: 50	20pp	m
gan	Findings			2+	3+ (%)	4+ (%)		1+ (%)	2- (%)	F	3+ (%)	4+ (%)		1+ (%)	2+ (%)	3+ (%)	4+ (%)		1+ (%)	2+ (%)	:	3+ %)	4 (%)
ervous syste	m}																						
ain	mineralization	0 ( 0			0	0 ( 0)	(	0 0)	0		0 0) (	0 ( 0)		1 2) (	<5 0 0)	0	0 ( 0)		1 2) (			0 0) (	0
	degeneration:focal	0 ( 0	) ( 0		0 0)	0 (0)	(	0 0)	0 ( 0)	(	0 0) (	0 ( 0)	(	0 0) (	0 0)	0 ( 0)	0 ( 0)		1 2) (	0 ( 0)		0 0) (	0 0
	gliosis	0 ( 0)	) ( 0	) )) (	0 0)	0 (0)	(	0 0)	0 ( 0)	(	0 0) (	0 ( 0)	(	0 0) (	0 0)	0 ( 0)	0 ( 0)	(	2 4) (	0 ( 0)	( (	0 0) (	0 0
inal cord	degeneration:focal			<50> , )) (	0	0 ( 0)	(	1 2)		(50> (	0 0) (	0 ( 0)		0 0) (	<5 0 0)	0	0 ( 0)		0 0) (	<5 0 ( 0)		D D) (	0 0
pecial sense	organs/appendage]																						
e	cataract	3 ( 6)		<50>	0	0 ( 0)	(	0 0)	2	(50> (				0 0) (		0	0 ( 0)		1 2) (	<5 1 (2)		) )) (	0
	retinal atrophy	0 ( 0)	0 ) ( 0		5 10) (	0 ( 0)	(	0 0)	0 ( 0)	(	2 4) (	0 ( 0)		0 0) (	0 0)	2 (4)	0 ( 0)		0 0) (	0 (0)	1		0

Significant difference ; \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01 Test of Chi Square

(HPT150)

Findings\_\_\_

#### HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

Group Name	<u>.</u>		Contro	ol –			3. 2p	m		_	8pj	om			20pj	m
No. of Animals on		50				50				50	)			50	)	
Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4 (9

#### {Special sense organs/appendage}

Organ\_\_\_\_

eye	keratitis	<50> 3 0 0 0 ( 6) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 3 0 0 0 ( 6) ( 0) ( 0) ( 0)	<50> 5 4 0 0 (10) (8) (0) (0)
	iritis	2 0 0 0 (4)(0)(0)(0)	1 0 0 0 (2)(0)(0)(0)	2 1 0 0 (4)(2)(0)(0)	5 1 0 0 (10) (2) (0) (0)
	mineralization:cornea	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 (0)(0)(0)(0)	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	2 0 0 0 ( 4) ( 0) ( 0) ( 0)
	ulcer:cornea	0 0 0 0 ( 0) ( 0) ( 0) ( 0)	0 0 0 0 (0)(0)(0)(0)(0)	0 2 0 0 ( 0) ( 4) ( 0) ( 0)	0 2 0 0 ( 0) ( 4) ( 0) ( 0)
Harder gl	degeneration:focal	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 1 0 0 0 ( 2) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)	<50> 0 0 0 0 ( 0) ( 0) ( 0) ( 0)
	lymphocytic infiltration	4 0 0 0 (8)(0)(0)(0)	2 0 0 0 (4)(0)(0)(0)	1 0 0 0 (2)(0)(0)(0)	2 0 0 0 (4)(0)(0)(0)
{Musculoskelet	al system]				

bone	<50>	<50>	<50>	<50>
osteosclerosis	4 1 0 0	3 0 0 0	4 5 0 0	3 3 0 0
		(6) (0) (0) (0)	(8)(10)(0)(0)	

### Grade1+: Slight2+: Moderate3+: Marked4+: Severe< a >a : Number of animals examined at the site

b b: Number of animals with lesion (c) c: b / a \* 100 Significant difference :  $*: P \leq 0.05$  \*\* : P  $\leq 0.01$  Test of Chi Square

## TABLE M1

## NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS-TIME RELATED : MALE

#### STUDY NO. : 0794 NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 : MALE

PAGE : 1

ime-related Weeks	ltems	Group Name	Control	3.2ppm	8ppm	20ppm	
0 - 52	NO. OF EXAMINED ANIMALS		0	0	0	0	
	NO. OF ANIMALS WITH TUMORS		0	0	0	0	
	NO. OF ANIMALS WITH SINGLE TUMORS		0	ů 0	ů 0	õ	
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0	
	NO. OF BENIGN TUMORS		0	0	0	0	
	NO. OF MALIGNANT TUMORS		0	0	0	0	
	NO. OF TOTAL TUMORS		0	0	0	0	
53 - 78	NO. OF EXAMINED ANIMALS		0	0	4	9	
	NO. OF ANIMALS WITH TUMORS		0	0	3	9	
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0	0	6	
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	3	3	
	NO. OF BENIGN TUMORS		0	0	2	5	
	NO. OF MALIGNANT TUMORS		0	0	4	9	
	NO. OF TOTAL TUMORS		0	0	6	14	
79 - 104	NO. OF EXAMINED ANIMALS		9	6	7	32	
	NO. OF ANIMALS WITH TUMORS		9	6	7	32	
	NO. OF ANIMALS WITH SINGLE TUMORS		4	0	0	3	
	NO. OF ANIMALS WITH MULTIPLE TUMORS		5	6	7	29	
	NO. OF BENIGN TUMORS		10	12	10	45	
	NO. OF MALIGNANT TUMORS		9	4	7	42	
,	NO. OF TOTAL TUMORS		19	16	17	87	
105 - 105	NO. OF EXAMINED ANIMALS		41	44	39	9	
	NO. OF ANIMALS WITH TUMORS		40	44	39	9	
	NO. OF ANIMALS WITH SINGLE TUMORS		17	12	7	0	
	NO. OF ANIMALS WITH MULTIPLE TUMORS		23	32	32	9	
	NO. OF BENIGN TUMORS		65	83	76	26	
	NO. OF MALIGNANT TUMORS		6	18	28	14	
	NO. OF TOTAL TUMORS		71	101	104	40	

SEX

#### NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

PAGE: 2

Weeks	Items	Group Name	Control	3. 2ppm	8ppm	20ppm	
0 - 105	NO. OF EXAMINED ANIMALS		50	50	50	50	
	NO. OF ANIMALS WITH TUMORS		49	50	49	50	
	NO. OF ANIMALS WITH SINGLE TUMORS		21	12	7	9	
	NO. OF ANIMALS WITH MULTIPLE TUMORS		28	38	42	41	
	NO. OF BENIGN TUMORS		75	95	88	76	
	NO. OF MALIGNANT TUMORS		15	22	39	65	
	NO. OF TOTAL TUMORS		90	117	127	141	

(HPT070)

BAIS5

TABLE M2

## NUMBER OF ANIMALS WITH TUMORS

## AND NUMBER OF TUMORS-TIME RELATED : FEMALE

#### NUMBER OF ANIMALS WITH TUMORS AND NUMBER OF TUMORS - TIME RELATED

STUDY NO.		0794
ANIMAL	:	RAT F344/DuCrICrIj[F344/DuCrj]
REPORT TYPE	:	A1
SEX	:	FEMALE

ime-related Weeks	tems	Group Name	Control	3. 2ppm	8ppm	20ppm	
0 - 52	NO. OF EXAMINED ANIMALS		0	0	1	0	
	NO. OF ANIMALS WITH TUMORS		0	0	1	0	
	NO. OF ANIMALS WITH SINGLE TUMORS		0	0	1	0	
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	0	
	NO. OF BENIGN TUMORS		0	0	0	0	
	NO. OF MALIGNANT TUMORS		0	0	1	0	
	NO. OF TOTAL TUMORS		0	0	1	0	
53 - 78	NO. OF EXAMINED ANIMALS		2	0	2	4	
	NO. OF ANIMALS WITH TUMORS		2	0	2	4	
	NO. OF ANIMALS WITH SINGLE TUMORS		2	0	2	3	
	NO. OF ANIMALS WITH MULTIPLE TUMORS		0	0	0	1	
	NO. OF BENIGN TUMORS		2	0	1	1	
	NO. OF MALIGNANT TUMORS		0	0	1	4	
	NO. OF TOTAL TUMORS		2	0	2	5	
79 - 104	NO. OF EXAMINED ANIMALS		9	11	12	17	
	NO. OF ANIMALS WITH TUMORS		8	11	11	17	
	NO. OF ANIMALS WITH SINGLE TUMORS		5	4	4	6	
	NO. OF ANIMALS WITH MULTIPLE TUMORS		3	7	7	11	
	NO. OF BENIGN TUMORS		9	11	14	19	
	NO. OF MALIGNANT TUMORS		4	8	7	16	
	NO. OF TOTAL TUMORS		13	19	21	35	
105 - 105	NO. OF EXAMINED ANIMALS		39	39	35	29	
	NO. OF ANIMALS WITH TUMORS		22	30	28	26	
	NO. OF ANIMALS WITH SINGLE TUMORS		15	10	12	9	
	NO. OF ANIMALS WITH MULTIPLE TUMORS		7	20	16	17	
	NO. OF BENIGN TUMORS		24	42	45	37	
	NO. OF MALIGNANT TUMORS		5	11	5	13	
	NO. OF TOTAL TUMORS		29	53	50	50	

### $\bigcirc$

 $\bigcirc$ 

ANIMAL : REPORT TYPE :	0794 RAT F344/DuCrICrIj[F344/DuCrj] A1 FEMALE	NUMBER OF ANIMALS WIT	'H TUMORS AND NUMBER O	F TUMORS - TIME RELA	TED		PAGE : 4
Time-related Weeks	ltems	Group Name	Control	3.2ppm	8ppm	20ppm	
0 - 105	NO. OF EXAMINED ANIMALS		50	50	50	50	
	NO. OF ANIMALS WITH TUMORS		32	41	42	47	
	NO. OF ANIMALS WITH SINGLE TUMORS		22	14	19	18	
	NO. OF ANIMALS WITH MULTIPLE TUMORS		10	27	23	29	
	NO. OF BENIGN TUMORS		35	53	60	57	
	NO. OF MALIGNANT TUMORS		9	19	14	33	
	NO. OF TOTAL TUMORS		44	72	74	90	

(HPT070)

BAIS5

TABLE N1

## HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : MALE

#### HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

STUDY NO. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

PAGE: 1

rgan	Findings	Group Name No. of animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
Integumentar	y system/appandage}					
kin/app	squamous cell papilloma	:	<50> 2 ( 4%)	<50> 1 ( 2%)	<50> 2 ( 4%)	<50> 1 ( 2%)
	trichoepithelioma	(	0 ( 0%)	0 ( 0%)	0 ( 0%)	2 ( 4%)
	basal cell epithelioma	(	0 ( 0%)	1 ( 2%)	1 ( 2%)	4 ( 8%)
	keratoacanthoma	(	0 ( 0%)	4 ( 8%)	3 ( 6%)	3 ( 6%)
	tricho lemoma	(	0 ( 0%)	1 ( 2%)	0 ( 0%)	0 ( 0%)
	squamous cell carcinoma	(	0 ( 0%)	2 ( 4%)	1 ( 2%)	2 ( 4%)
	trichoepithelioma:malignant	(	0 ( 0%)	1 ( 2%)	0 ( 0%)	0 ( 0%)
	basal cell carcinoma	(	0 ( 0%)	0 ( 0%)	1 ( 2%)	1 ( 2%)
bcutis	fibroma	ł	<50> 5 ( 10%)	<50> 4 ( 8%)	<50> 4 ( 8%)	<50> 13 ( 26%)
	lipoma	(	0 ( 0%)	1 ( 2%)	0 ( 0%)	0 ( 0%)
	schwannoma	1	1 ( 2%)	0 ( 0%)	0 ( 0%)	1 ( 2%)
	hemangioma	(	0 ( 0%)	0 ( 0%)	1 ( 2%)	0 ( 0%)
	fibrosarcoma	(	0 ( 0%)	2 (4%)	1 ( 2%)	0 ( 0%)

<a> a : Number of animals examined at the site

b (c) b: Number of animals with neoplasm c: b/a \* 100

#### HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

Organ	Findings	Group Name No. of animals on Study		Control 50		3.2ppm 50		8ppm 50		20ppm 50
{Integumentary	y system/appandage}									
subcutis	leiomyosarcoma			(50) ( 2%)	0	<50> ( 0%)	1	<50> ( 2%)	0	<50> ( 0%)
	histiocytic sarcoma		0	( 0%)	0	( 0%)	1	( 2%)	0	( 0%)
	sarcoma:NOS		0	( 0%)	0	( 0%)	1	( 2%)	0	( 0%)
{Respiratory s	system}									
nasal cavit	squamous cell papilloma			(50) (0%)	0	<50> ( 0%)	0	<50> ( 0%)	1	<50> ( 2%)
	adenoma		0	( 0%)	7	( 14%)	9	(18%)	0	( 0%)
	squamous cell carcinoma		0	( 0%)	0	( 0%)	0	( 0%)	29	(58%)
	adenocarcinoma		0	( 0%)	0	( 0%)	0	(0%)	2	( 4%)
	sarcoma:NOS		0	( 0%)	0	( 0%)	0	( 0%)	1	( 2%)
	adenosquamous carcinoma		0	( 0%)	0	( 0%)	1	( 2%)	1	( 2%)
	esthesioneuroepithelioma		0	( 0%)	0	( 0%)	0	( 0%)	7	(14%)
lung	bronchiolar-alveolar adenoma			(50)> ( 4%)	4	<50> ( 8%)	2	<50> ( 4%)	0	<50> ( 0%)
	bronchiolar-alveolar carcinoma		0	( 0%)	0	( 0%)	2	( 4%)	1	(2%)

b (c) b: Number of animals with neoplasm c: b/a \* 100

# STUDY NO. : 0794 ANIMAL : RAT E344/DuCriCriti[E344/DuCri]

#### HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

ANIMAL	:	RAI F344/Ducricrij[F344/Ducrj]
REPORT TY	'PE :	A1
SEX	:	MALE

PAGE : 3

Prgan	Findings	Group Name No. of animals on Study		Control 50		3.2ppm 50		8ppm 50		20ppm 50
Hematopoietic	; system]									
one marrow	histiocytic sarcoma		0	<50> ( 0%)	0	<50> ( 0%)	1	<50> ( 2%)	0	<50> ( 0%)
pleen	hemangioma		0	<50> ( 0%)	0	<50> ( 0%)	1	<50> ( 2%)	0	<50> ( 0%)
	mononuclear cell leukemia		4	( 8%)	6	(12%)	3	( 6%)	4	( 8%)
Digestive sys	tem)									
ral cavity	squamous cell papilloma		0	<50> ( 0%)	1	<50> ( 2%)	0	<50> ( 0%)	0	<50> ( 0%)
ongue	squamous cell carcinoma		0	<50> ( 0%)	1	<50> ( 2%)	0	<50> ( 0%)	0	<50> ( 0%)
omach	squamous cell papilloma		0	<50> ( 0%)	1	<50> ( 2%)	0	<50> ( 0%)	1	<50> ( 2%)
	neuroendocrine cell tumor:benign		0	( 0%)	0	( 0%)	1	( 2%)	0	( 0%)
	squamous cell carcinoma		0	( 0%)	0	( 0%)	1	( 2%)	0	( 0%)
ver	hepatocellular adenoma		1	<50> ( 2%)	1	<50> ( 2%)	1	<50> ( 2%)	2	<50> ( 4%)
ancreas	islet cell adenoma		2	<50> ( 4%)	4	<50> ( 8%)	2	<50> ( 4%)	2	<50> ( 4%)
,	acinar cell adenoma		0	( 0%)	1	( 2%)	0	( 0%)	0	( 0%)
	islet cell adenocarcinoma		1	( 2%)	1	( 2%)	2	( 4%)	2	( 4%)

<a>> a : Number of animals examined at the site

b (c) b : Number of animals with neoplasm c : b / a \* 100

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

Organ	Findings	Group Name No. of animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
{Endocrine sy	vstem}					
pituitary	adenoma	1	<50> 3 (26%)	<50> 7 ( 14%)	<50> 5 ( 10%)	<50> 0 ( 0%)
thyroid	C-cell adenoma		<50> 4 ( 8%)	<50> 5 ( 10%)	<50> 3 ( 6%)	<50> 4 ( 8%)
	follicular adenoma		0 ( 0%)	1 ( 2%)	0 ( 0%)	1 ( 2%)
	C-cell carcinoma		1 ( 2%)	1 ( 2%)	3 ( 6%)	1 ( 2%)
	follicular adenocarcinoma		0 ( 0%)	1 ( 2%)	0 ( 0%)	0 ( 0%)
parathyroid	adenoma		<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 1 ( 2%)
idrena l	pheochromocytoma		<50> 3 ( 6%)	<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 2 ( 4%)
	cortical adenoma		0 ( 0%)	1 ( 2%)	0 ( 0%)	0 ( 0%)
	pheochromocytoma:malignant		1 ( 2%)	0 ( 0%)	2 ( 4%)	0 ( 0%)
{Reproductive	e system)					
testis	interstitial cell tumor	4	<50> 0 ( 80%)	<50> 46 (92%)	<50> 47 (94%)	<50> 36 ( 72%)
prostate	adenoma		<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 1 ( 2%)	<50> 0 ( 0%)
mammary gl	adenoma		<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)

< a > a : Number of animals examined at the site

b (c) b: Number of animals with neoplasm c: b/a \* 100

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

PAGE: 5

rgan	Findings	Group Name No. of animals on Study		Control 50		3.2ppm 50		8ppm 50		20ppm 50
Reproductive	system]									
ammary gl	fibroadenoma			<50> ( 0%)	0	<50> ( 0%)	2	<50> ( 4%)	1	<50> ( 2%)
	adenocarcinoma		1	( 2%)	0	( 0%)	0	( 0%)	0	( 0%)
rep/cli gl	adenoma			<50> ( 4%)	1	<50> ( 2%)	1	<50> ( 2%)	1	<50> ( 2%)
Nervous syste	əm)									
rain	leiomyosarcoma			<50> ( 0%)	0	<50> ( 0%)	1	<50> (2%)	0	<50> ( 0%)
	glioma		1	( 2%)	0	( 0%)	0	( 0%)	0	( 0%)
pecial sense	e organs/appendage}									
rder gl	adenoma			<50> ( 0%)	1	<50> ( 2%)	0	<50> ( 0%)	0	<50> ( 0%)
mbal gl	Zymbal gland tumor:malignant			<50> ( 2%)	0	<50> ( 0%)	0	<50> ( 0%)	0	<50> ( 0%)
Musculoskelet	cal system}									
uscle	rhabdomyosarcoma			<50> ( 2%)	0	<50> ( 0%)	0	<50> ( 0%)	0	<50> ( 0%)
one	osteosarcoma			<50> (2%)	0	<50> ( 0%)	1	<50> ( 2%)	0	<50> ( 0%)
Body cavities	3]									
eritoneum	leiomyosarcoma			<50> ( 2%)	0	<50> ( 0%)	0	<50> ( 0%)	0	<50> ( 0%)

< a > a : Number of animals examined at the site

b (c) b: Number of animals with neoplasm c: b/a \* 100

.

#### STUDY NO. : 0794 : RAT F344/DuCrICrIj[F344/DuCrj] ANIMAL REPORT TYPE : A1 : MALE SEX

#### HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

gan	Findings	Group Name No. of animals on Study	Control 50		3.2ppm 50		8ppm 50		20ppm 50
dy cavities	5]								
itoneum	mesothelioma		(50> ( 2%)	7	<50> ( 14%)	16	<50> ( 32%)	14	<50> ( 28%)
pose	lipoma		(50> ( 0%)	0	<50> ( 0%)	1	<50> ( 2%)	0	<50> ( 0%)

b (c) b : Number of animals with neoplasm c : b / a \* 100

(HPT085)

BAIS5

TABLE N2

## HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS : FEMALE

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : FEMALE

PAGE : 7

-gan	Findings	Group Name No. of animals on Study	Control 50	3. 2ppm 50	8ppm 50	20ppm 50
Integumenta	ry system/appandage}					
kin/app	squamous cell papilloma		<50> 0 ( 0%)	<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)
	basal cell epithelioma		0 ( 0%)	0 ( 0%)	1 ( 2%)	0 ( 0%)
	squamous cell carcinoma		0 ( 0%)	0 ( 0%)	0 ( 0%)	1 ( 2%)
	basal cell carcinoma		1 ( 2%)	0 ( 0%)	0 ( 0%)	0 ( 0%)
ubcutis	fibroma		<50> 0 ( 0%)	<50> 2 ( 4%)	<50> 2 ( 4%)	<50> 3 ( 6%)
	lipoma		1 ( 2%)	0 ( 0%)	1 ( 2%)	0 ( 0%)
	schwannoma		0 ( 0%)	0 ( 0%)	1 ( 2%)	0 ( 0%)
	sarcoma:NOS		0 ( 0%)	0 ( 0%)	1 ( 2%)	O ( 0%)
espiratory	system}					
asal cavit	adenoma		<50> 0 ( 0%)	<50> 3 ( 6%)	<50> 3 ( 6%)	<50> 1 ( 2%)
	squamous cell carcinoma		0 ( 0%)	0 ( 0%)	0 ( 0%)	10 ( 20%)
	adenosquamous carcinoma		0 ( 0%)	0 ( 0%)	0 ( 0%)	1 ( 2%)
	esthesioneuroepithelioma		0 ( 0%)	0 ( 0%)	0 ( 0%)	2 (4%)

< a > a : Number of animals examined at the site

b (c) b: Number of animals with neoplasm c: b / a \* 100

(HPT085)

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : FEMALE

PAGE : 8

Prgan	Findings	Group Name No. of animals on Study		Control 50		3.2ppm 50		8ppm 50		20ppm 50
Respiratory	system]									
asal cavit	hemangiosarcoma			<50> ( 0%)	0	<50> ( 0%)	0	<50> ( 0%)	1	<50> ( 2%)
ung	bronchiolar-alveolar adenoma			<50> (2%)	1	<50> ( 2%)	0	<50> ( 0%)	1	<50> ( 2%)
	bronchiolar-alveolar carcinoma		0	( 0%)	1	( 2%)	0	( 0%)	0	( 0%)
Hematopoieti	c_system]									
pleen	mononuclear cell leukemia			<50> ( 10%)	10	<50> ( 20%)	8	<50> ( 16%)	6	<50> ( 12%)
)igestive sy	stem}									
al cavity	squamous cell papilloma			<50> ( 2%)	0	<50> ( 0%)	0	<50> ( 0%)	0	<50> ( 0%)
ongue	squamous cell papilloma	(		<50> ( 0%)	1	<50> (2%)	0	<50> ( 0%)	1	<50> ( 2%)
	squamous cell carcinoma	(	0	( 0%)	0	( 0%)	0	( 0%)	1	( 2%)
tomach	squamous cell papilloma	(		<50> ( 0%)	0	<50> ( 0%)	1	<50> ( 2%)	0	<50> ( 0%)
	squamous cell carcinoma	(	0	( 0%)	0	( 0%)	0	( 0%)	1	( 2%)
iver	hepatocellular adenoma			<50> ( 2%)	0	<50> ( 0%)	1	<50> ( 2%)	0	<50> ( 0%)
ancreas	islet cell adenoma			<50> ( 2%)	0	<50> ( 0%)	1	<50> (2%)	1	<50> (2%)

 $\langle a \rangle$  a : Number of animals examined at the site

b (c) b: Number of animals with neoplasm c: b/a \* 100

#### STUDY NO. : 0794 : RAT F344/DuCrlCrlj[F344/DuCrj] ANIMAL REPORT TYPE : A1 SEX : FEMALE

)rgan	Findings	Group Name No. of animals on Study		Control 50		3.2ppm 50		8ррт 50		20ррт 50
Digestive sys	stem]									
ancreas	acinar cell adenoma			<50> ( 2%)	0	<50> ( 0%)	0	<50> ( 0%)	0	<50> ( 0%)
	islet cell adenocarcinoma		0	( 0%)	1	( 2%)	0	( 0%)	0	( 0%)
Jrinary syste	em]									
rin bladd	transitional cell papilloma			<50> ( 4%)	0	<50> ( 0%)	0	<50> ( 0%)	0	<50> ( 0%)
Endocrine sys	stem]									
ituitary	adenoma	. 1		<50> ( 22%)	16	<50> ( 32%)	13	<50> ( 26%)	8	<50> (16%)
	adenocarcinoma		1	( 2%)	2	( 4%)	0	( 0%)	0	( 0%)
nyroid	C-cell adenoma			<50> ( 2%)	1	<50> ( 2%)	3	<50> ( 6%)	4	<50> ( 8%)
	follicular adenoma		1	( 2%)	2	( 4%)	3	( 6%)	1	( 2%)
	C-cell carcinoma		0	( 0%)	0	( 0%)	2	( 4%)	0	( 0%)
drenal	pheochromocytoma			<50> ( 2%)	0	<50> ( 0%)	2	<50> ( 4%)	0	<50> ( 0%)
	pheochromocytoma:malignant		1	( 2%)	0	( 0%)	0	( 0%)	0	( 0%)
Reproductive	system]									
vary	granular cell tumor			<50> ( 0%)	0	<50> ( 0%)	0	<50> ( 0%)	1	<50> ( 2%)

<a>> a : Number of animals examined at the site b (c)

c:b/a\*100 b : Number of animals with neoplasm

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : FEMALE

PAGE : 10

Organ	Findings	Group Name No. of animals on Study		Control 50		3. 2ppm 50		8ppm 50		20ppm 50
{Reproductive	system]									
ovary	granulosa-theca cell tumor			<50> ( 0%)	0	<50> ( 0%)	1	<50> (2%)	0	<50> ( 0%)
	Sertoli cell tumor:malignant		0	( 0%)	0	( 0%)	0	( 0%)	1	( 2%)
	granulosa cell tumor:malignant		0	( 0%)	1	(2%)	0	( 0%)	0	( 0%)
iterus	adenoma			<50> ( 0%)	0	<50> ( 0%)	0	<50> ( 0%)	2	<50> ( 4%)
	endometrial stromal polyp		6	( 12%)	10	(20%)	7	( 14%)	7	(14%)
	adenocarcinoma		0	( 0%)	1	( 2%)	0	( 0%)	1	( 2%)
	endometrial stromal sarcoma		1	( 2%)	1	( 2%)	1	( 2%)	5	(10%)
agina	squamous cell papilloma			<50> ( 0%)	0	<50> ( 0%)	1	<50> ( 2%)	0	<50> ( 0%)
ammary gl	adenoma			<50> ( 0%)	0	<50> ( 0%)	1	<50> (2%)	0	<50> ( 0%)
	fibroadenoma		7	( 14%)	14	( 28%)	14	( 28%)	23	(46%)
	adenocarcinoma		0	( 0%)	1	( 2%)	1	( 2%)	1	( 2%)
orep/cli gl	adenoma			<50> ( 0%)	3	<50> ( 6%)	3	<50> ( 6%)	4	<50> ( 8%)
Special sense	e organs/appendage)									
Ymbal gl	Zymbal gland tumor:malignant			<50> ( 0%)	0	<50> ( 0%)	0	<50> ( 0%)	1	<50> ( 2%)

 $\langle a \rangle$  a : Number of animals examined at the site

b (c) b: Number of animals with neoplasm c:b/a\*100

#### STUDY NO. : 0794 : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 : FEMALE

#### HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

		Group Name	Control	3. 2ppm	8ppm	20ppm
rgan	Findings	No. of animals on Study	50	50	50	50
usculoskele	etal system]					
scle	leiomyosarcoma		<50> 0 ( 0%)	<50> 1 ( 2%)	<50> 0 ( 0%)	<50> 0 ( 0%)
ody cavitie	es)				·	
eura			<50>	<50>	<50>	<50>
	histiocytic sarcoma		0 ( 0%)	0 ( 0%)	0 ( 0%)	1 ( 2%)
ritoneum			<50>	<50>	<50>	<50>
	sarcoma:NOS		0 ( 0%)	0 ( 0%)	1 (2%)	0 ( 0%)

\_ < a > a : Number of animals examined at the site

b (c) b : Number of animals with neoplasm c:b/a\*100

(HPT085)

ANIMAL

TABLE O1

## NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS : MALE

STUDY No. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] SEX : MALE

PAGE: 1

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : skin/appendage			
	TUMOR : basal cell epithelioma			
umor rate				
Overall rates(a)	0/50(0.0)	1/50(2.0)	1/50(2.0)	4/50 ( 8.0)
Adjusted rates(b)	0.0	2. 27	2.56	23.08
Terminal rates(c)	0/41(0.0)	1/44 ( 2.3)	1/39(2.6)	1/9(11.1)
tatistical analysis				
Peto test				
Standard method(d)	P =			
Prevalence method(d)	P = 0.0003**			
Combined analysis(d)	P =			
Cochran-Armitage test(e)	P = 0.0154*			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.0587
	SITE : skin/appendage			
	TUMOR : keratoacanthoma			
umor rate				
Overall rates(a)	0/50(0,0)	4/50 ( 8.0)	3/50 ( 6.0)	3/50 ( 6.0)
Adjusted rates(b)	0.0	8.00	7.69	23.08
Terminal rates(c)	0/41(0,0)	2/44 ( 4, 5)	3/39(7.7)	1/9(11.1)
tatistical analysis	,			
Peto test				
Standard method(d)	P =			
Prevalence method(d)	P = 0.0250*			
Combined analysis(d)	P =			
Cochran-Armitage test(e)	P = 0.4221			
Fisher Exact test(e)		P = 0.0587	P = 0.1212	P = 0.1212
			<b>ANNOUND FUNCTION OF A CONTRACT OF A CONTRACT</b>	
	SITE : skin/appendage			
	TUMOR : squamous cell papilloma,	keratoacanthoma		
umor rate				
Overall rates(a)	2/50( 4.0)	5/50(10.0)	4/50 ( 8.0)	4/50 ( 8.0)
Adjusted rates(b)	4.44	10.00	10.26	23.08
Terminal rates(c)	1/41 ( 2.4)	2/44 ( 4.5)	4/39(10.3)	1/9(11.1)
tatistical analysis				
Peto test				
Standard method(d)	P =			
Prevalence method(d)	P = 0.0720			
Combined analysis(d)	P =			
Cochran-Armitage test(e)	P = 0.6975			
Fisher Exact test(e)		P = 0.2180	P = 0.3389	P = 0.3389

STUDY No.	:	0794
ANIMAL	:	RAT F344/DuCrICrIj[F344/DuCrj]
SEX	:	MALE

•					
Group Name	Control	3. 2ppm	8ppm	20ppm	
	SITE : skin/appendage				
	TUMOR : basal cell epithelio	oma,basal cell carcinoma			
umor rate					
Overall rates(a)	0/50( 0.0)	1/50 ( 2.0)	2/50( 4.0)	5/50(10.0)	
Adjusted rates(b)	0.0	2. 27	2.56	23. 08	
Terminal rates(c)	0/41(0.0)	1/44 ( 2.3)	1/39(2.6)	1/9(11.1)	
tatistical analysis					
Peto test					
Standard method(d)	P = 0.2314				
Prevalence method(d)	P = 0.0001**				
Combined analysis(d)	P = 0.0001**				
Cochran-Armitage test(e)	P = 0.0070**				
Fisher Exact test(e)		P = 0.5000	P = 0.2475	P = 0.0281*	
	SITE : skin/appendage				
	TUMOR : squamous cell papil	oma, keratoacanthoma, squamous cell carci	noma		
umor rate					
Overall rates(a)	2/50 ( 4.0)	7/50(14.0)	5/50(10.0)	6/50(12.0)	
Adjusted rates(b)	4.44	12. 24	12.82	30. 77	
Terminal rates(c)	1/41 ( 2.4)	3/44 ( 6.8)	5/39(12.8)	2/ 9( 22.2)	
tatistical analysis					
Peto test					
Standard method(d)	P = 0.4952				
Prevalence method(d)	P = 0.0132*				
Combined analysis(d)	P = 0.0180*				
Cochran-Armitage test(e)	P = 0.4128				
Fisher Exact test(e)		P = 0.0798	P = 0.2180	P = 0.1343	
	SITE : subcutis				
	TUMOR : fibroma				
umor rate					
Overall rates(a)	5/50(10.0)	4/50 ( 8.0)	4/50 ( 8.0)	13/50 ( 26. 0)	
djusted rates(b)	10.64	9.09	10.26	60.00	
ferminal rates(c)	3/41 ( 7.3)	4/44(9.1)	4/39( 10.3)	5/9(55.6)	
atistical analysis					
eto test	_				
Standard method (d)	P =				
Prevalence method(d)	P < 0.0001**				
Combined analysis(d)	P =				
Cochran-Armitage test(e)	P = 0.0048**				
Fisher Exact test(e)					

PAGE : 2

#### STUDY No. : 0794 ANIMAL : RAT F344/DuCriCrij[F344/DuCrj] SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

EX : MALE				Р	AGE :
Group Name	Control	<b>3.</b> 2ppm	8ppm	20ppm	
	SITE : subcutis				
umor rate	TUMOR : fibroma,fibrosarcoma				
Overall rates(a)	5/50(10.0)	6/50(12.0)	5/50(10.0)	13/50 ( 26.0)	
Adjusted rates (b)	10.64	13.64	12.82	60.00	
Terminal rates(c)	3/41 ( 7.3)	6/44 ( 13. 6)	5/39(12.8)	5/9(55.6)	
tatistical analysis Peto test	0, 11 ( )10,	0, 11( 10.0)	0,00 ( 12.0)		
Standard method(d)	P =				
Prevalence method(d)	P = 0.0002**				
Combined analysis(d)	P =				
Cochran-Armitage test(e)	P = 0.0140*				
Fisher Exact test(e)		P = 0.5000	P = 0.6297	P = 0.0332*	
	SITE : nasal cavity TUMOR : adenoma				
umor rate					
Overall rates(a)	0/50(0.0)	7/50(14.0)	9/50(18.0)	0/50( 0.0)	
Adjusted rates(b)	0.0	15.91	20.51	0.0	
Ferminal rates(c) tatistical analysis Peto test	0/41 ( 0.0)	7/44 ( 15.9)	8/39 (20.5)	0/9(0.0)	
Standard method(d)	P =				
Prevalence method(d)	P = 0.2473				
Combined analysis(d)	P =				
Cochran-Armitage test(e)	P = 0.2970				
Fisher Exact test(e)		P = 0.0062**	P = 0.0013**	P = N.C.	
	SITE : nasal cavity				
umor rate	TUMOR : squamous cell carcinom	a			
umor rate Overall rates(a)	0/50(0.0)	0/50( 0.0)	0/50( 0.0)	29/50(58,0)	
Adjusted rates(b)	0.0	0.0	0.0	40.00	
ferminal rates(c)	0/41 ( 0.0)	0/44 ( 0.0)	0/39(0.0)	3/9(33.3)	
catistical analysis Peto test	-,	0,11( 0.0)	0,000 0.07	3, 5, 50, 50, 5,	
Standard method (d)	P < 0.0001 <b>*</b> *?				
Prevalence method(d)	P < 0.0001 <b>*</b> *?				
Combined analysis(d)	P < 0.0001**?				
Cochran-Armitage test(e)	P < 0.0001**				
Fisher Exact test(e)		P = N.C.	P = N.C.	₽ < 0.0001**	

3.2ppm

STUDY No.	:	0794
ANIMAL	:	RAT F344/DuCrlCrlj[F344/DuCrj]
SEX	:	MALE

Control

0/50( 0.0)

0/41(0.0)

P < 0.0001**\***\*?

P = 0.0328\* ?

P < 0.0001\*\*?

P < 0.0001**\***\*

0.0

Group Name

Tumor rate Overall rates(a)

Adjusted rates(b)

Terminal rates(c)

Statistical analysis Peto test

Standard method(d)

Prevalence method(d)

Combined analysis(d)

Fisher Exact test(e)

Cochran-Armitage test(e)

SITE : nasal cavity TUMOR : esthesioneuroepithelioma 0/50( 0.0) 0/50(0.0) 7/50(14.0) 0.0 0.0 6.67 0/9(0.0) 0/44(0.0) 0/39(0.0) P = N.C.P = N.C.P = 0.0062\*\* SITE : nasal cavity TUMOR : squamous cell papilloma, squamous cell carcinoma

8ppm

	rement · equalicate corr papri	roma, oquamouo oorr ou	l o mona				
Tumor rate							
Overall rates(a)	0/50(0.0)	0/50(	0.0)	0/50(	0.0)	30/50(60.0)	
Adjusted rates(b)	0.0		0.0		0.0	50.00	
Terminal rates(c)	0/41(0.0)	0/44(	0.0)	0/39(	0. 0)	4/9(44.4)	
Statistical analysis							
Peto test							
Standard method(d)	P < 0.0001**?						
Prevalence method(d)	P < 0.0001 <b>∗</b> ∗?						
Combined analysis(d)	P < 0.0001**?						
Cochran-Armitage test(e)	P < 0.0001 <b>*</b> *						
Fisher Exact test(e)		P = N.C.		P = N.C.		P < 0.0001 <b>*</b> *	

	SITE : nasal cavity TUMOR : adenoma,adenocarci	noma			
Tumor rate					
Overall rates(a)	0/50(0.0)	7/50(14.0)	9/50(18.0)	2/50( 4.0)	
Adjusted rates(b)	0.0	15.91	20. 51	11. 11	
Terminal rates(c)	0/41(0.0)	7/44(15.9)	8/39(20.5)	1/9(11.1)	
Statistical analysis					
Peto test					
Standard method(d)	P = 0.0508 ?				
Prevalence method(d)	P = 0.0916				
Combined analysis(d)	P = 0.0320*				
Cochran-Armitage test(e)	P = 0.8453				
Fisher Exact test(e)		P = 0.0062**	P = 0.0013**	P = 0.2475	

PAGE :

20ppm

4

### $\bigcirc$

 $\bigcirc$ 

STUDY No.:0794ANIMAL:RAT F344/DuCrlCrlj[F344/DuCrj]SEX:MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	3. 2ppm	8ppm	20ppm	
	SITE : nasal cavity				
	TUMOR : squamous cell carcir	oma, adenocarcinoma, adenosquamous carcin	oma,esthesioneuroepithelioma		
umor rate					
Overall rates(a)	0/50(0.0)	0/50( 0.0)	1/50( 2.0)	38/50(76.0)	
djusted rates(b)	0.0	0.0	2.56	63.64	
erminal rates(c)	0/41(0.0)	0/44(0.0)	1/39( 2.6)	5/9(55.6)	
tatistical analysis					
eto test	- /				
Standard method(d)	P < 0.0001**?				
Prevalence method(d)	P < 0.0001**?				
Combined analysis(d)	P < 0.0001**?				
Cochran-Armitage test(e)	P < 0.0001**			- /	
Fisher Exact test(e)		P = N. C.	P = 0.5000	P < 0.0001 <b>*</b> *	
	SITE : nasal cavity				
		oma, adenoma, squamous cell carcinoma, ade	nocarcinoma adenosquamous carcinoma		
imor rate					
Overall rates(a)	0/50(0.0)	7/50(14.0)	10/50 ( 20. 0)	33/50(66.0)	
Adjusted rates(b)	0.0	15.91	23.08	70.00	
ferminal rates (c)	0/41 ( 0.0)	7/44(15.9)	9/39(23.1)	6/9(66.7)	
tatistical analysis		.,	-, (,	-, - ( , ,	
Peto test					
Standard method(d)	₽ < 0.0001**?				
Prevalence method(d)	P < 0.0001**				
Combined analysis(d)	P < 0.0001 <b>*</b> *?				
Cochran-Armitage test(e)	P < 0.0001 <b>*</b> *				
Fisher Exact test(e)		P = 0.0062**	P = 0.0006**	P < 0.0001 <b>*</b> *	
	SITE : lung				
	TUMOR : bronchiolar-alveolar	adenoma			
umor rate					
Overall rates(a)	2/50( 4.0)	4/50( 8.0)	2/50 ( 4.0)	0/50( 0.0)	
Adjusted rates(b)	4.88	9.09	4.55	0.0	
Terminal rates(c)	2/41( 4.9)	4/44 ( 9.1)	1/39(2.6)	0/9(0.0)	
tatistical analysis					
Peto test					
Standard method(d)	P =				
Prevalence method(d)	P = 0.7960				
Combined analysis(d)	P =				
Cochran-Armitage test(e)	P = 0.1105				
Fisher Exact test(e)		P = 0.3389	P = 0.6913	P = 0.2475	

#### STUDY No. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] SEX : MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	3.2ppm	8ppm	20ppm	
к	SITE : lung				
	TUMOR : bronchiolar-alveolar	adenoma,bronchiolar-alveolar carcinoma			
Tumor rate					
Overall rates(a)	2/50 ( 4.0)	4/50 ( 8.0)	4/50 ( 8.0)	1/50( 2.0)	
Adjusted rates(b)	4.88	9.09	8.16	11. 11	
Terminal rates(c) Statistical analysis Peto test	2/41 ( 4.9)	4/44(9.1)	2/39( 5.1)	1/9(11.1)	
Standard method(d)	P =				
Prevalence method(d) Combined analysis(d)	P = 0.5456 P =				
Cochran-Armitage test(e)	P = 0.3913				
Fisher Exact test(e)	1 0.0010	P = 0.3389	P = 0.3389	P = 0.5000	
	SITE : spleen				
	TUMOR : mononuclear cell leuk	emia			
umor rate	4/50( 0.0)				
Overall rates(a) Adjusted rates(b)	4/50 ( 8.0)	6/50 ( 12.0)	3/50 ( 6.0)	4/50 ( 8.0)	
Terminal rates(c)	2.44 1/41 (2.4)	6.82 3/44 ( 6.8)	5.13 2/39( 5.1)	0.0	
tatistical analysis	1/41( 2.4)	3/44( 0.8)	2/39( 5.1)	0/9(0.0)	
Peto test					
Standard method(d)	P = 0.0456*				
Prevalence method(d)	P = 0.5503				
Combined analysis(d)	P = 0.0865				
Cochran-Armitage test(e)	P = 0.7537				
Fisher Exact test(e)		P = 0.3703	P = 0.5000	P = 0.6425	
	SITE : pancreas				
	TUMOR : islet cell adenoma				
fumor rate					
Overall rates (a)	2/50(4.0)	4/50 ( 8.0)	2/50 ( 4.0)	2/50 ( 4.0)	
Adjusted rates(b) Terminal rates(c)	4.88	9.09	5.13	11.11	
tatistical analysis	2/41 ( 4.9)	4/44 ( 9.1)	2/39( 5.1)	1/9(11.1)	
Peto test					
Standard method(d)	P =				
Prevalence method(d)	P = 0.1905				
Combined analysis(d)	P =				
Cochran-Armitage test(e)	P = 0.6944				

STUDY No. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] SEX : MALE

Group Name	Control	3.2ppm	8ppm	20ppm	
	SITE : pancreas				
	TUMOR : islet cell adenoma, is	et cell adenocarcinoma			
lumor rate	· · · · · · · · · · · · · · · · · · ·				
Overall rates(a)	3/50( 6.0)	5/50(10.0)	4/50( 8.0)	4/50( 8.0)	
Adjusted rates(b)	7.32	11.36	10. 26	22. 22	
Terminal rates(c)	3/41 ( 7.3)	5/44(11.4)	4/39( 10.3)	2/ 9( 22.2)	
tatistical analysis					
Peto test					
Standard method(d)	P =				
Prevalence method(d)	P = 0.0406*				
Combined analysis(d)	P =				
Cochran-Armitage test(e)	P = 0.9126	D 0 0575			
Fisher Exact test(e)		P = 0.3575	P = 0.5000	P = 0.5000	
	SITE : pituitary gland				
	TUMOR : adenoma				
lumor rate					
Overall rates(a)	13/50 ( 26.0)	7/50(14.0)	5/50(10.0)	0/50(0.0)	
Adjusted rates(b)	25.00	11.36	10. 26	0.0	
Terminal rates(c)	10/41 (24.4)	5/44(11.4)	4/39(10.3)	0/9(0.0)	
tatistical analysis					
Peto test					
Standard method(d)	P = 0.6722				
Prevalence method(d)	P = 0.9991				
Combined analysis(d)	P = 0.9990				
Cochran-Armitage test(e)	P = 0.0002**				
Fisher Exact test(e)		P = 0.1054	P = 0.0332*	P < 0.0001**	
	SITE : thyroid				
	TUMOR : C-cell adenoma				
umor rate					
Overall rates (a)	4/50( 8.0)	5/50(10.0)	3/50 ( 6.0)	4/50 ( 8.0)	
Adjusted rates (b)	9.76	11.36	6.98	33. 33	
Terminal rates (c)	4/41 ( 9.8)	5/44 ( 11. 4)	2/39(5.1)	3/9(33.3)	
tatistical analysis		-,	_, _, _, , , , , ,	-, -, -, -, -, -, -, -, -, -, -, -, -, -	
Peto test					
Standard method(d)	P =				
Prevalence method(d)	P = 0.0783				
Combined analysis(d)	P =				
Cochran-Armitage test(e)	P = 0.8692				
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.6425	

STUDY No.	:	0794
AN I MAL SEX	::	RAT F344/DuCrICrIj[F344/DuCrj] MALE

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : thyroid			
	TUMOR : C-cell carcinoma			
umor rate				
Overall rates(a)	1/50(2.0)	1/50(2.0)	3/50(6.0)	1/50 ( 2.0)
Adjusted rates(b)	2.44	2. 27	7.69	11. 11
Terminal rates(c) tatistical analysis Peto test	1/41 ( 2.4)	1/44 ( 2.3)	3/39(7.7)	1/9(11.1)
Standard method(d)	P =			
Prevalence method(d)	P = 0.0809			
Combined analysis(d)	P =			
Cochran-Armitage test(e)	P = 0.9826			
Fisher Exact test(e)		P = 0.7525	P = 0.3087	P = 0.7525
	SITE : thyroid			
	TUMOR : C-cell adenoma, C-cell (	carcinoma		
umor rate	F (FO ( 10 O)			
)verall rates(a) Adjusted rates(b)	5/50(10.0) 12.20	6/50(12.0) 13.64	6/50(12.0) 13.95	5/50 ( 10. 0) 44. 44
ferminal rates(c)	5/41 ( 12. 2)	6/44 ( 13.6)	5/39(12.8)	44.44 4/9(44.4)
atistical analysis	0, 11( 1212)	0,44(10.0)	0,00 ( 12.0)	47 3 ( 44.47
Peto test				
Standard method(d)	P =			
Prevalence method(d)	P = 0.0234*			
Combined analysis(d)	P =			
Cochran-Armitage test(e)	P = 0.8959			
isher Exact test(e)	·	P = 0.5000	P = 0.5000	P = 0.6297
	SITE : adrenal gland			
mag yata	TUMOR : pheochromocytoma			
umor rate Dverall rates(a)	3/50 ( 6.0)	1/50 ( 2.0)	0/50( 0.0)	0/50( 4.0)
Adjusted rates(b)	7.32	2. 13	0/50( 0.0) 0.0	2/50 ( 4.0) 11.11
ferminal rates(c)	3/41(7.3)	0/44( 0.0)	0/39(0.0)	1/ 9( 11. 1)
atistical analysis	-,	0,11, 0.0,	0,00 ( 0.0)	1/ 2/ 11/1/
Peto test				
Standard method(d)	P =			
Prevalence method(d)	P = 0.4240			
Combined analysis(d)	P =			
Cochran-Armitage test(e) Fisher Exact test(e)	P = 0.8443	P = 0, 3087	P = 0.1212	

STUDY No.	:	0794
ANIMAL	:	RAT F344/DuCrICrIj[F344/DuCrj]
SEX	:	MALE

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : adrenal gland			
	TUMOR : pheochromocytoma, ph	eochromocytoma:malignant		
umor rate				
Overall rates(a)	4/50(8.0)	1/50 ( 2.0)	2/50(4.0)	2/50( 4.0)
Adjusted rates(b)	9.76	2. 13	4.44	11. 11
Terminal rates(c)	4/41 ( 9.8)	0/44( 0.0)	1/39( 2.6)	1/9(11.1)
tatistical analysis				
Peto test				
Standard method(d)	P =			
Prevalence method(d)	P = 0.5013			
Combined analysis(d)	P =			
Cochran-Armitage test(e)	P = 0.6214	D = 0.4011		
Fisher Exact test(e)		P = 0. 1811	P = 0.3389	P = 0.3389
	SITE : testis			
	TUMOR : interstitial cell to	Jmor		
umor rate				
Overall rates(a)	40/50 ( 80.0)	46/50 (92.0)	47/50 (94.0)	36/50 (72.0)
Adjusted rates(b)	88.10	92.00	100.00	100.00
Terminal rates(c)	36/41 (87.8)	40/44 ( 90. 9)	39/39 (100. 0)	9/ 9(100.0)
tatistical analysis		···•••••••••••••••••••••••••••••••••••		-, ,
Peto test				
Standard method(d)	P =			
Prevalence method(d)	P = 0.0031**			
Combined analysis(d)	P =			
Cochran-Armitage test(e)	P = 0.0538			
Fisher Exact test(e)		P = 0.0739	P = 0.0357*	P = 0.2415
	SITE : mammary gland			
	TUMOR : adenoma, fibroadenoma			
umor rate		•		
Overali rates(a)	0/50(0.0)	0/50(0.0)	3/50 ( 6.0)	1/50 ( 2.0)
Adjusted rates(b)	0.0	0,50( 0.0)	7.69	1730( 2.0)
Terminal rates(c)	0/41(0.0)	0/44 ( 0.0)	3/39(7.7)	1/ 9( 11. 1)
tatistical analysis	0/41( 0.0)	0/44( 0.0/	3/39 ( 1.1)	1/ 3/ 11.1/
Peto test				
Standard method(d)	P =			
Prevalence method(d)	P = 0.0200*			
Combined analysis(d)	P =			
Cochran-Armitage test(e)	P = 0.3948			
Fisher Exact test(e)	1 - 0,0340		D - 0 1010	p = 0.5000
LAGE LESL(8)		P = N.C.	P = 0.1212	P = 0.5000

PAGE :

9

STUDY No. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] SEX : MALE

PAGE : 10 Group Name Control 3.2ppm 8ppm 20ppm SITE : mammary gland TUMOR : adenoma, fibroadenoma, adenocarcinoma Tumor rate Overall rates(a) 1/50( 2.0) 3/50(6,0) 1/50( 2.0) 0/50(0,0)Adjusted rates(b) 2.44 0.0 7.69 11.11 3/39(7.7) Terminal rates(c) 1/41 ( 2.4) 0/44(0.0) 1/9(11.1) Statistical analysis Peto test Standard method(d) P = -----Prevalence method(d) P = 0.0551 Combined analysis(d) P = -----Cochran-Armitage test(e) P = 0,7656 Fisher Exact test(e) P = 0.5000P = 0.3087 P = 0.7525SITE : peritoneum TUMOR : mesothelioma Tumor rate 1/50( 2.0) Overall rates(a) 7/50(14.0) 16/50(32.0)14/50 (28.0) Adjusted rates(b) 0.0 15.91 33.33 55.56 Terminal rates(c) 0/41(0.0) 7/44 (15.9) 13/39(33.3) 5/9(55.6) Statistical analysis Peto test Standard method(d) P = 0.0005\*\* Prevalence method(d) P < 0.0001\*\* Combined analysis(d) P < 0.0001\*\* Cochran-Armitage test(e) P = 0.0015\*\* Fisher Exact test(e) P = 0.0297\* Pく0.0001\*\* P = 0.0002\*\*

(HPT360A)

(a): Number of tumor-bearing animals/number of animals examined at the site.

(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.

(c): Observed tumor incidence at terminal kill.

(d): Beneath the control incidence are the P-values associated with the trend test.

Standard method : Death analysis

Prevalence method : Incidental tumor test

Combined analysis : Death analysis + Incidental tumor test

(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.

? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.

----- : There is no data which should be statistical analysis.

Significant difference ; \* : P  $\leq$  0.05 \*\* : P  $\leq$  0.01

N.C.:Statistical value cannot be calculated and was not significant.

BAIS5

TABLE O2

## NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS : FEMALE

STUDY No.	:	0794
ANIMAL	:	RAT F344/DuCrICrIj[F344/DuCrj]
0.00		

SEX : FEMALE

PAGE: 1

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : subcutis			
Tumor rate	TUMOR : fibroma			
Overall rates(a)	0/50(0.0)	2/50(4.0)	2/50(4,0)	3/50 ( 6.0)
Adjusted rates(b)	0.0	0.0	5. 71	7.69
Terminal rates(c)	0/39( 0.0)	0/39( 0.0)	2/35(5.7)	2/29(6.9)
Statistical analysis				
Peto test	D - 0 7071			
Standard method(d) Prevalence method(d)	P = 0.7271 P = 0.0126*			
Combined analysis(d)	P = 0.0608			
Cochran-Armitage test(e)	P = 0.1592			
Fisher Exact test(e)		P = 0.2475	P = 0.2475	P = 0.1212
Tumor rate Overali rates(a) Adjusted rates(b)	SITE : nasal cavity TUMOR : adenoma 0/50( 0.0) 0.0	3/50( 6.0) 7.69	3/50 ( 6. 0) 5. 71	1/50 ( 2.0) 3.45
Terminal rates(c) tatistical analysis Peto test	0/39( 0.0)	3/39 ( 7.7)	2/35 ( 5.7)	1/29 ( 3.4)
Standard method(d) Prevalence method(d) Combined analysis(d) Cochran-Armitage test(e)	P = 0.3519 P = 0.3883 P = 0.3809 P = 0.9596			
Fisher Exact test(e)		P = 0.1212	P = 0.1212	P = 0.5000
lumor rate	SITE : nasal cavity TUMOR : squamous cell carcinoma			
Overall rates(a)	0/50(0.0)	0/50(0.0)	0/50(0.0)	10/50 ( 20. 0)
Adjusted rates (b)	0.0	0.0	0.0	16.67
Terminal rates(c)	0/39(0.0)	0/39( 0.0)	0/35( 0.0)	4/29 ( 13.8)
tatistical analysis Peto test				
Standard method(d)	P = 0.0001**?			
Prevalence method(d)	P < 0.0001**?			
Combined analysis(d)	P < 0.0001 <b>*</b> *?			
Cochran-Armitage test(e)	P < 0.0001 <b>*</b> *			
Fisher Exact test(e)		P = N.C.	P = N.C.	P = 0.0006**

STUDY No.:0794ANIMAL:RAT F344/DuCrlCrlj[F344/DuCrj]SEX:FEMALE

PAGE: 2

Group Name	Control	3. 2ppm	8ppm	20ppm
	SITE : nasal cavity			
	TUMOR : adenoma, squamous cel	l carcinoma, adenosquamous carcinoma		
umor rate Overall rates(a)				
Adjusted rates(b)	0/50( 0.0)	3/50 ( 6.0)	3/50 ( 6.0)	12/50 ( 24. 0)
Terminal rates(c)	0.0 0/39( 0.0)	7.69	5.71	20.00
tatistical analysis	0/39( 0.0/	3/39 (7.7)	2/35 ( 5.7)	5/29 ( 17. 2)
Peto test	D 00004			
Standard method(d)	P = 0.0001**			
Prevalence method(d)	P = 0.0028**			
Combined analysis(d)	P < 0.0001**			
Cochran-Armitage test(e)	P < 0.0001 <b>*</b> *	D = 0.1010	D = 0.1010	D = 0.0001 (t)
Fisher Exact test(e)		P = 0. 1212	P = 0. 1212	P = 0.0001**
	SITE : nasal cavity			
	TUMOR : squamous cell carcin	oma, adenosquamous carcinoma, esthesioneu	roepithelioma, hemangiosarcoma	
umor rate				
Overall rates(a)	0/50( 0.0)	0/50( 0.0)	0/50( 0.0)	14/50(28.0)
Adjusted rates(b)	0.0	0. 0	0.0	25. 81
Terminal rates(c)	0/39( 0.0)	0/39( 0.0)	0/35( 0.0)	6/29(20.7)
tatistical analysis				
Peto test				
Standard method(d)	P < 0.0001 <b>*</b> *?			
Prevalence method(d)	₽ < 0.0001**?			
Combined analysis(d)	P < 0.0001**?			
Cochran-Armitage test(e)	P < 0.0001 <b>*</b> *			
Fisher Exact test(e)		P = N. C.	P = N. C.	P < 0.0001 <b>*</b> *
	- 111 - 177 - ЛИКТИКИ МИКИ В В И ОРЕАЛУХЕТ			
	SITE : spleen			
	TUMOR : mononuclear cell leu	kemia		
umor rate				
	5/50(10.0)	10/50(20.0)	8/50(16.0)	6/50(12.0)
Adjusted rates(b)	5. 13	15.38	5. 71	3. 45
Adjusted rates(b) Terminal rates(c)	5.13 2/39(5.1)	15.38 6/39(15.4)	5. /1 2/35( 5. 7)	3. 45 1/29( 3. 4)
Adjusted rates(b) Terminal rates(c) tatistical analysis				
Overall rates(a) Adjusted rates(b) Terminal rates(c) tatistical analysis Peto test	2/39( 5.1)			1/29 ( 3.4)
Adjusted rates(b) Terminal rates(c) tatistical analysis Peto test Standard method(d)	2/39 ( 5. 1) P = 0. 1795			1/29 ( 3.4)
Adjusted rates(b) Ferminal rates(c) tatistical analysis Peto test Standard method(d) Prevalence method(d)	2/39 ( 5.1) P = 0.1795 P = 0.8143			1/29 ( 3.4)
Adjusted rates(b) Terminal rates(c) tatistical analysis Peto test Standard method(d) Prevalence method(d) Combined analysis(d)	2/39 ( 5.1) P = 0.1795 P = 0.8143 P = 0.4110			1/29 ( 3.4)
Adjusted rates(b) Terminal rates(c) tatistical analysis Peto test Standard method(d) Prevalence method(d)	2/39 ( 5.1) P = 0.1795 P = 0.8143			1/29 ( 3.4)

### $\bigcirc$

 $\bigcirc$ 

STUDY No. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] SEX : FEMALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

· · · · · · · · · · · · · · · · · · ·				······	
Group Name	Control	3. 2ррт	mqq8	20ppm	
	SITE : pituitary gland				
Turner and a	TUMOR : adenoma				
Tumor rate Overall rates(a)	11/50 ( 22.0)		10 (50 ( 00 0)		
Adjusted rates (b)	16.67	16/50(32.0) 35.00	13/50 ( 26. 0) 26. 32	8/50(16.0)	
Terminal rates(c)	6/39(15.4)	13/39(33,3)	26.32 8/35(22.9)	15.91 3/29( 10.3)	
Statistical analysis Peto test	0/39(13.4)	13/39 ( 33. 3)	8/35(22.9)	3/29(10.3)	
Standard method (d)	P = 0.8246				
Prevalence method(d)	P = 0.6858				
Combined analysis(d)	P = 0.8159				
Cochran-Armitage test(e)	P = 0.1970				
Fisher Exact test(e)		P = 0. 1839	P = 0. 4076	P = 0.3055	
	SITE : pituitary gland TUMOR : adenoma,adenocarcinoma				
Tumor rate					
Overall rates(a)	12/50(24.0)	18/50(36.0)	13/50 ( 26.0)	8/50(16.0)	
Adjusted rates(b)	17.07	35.00	26. 32	15.91	
Terminal rates(c)	6/39(15.4)	13/39( 33.3)	8/35 (22.9)	3/29(10.3)	
Statistical analysis Peto test					
Standard method(d)	P = 0.9242				
Prevalence method(d)	P = 0.7149				
Combined analysis(d)	P = 0.8951				
Cochran-Armitage test(e)	P = 0.1037				
Fisher Exact test(e)		P = 0. 1376	P = 0.5000	P = 0.2270	
	SITE : thyroid TUMOR : C-cell adenoma				
Tumor rate					
Overall rates(a)	1/50(2.0)	1/50( 2.0)	3/50( 6.0)	4/50( 8.0)	
Adjusted rates(b)	2.44	2.56	8.57	11. 43	
Terminal rates(c) Statistical analysis Peto test	0/39( 0.0)	1/39(2.6)	3/35( 8.6)	3/29 ( 10.3)	
Standard method(d)	P =				
Prevalence method (d)	P = 0.0327*				
Combined analysis(d)	P =				
	-				
Cochran-Armitage test(e)	P = 0.0967				

STUDT NO.	•	0794
ANIMAL	:	RAT F344/DuCrICrIj[F344/DuCrj]
SEX	:	FEMALE

. 0704

OTHOW N.

PAGE : 4 Group Name Control 3.2ppm 8ppm 20ppm SITE : thyroid TUMOR : follicular adenoma Tumor rate Overall rates(a) 1/50( 2.0) 2/50(4.0) 3/50( 6.0) 1/50( 2.0) Adjusted rates(b) 2.56 4.88 3.45 6.98 Terminal rates(c) 1/39( 2.6) 1/39( 2.6) 2/35( 5.7) 1/29( 3.4) Statistical analysis Peto test P = -----Standard method(d) Prevalence method(d) P = 0.4757 Combined analysis(d) P = -----Cochran-Armitage test(e) P = 0.8316Fisher Exact test(e) P = 0, 5000 P = 0.3087 P = 0.7525 SITE : thyroid TUMOR : C-cell adenoma, C-cell carcinoma Tumor rate Overall rates(a) 1/50( 2.0) 1/50(2.0) 5/50(10.0) 4/50( 8.0) Adjusted rates(b) 2.44 2.56 14.29 11.43 0/39( 0.0) Terminal rates(c) 1/39( 2.6) 5/35(14.3) 3/29(10.3) Statistical analysis Peto test Standard method(d) P = -----Prevalence method(d) P = 0.0396\* Combined analysis(d) P = -----Cochran-Armitage test(e) P = 0.1268 Fisher Exact test(e) P = 0.7525 P = 0.1022 P = 0, 1811 SITE : uterus TUMOR : endometrial stromal polyp

	i on dono en run o en onde	( polijp			
Tumor rate					
Overall rates(a)	6/50(12.0)	10/50 ( 20.0)	7/50(14.0)	7/50(14.0)	
Adjusted rates(b)	9.52	21.28	20.00	17.24	
Terminal rates(c)	3/39(7.7)	8/39 (20.5)	7/35(20.0)	5/29(17.2)	
Statistical analysis					
Peto test					
Standard method(d)	P = 0.9637				
Prevalence method(d)	P = 0.2895				
Combined analysis(d)	P = 0.4454				
Cochran-Armitage test(e)	P = 0.8757				
Fisher Exact test(e)		P = 0.2070	P = 0.5000	P = 0.5000	

STUDY No. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] SEX : FEMALE

PAGE: 5

Group Name	Control	3.2ppm	8ppm	20ppm
	SITE : uterus			
	TUMOR : endometrial stromal sa	rcoma		
fumor rate	1/50( 0.0)			
Overali rates(a) Adjusted rates(b)	1/50 ( 2.0)	1/50 ( 2.0)	1/50 ( 2.0)	5/50(10.0)
Terminal rates(c)	2.56 1/39(2.6)	0.0	0.0	6.90
Statistical analysis	1/39( 2.6)	0/39( 0.0)	0/35( 0.0)	2/29(6.9)
Peto test				
Standard method(d)	P = 0.0286*			
Prevalence method(d)	P = 0.0809			
Combined analysis(d)	P = 0.0083**			
Cochran-Armitage test(e)	P = 0.0205*			
Fisher Exact test(e)	1 0.0100	P = 0.7525	P = 0.7525	P = 0.1022
	· · · · · · · · · · · · · · · · · · ·			0. 1022
	SITE : mammary gland TUMOR : fibroadenoma			
umor rate				
Overall rates(a)	7/50(14.0)	14/50 (28.0)	14/50 ( 28.0)	23/50 ( 46.0)
Adjusted rates(b)	16.28	31.71	36. 11	57.89
Terminal rates (c)	6/39(15.4)	12/39 ( 30. 8)	12/35 ( 34. 3)	16/29 ( 55. 2)
tatistical analysis				
Peto test				
Standard method(d)	P = 0.1182			
Prevalence method(d)	P < 0.0001 <b>*</b> *			
Combined analysis(d)	P < 0.0001 <b>*</b> *			
Cochran-Armitage test(e)	P = 0.0007**			
Fisher Exact test(e)		P = 0.0698	P = 0.0698	P = 0.0004**
	SITE : mammary gland			
	TUMOR : adenoma, fibroadenoma, a	denocarcinoma		
umor rate				
Overall rates(a)	7/50(14.0)	15/50( 30.0)	15/50( 30.0)	23/50(46.0)
Adjusted rates(b)	16.28	31.71	38.46	57.89
Terminal rates(c)	6/39(15.4)	12/39( 30.8)	12/35(34.3)	16/29(55.2)
tatistical analysis				
Peto test				
Standard method(d)	P = 0.1182			
Prevalence method(d)	P = 0.0001 **			
Combined analysis(d)	P < 0.0001**			
Cochran-Armitage test(e)	P = 0.0012**			
Fisher Exact test(e)		P = 0.0448*	P = 0.0448*	P = 0,0004**

STUDY NO.	:	0794
ANIMAL	:	RAT F344/DuCriCrij[F344/DuCrj]
SEX	:	FEMALE

----

Group Name Control 3.2ppm 20ppm 8ppm SITE : preputial/clitoral gland TUMOR : adenoma Tumor rate Overall rates(a) 0/50(0,0)3/50(6.0) 3/50( 6.0) 4/50( 8.0) Adjusted rates(b) 0.0 7.69 5.71 4.35 Terminal rates(c) 0/39(0.0) 3/39(7.7) 2/35( 5.7) 1/29( 3.4) Statistical analysis Peto test Standard method(d) P = 0.0346\* Prevalence method(d) P = 0.2199Combined analysis(d) P = 0.0467\* Cochran-Armitage test(e) P = 0.1284Fisher Exact test(e) P = 0.1212P = 0.1212 P = 0.0587

(HPT360A)

-----

(a): Number of tumor-bearing animals/number of animals examined at the site.

(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.

(c): Observed tumor incidence at terminal kill.

(d): Beneath the control incidence are the P-values associated with the trend test.

Standard method : Death analysis

Prevalence method : Incidental tumor test

Combined analysis : Death analysis + Incidental tumor test

(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.

? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.

------ : There is no data which should be statistical analysis.

Significant difference :  $* : P \leq 0.05$   $** : P \leq 0.01$ 

N.C.:Statistical value cannot be calculated and was not significant.

BAIS5

PAGE :

6

TABLE P1

## HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR :

MALE

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

#### HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY) ALL ANIMALS (0-105W)

						r Auc.
rgan	Findings	Group Name No. of Animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
Respiratory :	system)					
asal cavit	leukemic cell infiltration		<50> 2	<50> 0	<50> 0	<50> 0
asopharynx	metastasis:nasal tumor		<50> 0	<50> 0	<50> 0	<50> 4
ing	leukemic cell infiltration		<50> 2	<50> 5	<50> 2	<50> 3
	metastasis:adrenal tumor		0	0	1	0
	metastasis:subcutis tumor		0	0	1	0
	metastasis:bone tumor		0	0	1	0
	metastasis:Zymbal gland tumor		1	0	0	0
	metastasis:skin/appendage tumor		0	0	1	0
ematopoietio	c system}					
ne marrow	leukemic cell infiltration		<50> 4	<50> 3	<50> 2	<50> 4
mph node	leukemic cell infiltration		<50> 2	<50> 3	<50> 2	<b>&lt;50&gt;</b> 1
	metastasis:bone tumor		0	0	1	0
	metastasis:skin/appendage tumor		0	0	1	0
ymus	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0
leen	metastasis:skin/appendage tumor		<50> 0	<50> 0	< <b>50&gt;</b> 1	<50> 0

b b: Number of animals with lesion

PAGE : 1

# STUDY NO.: 0794ANIMAL: RAT F344/DuCrICrIj[F344/DuCrj]REPORT TYPE: A1SEX: MALE

#### HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY) ALL ANIMALS (0-105W)

		Group Name No. of Animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
Organ	Findings	- 				
Circulatory s	:vstem}					
neart			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	2	0	1
	metastasis:subcutis tumor		0	0	1	0
Digestive sys	tem}					
alivary gl			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	0	0
tomach	leukemic cell infiltration		<50> 0	<50> 1	<50> 0	<50> 0
iver			<50>	<50>	<50>	<50>
i vei	leukemic cell infiltration		4	5	2	4
	metastasis:bone tumor		0	0	1	0
ancreas			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	1	0	0
	metastasis:subcutis tumor		0	0	0	1
	metastasis:bone tumor		0	0	1	0
Urinary syste	m)					
idney			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	2	0	0
Endocrine sys	tem}					
ituitary			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	1	0	1

< a > a : Number of animals examined at the site b b : Number of animals with lesion

(JPT150)

PAGE : 2

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : MALE

#### HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY) ALL ANIMALS (0-105W)

3

Organ	Findings	Group Name No. of Animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
Endocrine s	ystem]					
thyroid	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0
drenal	leukemic cell infiltration		<50> 1	<50> 3	<50> 2	<50> 2
Nervous syst	tem}					
orain	leukemic cell infiltration		< <b>50&gt;</b> 1	<50> 3	<b>&lt;50&gt;</b> 1	<50> 1
	metastasis:nasal tumor		0	0	0	5
pinal cord	leukemic cell infiltration		<50> 0	<50> 1	<50> 0	<50> 2
Musculoskele	etal system}					
nuscle	metastasis:peritoneum tumor		<50> 0	<50> 0	<50> 0	<50> 1
	metastasis:subcutis tumor		0	0	1	0
Body cavitie	263]					
leura	metastasis:peritoneum tumor		<50> 0	<50> 1	<50> 0	<50> 0
	metastasis:lung tumor		0	0	0	1
eritoneum	metastasis:bone tumor		<50> 0	<50> 0	<50> 1	<50> 0

TABLE P2

### HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR :

FEMALE

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : FEMALE

#### HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY) ALL ANIMALS (0-105W)

PAGE	:	4

Organ	Findings	Group Name No. of Animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
л ван	r mumgs					
{Integumentar	y system/appandage]					
subcutis	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0
Respiratory	system]					
nasal cavit	leukemic cell infiltration		<50> 3	<50> 0	<50> 0	<50> 0
asopharynx	leukemic cell infiltration		<50> 1	<50> 0	<50> 0	<50> 0
	metastasis:nasal tumor		0	0	0	1
arynx	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0
ung	leukemic cell infiltration		<50> 3	<50> 7	<50> 8	<50> 5
	metastasis:adrenal tumor		1	0	0	0
	metastasis:pleura tumor		0	0	0	1
Hematopoieti	c system}					
one marrow	leukemic cell infiltration		<50> 3	<50> 4	<50> 4	<50> 5
	metastasis:pleura tumor		0	0	0	1
ymph node	leukemic cell infiltration		<b>&lt;50&gt;</b> 1	<b>&lt;50&gt;</b> 1	<50> 2	<50> 2
hymus	metastasis:pleura tumor		<50> 0	<50> 0	<50> 0	<50> 1
<a>b</a>	a : Number of animals examined at b : Number of animals with lesion					

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : A1 SEX : FEMALE

#### HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY) ALL ANIMALS (0-105W)

Organ	Findings	Group Name No. of Animals on Study	Control 50	3.2ppm 50	8ppm 50	20ррт 50
-		ар на - на				
{Circulatory s	system)					
heart	leukemic cell infiltration		<50> 1	<50> 2	<50> 2	<50> 2
{Digestive sys	stem}					
large intes	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0
	metastasis:uterus tumor		0	0	0	1
liver	leukemic cell infiltration		<50> 5	<50> 9	<b>&lt;50&gt;</b> 7	<50> 5
	metastasis:pleura tumor		0	0	0	1
pancreas	leukemic cell infiltration		<50> 0	<50> 0	<50> 2	<50> 0
{Urinary syste	em)					
kidney	leukemic cell infiltration		<50> 2	<50> 0	<b>&lt;50&gt;</b> 1	<50> 3
urin bladd	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0
	metastasis:uterus tumor		0	0	0	1
{Endocrine sys	stem]					
pituitary	leukemic cell infiltration		<50> 0	<50> 1	<50> 1	<50> 0
<a>&gt; b</a>	a : Number of animals examined at the b : Number of animals with lesion	site				

PAGE : 5

#### STUDY NO. : 0794 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 SEX : FEMALE

#### HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY) ALL ANIMALS (0-105W)

PAGE: 6

Organ	Findings	Group Name No. of Animals on Study	Control 50	3.2ppm 50	8ppm 50	20ppm 50
			2 - 11 / 12 / 12 / 12 / 12 / 12 / 12 / 1			
{Endocrine sys	stem}					
thyroid	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0
drenal	leukemic cell infiltration		<50> 3	<50> 4	<50> 5	<50> 5
Reproductive	system]					
ovary	leukemic cell infiltration		<50> 4	<50> 2	<50> 5	<50> 3
	metastasis:pleura tumor		0	0	0	1
terus	leukemic cell infiltration		<b>&lt;50&gt;</b> 1	<50> 0	<50> 2	<50> 0
agina	leukemic cell infiltration		<b>&lt;50&gt;</b> 1	<50> 0	<50> 1	<50> 0
	metastasis:uterus tumor		0	1	1	2
Nervous syste	em]					
rain	leukemic cell infiltration		< <b>50&gt;</b> 1	<50> 0	<50> 1	<50> 2
	metastasis:pituitary tumor		2	2	0	0
	metastasis:nasal tumor		0	0	0	1
pinal cord	leukemic cell infiltration		<50> 1	<50> 0	<50> 0	<50> 1
Special sense	e organs/appendage}					
larder gl	leukemic cell infiltration		<50> 0	<50> 0	<50> 1	<50> 0

#### STUDY NO. : 0794 : RAT F344/DuCrlCrlj[F344/DuCrj] ANIMAL REPORT TYPE : A1 : FEMALE SEX

#### HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY) ALL ANIMALS (0-105W)

gan		Group Name No. of Animals on Study 	Control 50	3.2ppm 50	8ppm 50	20ppm 50
culoskele	stal system)	1 U - V				
cle			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
• >	a : Number of animals examined at the si b : Number of animals with lesion	te				

PAGE: 7

### TABLE Q1

# HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCrlCrlj MALE RATS

Organs	No. of animals	No. of animals	Incidence	Min Max.
Tumors	examined	bearing tumor	(%)	(%)
Skin	3048			
Basal cell epithelioma <sup>1)</sup>		2	0.1	0 - 2
Basal cell carcinoma <sup>2)</sup>		2	0.1	0 - 2
(1) + 2)		4	0.1	0 - 2
Keratoacanthoma		100	3.3	0 - 14
Subcutis	3048			
Fibroma		258	8.5	2 - 20
Nasal cavity	3048			
Adenoma		3	0.1	0 - 2
Adenocarcinoma		0	0.0	0 - 0
Adenosquamous carcinoma		0	0.0	0 - 0
Squamous cell papilloma		0	0.0	0 - 0
Squamous cell carcinoma		0	0.0	0 - 0
Esthesioneuroepithelioma		0	0.0	0 - 0
Spleen	3048			
Mononuclear cell leukemia		345	11.3	2 - 22
Pancreas	3047			
Islet cell adenoma <sup>1)</sup>		217	7.1	0 - 14
Işlet çell adenocarcinoma $^{2)}$		17	0.6	0 - 4
(1) + 2)		234	7.7	0 - 14
Thyroid	3041			
C-cell adenoma <sup>1)</sup>		461	15.2	2 - 36
$\mathbf{C}$ -cell carcinoma $^{2)}$		72	2.4	0 - 12
1) + 2)		532	17.5	4 - 38
Mammary	3048			
Adenoma <sup>1)</sup>		16	0.5	0 - 4
Fibroadenoma <sup>2)</sup>		55	1.8	0 - 6
(1) + 2)		71	2.3	0 - 8
Testis	3047			
Interstitial cell tumor		2508	82.3	56 - 98
Peritoneum	3046			
Mesothelioma		76	2.5	0 - 8

## TABLE Q1HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONSIN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCrlCrlj MALE

61 carcinogenicity studies examined in Japan Bioassay Research Center were used.

Study No.: 0043, 0059, 0061, 0063, 0065, 0067, 0095, 0104, 0115, 0130, 0141, 0158, 0162, 0189, 0205, 0210, 0224, 0242, 0246, 0267, 0269, 0278, 0284, 0288, 0294, 0296, 0318, 0328, 0342, 0347, 0365, 0371, 0396, 0399, 0401, 0407, 0417, 0421, 0437, 0448, 0457, 0461, 0497, 0535, 0560, 0579, 0581, 0610, 0612, 0641, 0667, 0675, 0684, 0686, 0691, 0704, 0711, 0731, 0739, 0753, 0774

## TABLE Q2

# HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCrlCrlj FEMALE RATS

Organs	No. of animals	No. of animals In	cidence	Min Max.	
Tumors	examined	bearing tumor	(%)	(%)	
Subcutis	2847				
Fibroma	2011	31	1.1	0 - 8	
Nasal cavity	2847				
Adenoma		2	0.1	0 - 2	
Adenosquamous carcinoma		0	0.0	0 - 0	
Squamous cell carcinoma		0	0.0	0 - 0	
Esthesioneuroepithelioma		0	0.0	0 - 0	
Hemangiosarcoma		0	0.0	0 - 0	
Thyroid	2838				
C-cell adenoma		296	10.4	0 - 20	
Uterus	2846				
Endometrial stromal sarcoma		54	1.9	0 - 8	
Mammary gland	2847				
Adenoma <sup>1)</sup>		60	2.1	0 - 18	
Fibroadenoma <sup>2)</sup>		329	11.6	0 - 28	
Adenocarcinoma <sup>3)</sup>		35	1.2	0 - 6	
(1) + 2) + 3)		416	14.6	4 - 30	
Clitoral gland	2847				
Adenoma		85	3.0	0 - 10	

## TABLE Q2HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONSIN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCrlCrlj FEMALE

57 carcinogenicity studies examined in Japan Bioassay Research Center were used.

Study No.: 0043, 0059, 0061, 0063, 0065, 0067, 0095, 0104, 0115, 0130, 0141, 0158, 0162, 0189, 0205, 0210, 0224, 0242, 0246, 0267, 0269, 0278, 0284, 0296, 0303, 0318, 0328, 0342, 0347, 0365, 0371, 0399, 0401, 0417, 0421, 0437, 0448, 0457, 0461, 0497, 0535, 0560, 0579, 0610, 0612, 0641, 0667, 0675, 0684, 0686, 0691, 0704, 0711, 0731, 0739, 0753, 0774

TABLE **R**1

CAUSE OF DEATH : MALE

STUDY NO. : 0794 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] SEX : MALE			COUSE OF DEATH (SUMMARY) (O-105W)		
Group Name	Control	3.2ppm	8ppm	20ppm	
Number of Dead and Moribund Animal	9	6	11	41	
no microscop confirm	0	0	1	0	
chronic nephropathy	1	0	0	0	

Number of Dead and	9	6	11	41
Moribund Animal				
no microscop confirm	0	0	1	0
chronic nephropathy	1	0	0	0
nasal lesion	0	Ó	0	1
tumor d:leukemia	3	3	1	4
tumor d:skin/app	0	1	1	0
tumor d:subcutis	1	0	2	0
tumor d:nasal cavit	0	0	0	31
tumor d:pituitary	1	2	1	0
tumor d:brain	1	0	1	0
tumor d:bone	0	0	1	0
tumor d:peritoneum	2	0	3	5

(B10120)

BA I S5

PAGE: 1

TABLE R2

### CAUSE OF DEATH : FEMALE

STUDY NO. : 0794 ANIMAL : RAT F344/Du SEX : FEMALE	ıCr∣Cr∣j[F344/DuCr	[[·		USE OF DEATH (SUMMARY) -105W)	PAGE : 2
Group Name	Control	3.2ppm	8ppm	20ppm	
Number of Dead and Moribund Animal	11	11	15	21	
deglutition disorder	1	0	1	0	
tumor d:leukemia	3	4	6	5	
tumor d:subcutis	0	2	1	0	
tumor d:nasal cavit	0	0	1	6	
tumor d:tongue	0	0	0	1	
tumor d:pituitary	5	4	3	1	
tumor d:ovary	0	0	0	1	
tumor d:uterus	2	1	1	3	
tumor d:mammary gl	0	0	0	1	
tumor d:prep/cli gl	0	0	1	2	
tumor d:Zymbal gl	0	0	0	1	
tumor d:peritoneum	0	0	1	0	

(BI0120)

BAIS5